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1 Biology and mathematical modelling of haematopoiesis
1.1 Haematopoiesis
Haematopoiesis is the process of blood cell production. In human adults, it occurs within the
bone marrow, whereas in mice haematopoietic organs are located in the bone marrow and in the
spleen. Blood cell production begins with haematopoietic stem cells (HSCs), which are multi-
FIGURE 1 – Haematopoiesis scheme.
potent cells with self-renewal capacity and the ability to generate all blood cell types [22, 124].
Stem cells were discovered by Till and McCulloch [109] in 1961. More information about stem
cells and their history can be found in [56]. Several types of stem cells can be distinguished :
 totipotent stem cells can differentiate into embryonic and extraembryonic cell types.
Such cells can construct a complete, viable organism. Cells produced by the ﬁrst few
divisions of the fertilised egg are also totipotent ;
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 pluripotent stem cells are the descendants of totipotent cells and can differentiate into
almost all cells ;
 multipotent stem cells can differentiate into a number of closely related cells ;
 oligopotent stem cells can differentiate into only a few cells, such as lymphoid or mye-
loid stem cells ;
 unipotent stem cells can produce only one cell type, their own (for example skin, liver).
The number of HCSs is very small and they are difﬁcult to identify. About 90% of HSCs
remain in quiescent stage and do not proliferate. All blood cells originate from HSCs and can
be divided into three categories (Figure 1) :
 Erythrocytes (red blood cells, RBC) are simple cells ﬁlled with haemoglobin. Their main
function is to transport oxygen to organs. In humans erythrocytes do not contain nucleus. The
process of red blood cell production is called erythropoiesis.
 Leukocytes (white blood cells) are cells of the immune system that defend the organism
against various infectious diseases and foreign debris. They are produced through leukopoiesis
and are divided into three subtypes :
 granulocytes possess granules in their cytoplasm. They phagocytose and destruct small
foreign organisms ;
 monocytes move from blood to infected organs and phagocytose microbes, whole cells
and also small pollutants ;
 lymphocytes are responsible for the speciﬁc recognition of foreign agents and their sub-
sequent removal from the organism. They are divided into two groups, T and B lympho-
cytes. T lymphocytes are agents of cellular immunity that recognise infected cells and
destroy them. B lymphocytes are involved in so-called humoral immunity. They destroy
foreign substances.
 Platelets (trombocytes) are produced by fragmentation of megakaryocytes. They play a fun-
damental role in haemostasis and blood coagulation.
In humans all these cells represent about 45% of blood volume, the rest of 55% is plasma
composed mostly of water. Life time of white blood cells is about 24 hours, one week for
platelets and about 120 days for red blood cells. One liter of blood contains 5× 1012 of RBCs,
109 of WBCs and 3 × 1011 of platelets. Almost the whole volume of circulating blood cells is
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occupied by RBCs.
1.2 Erythropoiesis
The focus of this work is, in particular, red blood cell lineage. Erythropoiesis is the process
by which red blood cells are produced.
Haematopoietic stem cells differentiate into immature erythroid cells, called erythroid pro-
genitors, which are undifferentiated cells committed to erythroid lineage. Then, through matu-
ration and differentiation stages, erythroid progenitors become reticulocytes, which are almost
mature red blood cells. These latter end their maturation to become red blood cells and enter
the blood stream.
Erythropoiesis consists in a series of cell divisions through which erythroid cells acquire
differentiation characteristics. This process allows the production of sufﬁcient amount of ery-
throcytes to transport oxygen to organs. Erythropoiesis can sometimes exhibit disorders, such
as excessive proliferation of immature cells, as observed in acute leukaemias [64, 74]. Such di-
sorders can be caused by alteration of intracellular regulatory networks, which control cell fate
(e.g. Madan et al. [70]), that is self-renewal (the ability to produce daughter cells of the same
maturity [123]), differentiation (the ability to produce more mature daughter cells) or apoptosis
(programmed cell death). Hence, the regulation of erythropoiesis depends on a precise control
of cell fate by means of intracellular proteins and growth factors.
Usually self-renewal is considered to be a property of stem cells. However recent stu-
dies [51, 83] have shown that erythroid progenitors, which are committed stem cells, also pos-
sess this ability. Differentiation allows the production of two daughter cells, one of which at
least being more mature than the mother cell. Apoptosis is a programmed cell death [108]. It is
a particular form of cell death, different from necrosis, which is controlled by various regulatory
mechanisms.
One of the most well studied growth factors, playing an important role in erythropoiesis
regulation, is erythropoietin (Epo), a glucoprotein released by the kidney in response to hypoxia,
that is a lack of oxygen in tissues. Glucocorticoids (GCs) are lipophilic hormones involved in
the regulation of various physiological responses, and in particular in stress erythropoiesis. They
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are known to favour cell proliferation [129]. Growth factors operate by activating membrane
receptors on cell surface to trigger intracellular protein activation.
Recently, Rubiolo et al. [96] proposed a description of the regulatory network that controls
erythroid progenitor fate : some proteins are involved in a self-renewal loop, some others in a
differentiation/apoptosis loop, see Figure 4. The ﬁrst loop self-activates and inhibits the second
one, whereas the second loop can inhibit the ﬁrst one and, depending on Epo levels, induce
either erythroid progenitor differentiation or apoptosis. Self-renewal loop relies on proteins of
the MAPK family, the other loop is mainly controlled by Fas, a protein of the tumour-necrosis
factor family.
FIGURE 2 – Summary of intracellular protein interactions that determine erythroid progenitor
fate, partially adapted from [96].
Cells in the bone marrow are known to exchange different signals that regulate cell beha-
viour. Hence, it is important to take into account spatial distribution of cells. In the next section
we discuss spatial organisation of the bone marrow.
1. Biology and mathematical modelling of haematopoiesis 15
1.3 Spatial structure of the bone marrow
Bone marrow is a ﬂexible tissue located in the hollow interior of bones. It is located mainly
in ﬂat bones, such as the hip bone, breast bone, skull, ribs, vertebrae, and in the cancellous
material at the epiphyseal ends of the long bones such as the femur and humerus.
Bone marrow cells have a certain spatial structure. Animal studies support the hypothesis
that the HSCs and progenitor cells are localised much closer to the bone trabecula surfaces and
decrease in concentration within deeper regions of bone marrow [80, 107]. Works by Frassoni
et al. [47], Lord [66], and Cui et al. [37] on the mouse femoral shaft have demonstrated a clear
spatial gradient in the distribution of different cell lines responding to marrow growth factors as
a function of distance inside the femoral medullary cavity.
One of recent studies of spatial distribution of cells in the bone marrow was published by
Watchman et al. [122]. The objective of this work was to directly measure the spatial concentra-
tion of HSCs and progenitor cells within human disease-free bone marrow. The authors obtained
that haematopoietic CD34+ cells (stem cells committed to erythroid lineage) were located along
a linear spatial gradient with a maximal areal concentration localised within the ﬁrst 50μm of
the bone surfaces.
For erythroid progenitors, an important role play erythroblastic islands. Erythroblastic is-
lands are speciﬁc microenvironmental compartments, within which erythroblasts proliferate
and differentiate. They have been ﬁrstly described by M. Bessis [18]. In the center of such
an island a macrophage is located surrounded by a ring of developing erythroblasts in various
stages of differentiation, ranging from CFU-E (immature erythroid progenitors) to young re-
ticulocytes [72]. Erythroblastic islands are uniformly distributed throughout the bone marrow
and contain variable number of erythroblasts. Rat femurs have about 10 cells per island, whe-
reas islands harvested from human bone marrow contain 5–30 erythroblasts. The interaction
between different components of these structures is essential through all stages of maturation.
It is suggested that during early stages of maturation, macrophages provide nutrients and proli-
ferative signals to erythroblasts, during late stages macrophages promote enucleation and pha-
gocytose injected nuclei. Both macrophages and erythroblasts display adhesive interactions that
maintain island integrity. These interactions enable regulatory feedbacks between cells within
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islands and also trigger intracellular signaling pathways that regulate gene expressions. Some
feedbacks between mature and immature erythroblasts as well as between macrophages and
immature erythroblasts carry out controls of apoptosis. The process of enucleation which is
governed by macrophages decreases the adhesion between the macrophages and well differen-
tiated erythroblasts (reticulocytes). These latter detach from the islands and are taken away by
the blood stream.
Different disorders can appear during these complex processes of cell production, among
which leukaemias. In the next section we discuss leukaemias and their treatment.
1.4 Leukaemias and treatments
Up to now, cancer was the second cause of death in developed countries, after cardio-
vascular diseases (CVDs). Since 1980’s and by 2004 the number of deaths due to CVDs has
decreased twice while that due to cancer has decreased only by 10%. Statistics on deaths in
France shows that cancer has become the ﬁrst cause of death in 2004 and will certainly keep
this position. Among cancers, leukaemia occupies the third place [8].
Leukaemia is a cancer of blood or bone marrow and is characterised by abnormal prolife-
ration of precursor cells or haematopoietic stem cells within the bone marrow. Leukaemia can
be acute (rapid increase of immature blood cells) or chronic (excessive production of relatively
mature blood cells). Leukaemias are generally classiﬁed according to the type of blood cells
affected. Four most common kinds of leukaemia are acute lymphoblastic leukaemia (ALL),
chronic lymphocytic leukaemia (CLL), chronic myeloid leukaemia (CML) and acute myeloid
leukaemia (AML). In 1970th so-called French-American-British (FAB) classiﬁcation of leu-
kaemias was elaborated. In this work the attention is focused on the AML, FAB classiﬁcation
for AML can be found in Figure 3.
Acute leukaemias, by its deﬁnition, develop abruptly and require urgent treatment, it pro-
gresses rapidly and is typically fatal within weeks or months if left untreated. The ﬁrst step in
diagnosis is the enumeration of blast cells (immature progenitors) in the blood and examina-
tion of their cytologic features. In [16, 106] more information about leukaemia diagnosis can
be found. AML (known also as acute myelogenous leukaemia or acute nonlymphocytic leu-
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FIGURE 3 – Myeloid cell differentiation - Schematic ﬁgure of myeloid differentiation including
the corresponding leukaemia and non-Hodgkin lymphomas as well as cell markers involved in
each stage, adapted from [86].
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kaemia) is a subtype of leukaemia in which myeloid lineage is involved. It is rare in childhood
(15% of childhood AL), but is much more frequent than ALL in adults [16] with median age
above 60 years. Usual symptoms of AML are fatigue, weight loss, shortness of breath, easy
bruising and bleeding and increased risk of infection. Although several risk factors for AML
have been identiﬁed, the speciﬁc cause of AML remains unclear.
The treatment of acute leukaemia consists generally of chemotherapy with or without stem
cell transplantation [24, 100]. Two phases of treatment are usually applied, the standard ﬁrst
phase of AML treatment is induction chemotherapy. The goal is to bring the disease into re-
mission, when the patient’s blood counts return to normal and bone marrow samples show no
sign of disease, i.e. less than 5% of cells are leukaemic. Induction chemotherapy is very in-
tense and usually lasts one week, followed by three or more weeks for the patient to recover
from the treatment. The second phase is consolidation chemotherapy, the goal is to destroy any
remaining leukaemic cells.
The majority of cytotoxic drugs that are used in chemotherapy are not speciﬁc to malignant
cells. They affect normal bone marrow cells as well, which is its great disadvantage. Generally,
chemotherapy drugs are cycle-active agents, it kills all cells that are in S phase of cell cycle.
Hence, such a treatment has many side effects. Stem cell transplantation is a powerful technique
but many side effects persist in early and late phases after the transplantation [112].
One of the standard and most important drugs currently available for the treatment of
AML is AraC (1-β-D-arabinofuranosylcytosine, cytarabine, cytosine arabinoside), see [61, 97].
AraC is administered in combination with other drugs, usually daunorubicin or idarubicin. It
is also active against other haematologic malignancies, including acute lymphoblastic leukae-
mia (ALL) and non-Hodgkin’s lymphoma. AraC is a cytotoxic nucleoside analog that has some
differences in chemical structure with respect to physiological nucleosides. Its metabolism and
mechanism of action are relatively well known [58], but its efﬁcacy is limited by numerous re-
sistances that occur during treatment [58, 102]. For example, AraC shows virtually no activity
with isolated leukaemic stem cells [57].
Active form of AraC is its triphosphate AraCTP, which competes with deoxycytidine tri-
phosphate (dCTP) for incorporation into DNA. When incorporated, AraCTP blocks DNA syn-
thesis and thus cell proliferation. At high intracellular concentrations, AraCTP is cytotoxic, at
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low intracellular concentrations there is still a pronounced cytostatic effect. The numbers of
killed malignant as well as normal cells are determined by intracellular AraCTP concentra-
tions. Thus, crucial importance has the knowledge of relationship between administered AraC
and intracellular AraCTP concentrations. The measurements of intracellular concentrations of
nucleoside analogs imply complex procedures. One of the approaches to measure several in-
tracellular nucleosides simultaneously has been recently developed and approved [34]. It is not
clear which dose of AraC is optimal for concrete patient, though some standard protocols are
usually applied. Some trials are currently being carried out, in which clinicians try to ﬁnd out
optimal conditions of treatment. For example, in [61] the authors study if high-dose AraC treat-
ment is more effective for patient survival than standard dose AraC treatment. Mathematical
modelling can be a good additional utility for that kind of research.
In the next section we present an overview of the works on mathematical modelling of
haematopoiesis and erythropoiesis. In Section 1.6 we discuss possible ways to model leukaemia
treatment.
1.5 Mathematical modeling of haematopoiesis and erythropoiesis
Mathematical modelling of haematopoiesis and HSC dynamics has been attracting much
attention since the end of the 1970’s. One of the ﬁrst models was proposed by Mackey [67]
in 1978, which described periodic haematopoiesis at the cellular level by delay equations. The
approach proposed in [67] was later used in many works devoted to the description of oscillatory
behaviours within haematopoietic systems. In [17] Bernard et al. focused on the white blood cell
production to bring an explanation to oscillatory phenomena observed in patients with cyclical
neutropenia. A global model of haematopoietic cell dynamics has been proposed by Colijn and
Mackey [32, 33] in 2005. Other works on haematopoiesis modelling have been proposed by
Loefﬂer and his collaborators since the beginning of the 1980’s, see [91, 93].
Pioneering models of erythropoiesis regulation were proposed by Wichmann and Loef-
ﬂer [126] in 1985. They modelled the dynamics of haematopoietic stem cells, erythroid proge-
nitors and erythroid precursors (reticulocytes). The authors considered feedback controls from
reticulocytes on progenitors and from progenitors on stem cells, confronted their models with
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experimental data on stress erythropoiesis (bleeding, irradiation) and ﬁtted model parameters.
Later Wulff et al. [128] and Wichmann et al. [127] improved Wichmann and Loefﬂer’s models.
In 1995, Bélair et al. [15] proposed a model of erythropoiesis, partially based on previous works
by Mackey [67, 68] and his collaborators [69] on haematopoietic stem cell dynamics. In [15]
the authors proposed an age-structured model describing erythroid cell dynamics, including
an explicit control of differentiation by erythropoietin. This model was then improved in [71].
Other works inspired by [15] proposed mathematical models of erythropoiesis [1, 2, 12]. The
erythropoietin-mediated inhibition of apoptosis has been considered in Adimy and Crauste [3].
The authors focused on the appearance of periodic haematological diseases (such as periodic
chronic myeloid leukemia [46]).
It is however noticeable that in all above-mentioned papers self-renewal ability is associa-
ted with haematopoietic stem cells only. Relatively new feature in erythropoiesis modelling is
related to self-renewal ability of erythroid progenitors. In [36] the authors concluded that ad-
ding self-renewing capacity to erythroid progenitors allows a better ﬁt of experimental data on
induced anaemia.
Modelling of regulatory networks involved in cell decision has been the subject of recent
analysis of lineage speciﬁcation. As it is known, erythrocytes and platelets have one myeloid
progenitor in common, called MEP (for Megakaryocytic-Erythroid Progenitor). As a result of
a competition between two proteins (PU.1 and GATA-1), the MEP differentiates either into an
erythroid progenitor or into a megakaryocytic progenitor. This choice has been modelled by
Roeder and Glauche [92] and Huang et al. [55]. In both studies, models proposed by the authors
demonstrated a bistable behaviour. This idea has been further developed in Chickarmane et
al. [30].
Cell-to-cell interactions inside bone marrow play a crucial role for haematopoiesis regula-
tion. One of the appropriate approaches that would allow taking into account these interactions
is the individual based modelling. This considers each cell as an independent element of the
whole system and, thus, every cell can have its own properties and protein concentrations. Some
IBM models of growth of cell populations were presented in [50]. In [43] the authors discussed
individual based models of growth of unstructured cell populations, that is spatial structure for-
mation of monolayers and multicellular spheroids. In [26] the authors compared two alternative
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theoretical approaches for simulating the growth of cell aggregates in vitro : individual based
models and continuous models.
There is an extensive literature devoted to modelling of solid tumors. Cell proliferation
results in the motion of the medium described by Darcy’s law or Navier-Stokes equations, see [7,
49, 87]. The PDE models of cell motion can be justiﬁed by probabilistic methods (see [27] and
the references therein). In [44] the authors described cell concentrations within the bone marrow
by reaction-diffusion equations and their motion by Darcy’s law.
1.6 PK/PD modelling
Pharmacokinetic-pharmacodynamic (PK/PD) models study drug distribution and efﬁcacy.
Such models include accurate description of drug delivery to the speciﬁc organs being treated
and introduce an insight into the understanding of the drug action. In the future it promises
an important tool for designing new drugs and protocols applicable for treatment of certain
diseases. Once the drug is delivered to the organ being treated it penetrates through the cell
membrane. Inside cells a scheme of metabolism provides detailed description of drug transfor-
mation into its active form. This set of events constitutes pharmacokinetics. Pharmacodynamics,
in turn, describes how active metabolite of the drug acts on diseased organs [111].
PK/PD modelling and simulations can be used as an applied tool to provide more insignts
into efﬁcacy and safety of new drugs faster and at a lower cost, it can be helpful through all cli-
nical and preclinical phases of drug development. Let us give an example from the current prac-
tice of PK/PD involvement into the drug design process. CPX-351 (cytarabine/daunorubicin
liposome injection) is a liposomal formulation of a synergistic, ﬁxed combination of AraC and
daunorubicin encapsulated within the liposomes for intravenous infusion. The two drugs leak
out much easier when liposomes are situated inside bone marrow. CPX-351 is currently under
Phase II of clinical trial. The paper [14] provides a pharmacokinetic model of CPX-351 lipo-
some injection in the mouse. The authors studied leak rates from liposomes in plasma and bone
marrow, which allowed the prediction of free drug concentrations. In [88] an interested reader
will ﬁnd a review of PK/PD applications for drug development and its use in pharmacological
industry.
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Sometimes modelers use the term WBPBPKPD, which stands for the Whole Body Physio-
logically Based PK/PD modelling. An interesting work was presented in [113], in which the
authors studied a WBPBPKPD model of the drug called capecitabine, which is a triple prodrug
of 5-FU. More general model of this type can be found in [121]. In [31] the author remarks that
developing such WBPBPKPD models needs a lot of experimental work in vitro as well as in
vivo and that this modelling is very drug speciﬁc.
Modelling of leukaemia and its treatment attracts much attention since 1970s. For example
in paper [94] by Rubinow et al., the authors proposed a dynamic mathematical model of the
acute myeloblastic leukaemic state, in which normal neutrophils (granulocytes) and their pre-
cursors, and leukemic myeloblasts, proliferate as distinct but interacting cell populations, G0
compartment (resting cells) is considered for each population. In [95] Rubinow et al. introdu-
ced a model of chemotherapy and by calculations they demonstrated that small changes in the
protocol can have signiﬁcant effects on efﬁcacy of treatment. They then found optimal treatment
protocol. Another mathematical model of AML can be found in [4], in which cell populations
are supposed to have Gompertzian dynamics. In [89] Ribba et al. considered a mathematical
model of treatment of non-Hodkin’s lympoma. The authors investigated drug pharmacokinetics
(PK) in order to determine drug concentrations in the vasculature at any given time and drug
pharmacodynamics (PD). They then investigated qualitatively some treatment regimens.
Recently, the work [25] was published, in which the authors considered a simple PK/PD mo-
del of treatment of non-small cell lung cancer and breast cancer. The integrated model contains
four major components : PK model, biomarker model, model of signal transduction and tumour
response model (PD). Some experiments were carried out in parallel with cell lines that allowed
the estimation of certain model parameters.
In [65, 76] Morrison and his collaborators proposed a very accurate PK/PD model of AML
treatment with AraC. They introduced a model of drug distribution in the body, drug meta-
bolism and drug action on DNA synthesis. The authors estimated all constants for L1210 cell
line (lymphocytic leukaemia cells derived from mice) and carried out computer simulations of
treatment. A PK/PD model presented in this thesis is based on these works.
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2 Summary of the results
The thesis deals with several aspects of haematopoiesis modelling and with modelling of
leukaemia treatment. Some of the results are published in [19, 20, 35, 40, 41, 42]. The work
consists of four chapters.
In the ﬁrst chapter we present two multiscale models of haematopoiesis regulation. In the
second chapter we consider spatial models of haematopoiesis. Third chapter is devoted to in-
dividual based modelling approach. The last chapter of the work describes a PK/PD model of
leukaemia treatment with AraC.
Multi-scale modelling of erythropoiesis. Haematopoiesis is a process of blood cell pro-
duction, which occurs mainly in the bone marrow. All blood cells are divided into three groups :
red blood cells, white blood cells and platelets. The process of production of red blood cells is
called erythropoiesis. We developed two mathematical models that describe haematopoiesis
regulation, one more speciﬁc to erythropoiesis. Normal erythropoiesis is maintained by the ba-
lance between self-renewal, differentiation and apoptosis. There are a number of intracellular
proteins and growth factors that control this balance. The scheme of the intracellular regulatory
network can be found in Figure 4. Two intracellular proteins, Erk and Fas, are supposed to be
determinant for regulation of self-renewal, differentiation and apoptosis.
Two models of the intracellular regulatory network, which governs these processes, are
proposed. We ﬁrst consider a general bistable dynamic system, which can be applied to haema-
topoiesis modelling as well. Then, we describe the intracellular regulatory network as a set of
chemical reactions and obtained the following system,
⎧⎪⎨⎪⎩
dE
dt
=
(
α(Epo,GC) + βEk
)
(1− E)− aE − bEF,
dF
dt
= γ(Pn)(1− F )− cEF − dF,
where E and F are Erk and Fas concentrations, functions α(Epo,GC) and γ(Pn) describe
feedback controls. We conclude that this system has a bistable behaviour for certain parameter
values.
We consider several compartments of erythroid progenitors according to maturity, denoted
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FIGURE 4 – Summary of intracellular protein interactions that determine erythroid progenitor
fate, partially adapted from [96].
by P1, . . . , Pn, and a population of erythrocytes, denoted by M , see Figure 5. For each sub-
FIGURE 5 – Differentiation scheme of erythroid progenitors. Pi, i = 1, . . . , n, denotes the
number of progenitors in the i-th sub-population per μl of blood, and by si, di and ai their rates
of self-renewal, differentiation and apoptosis, respectively.
population of progenitors we introduce self-renewal, differentiation and apoptosis rates, si, di
and ai. Dynamics of erythroid progenitors are described by the following differential equations,
dP1
dt
= HSC + s1P1 − d1P1 − a1P1,
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where HSC accounts for the cell inﬂux from the stem cell compartment, and for i = 2, . . . , n,
dPi
dt
= 2di−1Pi−1 + siPi − diPi − aiPi.
Dynamics of erythrocyte count satisﬁes
dM
dt
= dnPn − δM,
where δ is the natural mortality rate of erythrocytes.
Regulation of erythropoiesis is realised through several feedback controls, which are turned
on in stress situations, e.g. anaemia, lack of red blood cells. We introduce into the model two
growth factors, erythropoietin (Epo) and glucocorticoids (GC). Their dynamics are described
by
dEpo
dt
= fEpo(M)− kEpo Epo,
dGC
dt
= fGC(M)− kGC GC,
where kEpo and kGC are degradation constants, and fEpo and fGC are production terms, deter-
mined by the number of erythrocytes. We choose Michaelis-Menten functions to describe these
dependencies.
The rates are controlled through intracellular regulatory network, based on Erk and Fas.
We consider as well a direct inhibition of apoptosis by Epo, independently of the intracellular
network. Hence, functions the si, di and ai are deﬁned as
si = s(Ei, Fi), di = d(Ei, Fi), ai = a(Ei, Fi) faEpo(Epo),
The function faEpo describes a direct mechanism of apoptosis inhibition by Epo. We considered
Hill function to describe it.
We thus obtain two models of erythropoiesis. The ﬁrst one is a general model which can
be extended to haematopoiesis, it is presented in [40]. The second one contains more precise
description of the intracellular network involved in erythropoiesis regulation. The objective of
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this work is to evaluate the roles of the feedback controls in order to provide more insights into
the regulation of erythropoiesis. This work is presented in [35].
For each model we ﬁnd steady states and their stability using Implicit Function Theorem.
To test the models, we carry out computer simulations of anaemia, that is a lack of red blood
cells. The obtained results are confronted with experimental data on induced by phenylhydra-
zine anaemia in mice, see Figure 20. The second model allows the conclusion that feedback by
Epo on apoptosis rate, independently of the intracellular network based on Erk and Fas, is de-
terminant during early stages after anaemia induction, whereas intracellular regulatory network
is important later. These two models can be found in Chapter I.
Spatial models of erythropoiesis. Bone marrow has a particular structure. Current re-
search in this ﬁeld provides more and more insights into its spatial composition. A part of the
work is dedicated to spatial models of erythropoiesis.
We describe erythropoiesis by a system of reaction-diffusion-convection equations in a po-
rous medium,
∂ci
∂t
+∇.(civ) = dΔci + k(ci−1 − ci), i = 1, . . . , n, c0 = 0,
ΔP = k(c1 + . . . + cn), ∇P = νv,
which is considered in the domain
Ω = (0, Lx)× (0, Ly)
with boundary conditions
∂P
∂x
(0, y) = 0,
∂P
∂y
(x, 0) = 0,
∂P
∂y
(x, Ly) = 0, P (Lx, y) = 0,
c1(0, y) = 1,
∂c1
∂y
(x, 0) = 0,
∂c1
∂y
(x, Ly) = 0,
∂c1
∂x
(Lx, y) = 0,
∂ci
∂x
(0, y) = 0,
∂ci
∂y
(x, 0) = 0,
∂ci
∂y
(x, Ly) = 0,
∂ci
∂x
(Lx, y) = 0,
i = 2, . . . , n.
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where ci denotes concentration of cells in i-th sub-population, v is the velocity of the medium,
d is diffusion coefﬁcient. Reaction functions are determined from the populational model intro-
duced above.
Using Leray-Schauder method we prove the existence of a stationary solution in 1D case,
that is a solution of the following system,
dc′′i − (cip′)′ + k(ci−1 − ci) = 0, i = 1, ..., n, c0 = 0
p′′ = ν
(
n−1∑
k=1
(si + di)ci + (sn − dn)cn
)
,
together with the boundary conditions
c1(0) = 1, c
′
i(0) = 0 i = 2, ..., n,
c′i(L) = 0, i = 1, .., n,
p′(0) = 0, p(0) = 0.
To do so we introduce the following homotopy,
dc′′i − τ(cip′)′ + (τ2di−1ci−1 − bici) = 0, c0 = 0, i = 1, ..., n, τ ∈ [0, 1],
p′′ = ν
n∑
k=1
kici,
and ﬁnd a priori estimates of solutions of this system, which allows the application of Leray-
Schauder method.
Computer simulations in 2D case are carried out using COMSOL MULTIPHYSICS software.
In leukaemic case, malignant cells propagate as a travelling wave. We describe their distribution
in the bone marrow the following equation,
∂s
∂t
+∇.(sv) = dsΔs + kss,
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with the same boundary conditions as for other cells,
∂s
∂x
(0, y) = 0,
∂s
∂y
(x, 0) = 0,
∂s
∂y
(x, Ly) = 0,
∂s
∂x
(Lx, y) = 0.
We calculate wave speed of malignant cell propagation in two ways, using direct numerical
calculations and analytical approximations. We then compared results of the two methods of
wave speed calculation. This work was presented in the paper [41].
Cells in the bone marrow exchange bio-chemical signals. This communication has direct
impact on cell behaviour and is important for erythropoiesis regulation. A cell can perceive
signals from other cells that are located in certain neighbourhood. We study the existence of
a solution of the following non-local reaction-diffusion equation, which describes such a cell
communication,
∂u
∂t
=
∂2u
∂x2
+ J(u) u(1− u)− αu, x ∈ R,
where
J(u) =
∫ ∞
−∞
φ(x− y)u(y, t)dy.
Here φ(x) is a non-negative function with a bounded support, φ(x − y) shows how the cells
located at the point y inﬂuence the cells located at the point x.
We prove the existence of solution in the form of travelling wave u(x, t) = w(x − ct).
In [10] the authors proved the existence of solutions in the form of monotone travelling waves
for a similar integro-differential equation, in which function φ had a small support [−ε0, ε0].
We construct a homotopy with parameter τ ∈ [0, 1] that relies our equation to the equation with
function φ having a small support. A solution in the form of travelling wave satisﬁes
w′′ + cw′ + Jτ (w)w(1− w)− αw = 0 (0.1)
with
Jτ (u) =
∫ ∞
−∞
φτ (x− y)u(y)dy,
where
φτ (x) =
(ε0 − 1)τ + 1
ε0
φ
(
((ε0 − 1)τ + 1)x
ε0
)
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We are interested in solutions with the following conditions at inﬁnities,
lim
x→±∞
w(x) = w±. (0.2)
We work in Hölder weighted spaces. Obviously, any function u ∈ Ck+αμ (R) tends to zero
at inﬁnity. On the other hand, we look for solutions of Equation (0.1) with the limits (0.2).
Therefore, we introduce an inﬁnitely differentiable function ψ(x) such that ψ(x) = w+ for
x  1 and ψ(x) = w− for x  −1 and put w = u + ψ. Hence we can write Equation 0.1 in the
form
(u + ψ)′′ + c(u + ψ)′ + J(u + ψ)(u + ψ)(1− u− ψ)− α(u + ψ) = 0.
We consider the operator A(u) corresponding to the left-hand side of the previous equation,
Aτ (u) = (u + ψ)
′′ + c(u + ψ)′ + Jτ (u + ψ)(u + ψ)(1− u− ψ)− α(u + ψ)
Again, we use Leray-Schauder method to prove the existence of waves. In order to construct
the topological degree for operator Aτ (u) acting in weighted Hölder spaces,
A : C2+αμ (R) → Cαμ (R), μ(x) = 1 + x2
with norms
‖u‖C2+αμ (R) = ‖uμ‖C2+α(R),
we demonstrate that it is proper and its linearised operator L is Fredholm with zero index. Note
that due to the invariance of solutions u(x + h) obtained by a translation of the solution u(x),
they are not bounded in the weighted Hölder space C2+αμ (R). This makes impossible to ﬁnd a
priori estimate of solutions. In order to get rid of this invariance, we apply a functionalisation
of parameter c. We introduce functional
c(u) = ln
∫
R
(u(x) + ψ(x)− w+)2σ(x)dx,
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where σ(x) is an increasing function, with σ(−∞) = 0, σ(+∞) = 1 and
∫ 0
−∞
σ(x)dx < ∞.
We ﬁnd a priori estimates of solutions that allows the application of Leray-Schauder method [42].
These two models can be found in Chapter II.
Individual based modelling approach. Cell-to-cell communications are very important
for the erythropoiesis regulation. One of the appropriate approaches that would allow taking
into account this communication is the individual based modelling. This considers each cell as
an independent element of the whole system and, thus, allows considering communications of
every single cell with its neighbours that can provide additional insights into the behaviour of
cell populations.
In Section 10 a multi-agent software that describes such a communication is presented [20].
It allows us to numerically study spatial distribution of erythroid progenitors in the bone mar-
row, see Section 11. Using this software we demonstrate that cell division can generate random
cell motion, see Section 12. Random cell motion, in turn, can be described by a diffusion term
when dealing with continuous models [19]. This modelling together with the description of the
software are presented in Chapter III.
PK/PD modelling of AML treatment with AraC. Acute myeloid leukaemia, known also
as non-lymphocytic or myelogenous leukaemia, is a type of leukaemia characterised by abnor-
mal proliferation of immature myeloid cells. One of the most common and effective chemo-
therapeutic agents against AML is AraC (cytosine arabinoside, cytarabine), which is used in
combination with other drugs. Pharmacokinetics-pharmacodynamics approach is one of mo-
dern ways to study drug efﬁciency for treatment of certain diseases. The last part of the work is
devoted to the PK/PD modelling of AML treatment with AraC.
We built a mathematical model of AraC distribution in the body and of its action. The mo-
del consists of two parts. First part describes pharmacokinetics of AraC, that is drug delivery
to the bone marrow, penetration through cell membrane and its metabolism, which is a set of
interactions between the drug and intracellular proteins, its degradation, phosphorylation and
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deamination. We consider AraC distribution between two compartments, blood and bone mar-
row. Using Michaelis-Menten kinetics we describe metabolism of AraC. Its scheme is presented
in Figure 6. Dynamics of extracellular AraC concentration in blood (ab) and in bone marrow
(am) are given by
dab
dt
= I(t)− kbm(ab − am)− γbab,
dam
dt
= kbm(ab − am)− khENT1(am − ami)− γmam,
where I(t) determines treatment protocol, γb and γm are clearance constants in blood and
in bone marrow, kbm describes the rate of AraC distribution between the two compartments,
khENT1 describes thansmembrane transport of AraC in the bone marrow. This simple model
allows us to take into account transmembrane transport of AraC.
Dynamics of intracellular AraC (ami) and AraCTP (ap3) concentrations are given by
dai
dt
= khENT1(a− ami)− r˙p + r˙dp − r˙da,
dap3
dt
= (r˙p − r˙dp)/α˜,
where phosphorylation rate of AraC is given by
r˙p ≡
[
d(ap1 + ap2 + ap3)
dt
]
p
=
Vk
1 + Km
ami
(
1 + c
Ki
+ dC
KI
+ ap3
K′i
)
+ Km
(
c
KiK′m
+ ap3
K′iK′′m
) ,
dephosphorylation rate is given by
r˙dp ≡
[
d(ap1 + ap2 + ap3)
dt
]
dp
=
(
1 +
1
α1α2
+
1
α1
)[
d ap3
dt
]
dp
=
Vdp
1 +
α1α2Kdp
ap3
,
and deamination rate is given by
r˙da =
da
dt
=
Vda
1 + Kda
ami
.
Second part of the modelling is pharmacodynamics. We consider the following spatial mo-
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FIGURE 6 – The metabolism of AraC, adapted from [76].
del of erythroleukaemia,⎧⎪⎪⎨⎪⎪⎩
∂P
∂t
= DP
∂2P
∂x2
+ H + (s− d)P (P0 − P −Q)− aP,
∂Q
∂t
= DQ
∂2Q
∂x2
+ (sm − dm)Q(P0 − P −Q)− amQ,
where P denotes normal cell population and Q denotes malignant cell population, H denotes
the inﬂux of haematopoietic stem cells, s, d and a are respectively self-renewal, differentiation
and apoptosis rates (sm, dm and am are the rates for malignant cells). We suppose that cell
concentrations cannot surpass certain threshold value P0. We ﬁnd conditions of existence of
leukaemic equilibrium (P ∗m, Q
∗
m) for the system without diffusion terms. Then we demonstrate
that this equilibrium is globally assimptotically stable in the sense that any solution with the ini-
tial condition (P0(x), Q0(x)), where P0(x)  ε, Q0(x)  ε, ε is a positive constant, converges
uniformly to (P,Q) = (P ∗m, Q
∗
m) as t →∞.
We describe the drug action as a dependence of the three rates on AraCTP concentration.
s = s(ap3), d = d(ap3), a = a(ap3),
We then carry out simulations of WBPBPK model and PK/PD and test different treatment pro-
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tocols. The work has been developed in the frame of ANR project AnaTools and is presented in
Chapter IV.
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Première partie
Multi-scale Modelling of Erythropoiesis
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This part of the work is devoted to mathematical modelling of erythropoiesis. We propose
two multi-scale models, in which we bring together erythroid progenitor dynamics and intra-
cellular regulatory network that determines erythroid cell fate. First model is based on a general
bistable system which describes intracellular regulatory network. In the second model we des-
cribe intracellular regulatory network as a set of chemical reactions. All erythroid progenitors
are divided into several sub-populations according to their maturity. Two intracellular proteins,
Erk and Fas, are supposed to be determinant for regulation of self-renewal, differentiation and
apoptosis. We consider two growth factors, erythropoietin and glucocorticoids, and describe
their dynamics. Several feedback controls are introduced in the model. We carry out computer
simulations of anaemia and compare the obtained results with available experimental data on
induced anaemia in mice. The main objective of this work is to evaluate the roles of the feed-
back controls in order to provide more insights into the regulation of erythropoiesis. Feedback
by Epo on apoptosis is shown to be determinant in the early stages of the response to anaemia,
whereas regulation through intracellular regulatory network, based on Erk and Fas, appears to
operate on a long-term scale.
3 Intracellular regulatory network
In a recent paper, Rubiolo et al. [96] investigated the differentiation process of erythroid
progenitors. In particular, they identiﬁed key proteins involved in self-renewal and differentia-
tion/apoptosis, see Figure 7. Differentiation and apoptosis appear to be controlled by the same
proteins. In fact, different proteins are involved both in cell differentiation and cell apoptosis,
however, depending on external conditions, cells undergo either differentiation or apoptosis.
For example, Epo has been shown to inhibit erythroid progenitor apoptosis [63]. Hence, when
Epo levels are low, erythroid progenitors preferentially die by apoptosis, whereas with high Epo
levels they differentiate.
Rubiolo et al. [96] showed that self-renewal was controlled by the self-activated cascade
Raf-1 - Mek - Erk, whereas differentiation was controlled by the cascade Fas - Ask-1 - Jnk/p38,
Fas triggering also cell apoptosis. This latter protein cascade is inhibited by the former, and
vice versa. Hence erythroid progenitor self-renewal and differentiation/apoptosis processes are
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FIGURE 7 – Summary of intracellular protein interactions that determine erythroid progenitor
fate, partially adapted from [96].
controlled by two inhibitor loops, one being self-activating. Two proteins are of particular inter-
est : Erk and Fas. The former is the cornerstone of the inhibition of differentiation and apoptosis.
Erk (Extracellular signal-Regulated Kinase) is a member of the MAPK family, also known as
the classical MAP kinase, it regulates cell proliferation and differentiation. Fas belongs to the
tumour necrosis factor family (TNF), it induces cell apoptosis. We focus our attention on the
interaction between these two proteins, that are key regulators of erythroid progenitor fate.
As mentioned in Figure 7, external signals activate intracellular proteins. Epo is known
to have the dual action of being both a mitogen and a survival factor [103]. The molecular
mechanisms involved have been clariﬁed (for a review, see [98]) : Epo prevents apoptosis of
erythroid progenitors through Stat5/GATA-1/Bcl-xL pathway [53], that is largely independent
of the ERK pathway [28, 79, 105]. Self-renewal promoting activity of Epo, on the contrary,
seems to rely mainly on the activation of the ERK kinase [96, 104]. We therefore decided to
integrate separately these two aspects of Epo action in the model : prevention of apoptosis is
modelled as a direct mechanism, i.e. the molecular players are not explicitly taken into account.
This feedback is assumed to be independent of the intracellular regulatory network based on
Erk and Fas interactions. This is introduced in Section 5.1, Equation (1.18). On the contrary,
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self-renewal is modelled as an ERK-dependent mechanism. GCs are involved in regulation of
stress erythropoiesis [13, 51]. They activate self-renewing loop by increasing the level of Raf-1
expression.
One source term of activation appears in Figure 7 concerning the differentiation/apoptosis
part. Fas-ligand, denoted by FasL, a membrane protein, activates the transmembrane protein
Fas. De Maria et al. [39] suggested the existence of a negative regulatory feedback between
mature and immature erythroid progenitors, in which mature cells exert a cytotoxic effect on
immature cells. Mature erythroid progenitors, called reticulocytes, express FasL, which stimu-
lates activation of Fas in immature erythroid progenitors. Sensitivity to FasL decreases with cell
maturation. Other external factors, such as c-Kit, the protein associated with the stem cell factor
(SCF) [77], proteins from the JAK family [114], etc., regulate the levels of activated intracellu-
lar proteins. Yet, we cannot take all these proteins into account, and we focus, in the following,
on Epo, GCs, and FasL.
Further we discuss two different approaches to describe the intracellular regulatory net-
work. First approach considers a bistable system that describes interaction between Erk and Fas
(Section 3.1). In the second approach we make transition from a linear system describing inter-
actions presented in Figure 7 to a nonlinear system that can have either monostable or bistable
behaviour depending on parameter values (Section 3.2). Consider the ﬁrst approach.
3.1 General bistable system
We focus our attention on two proteins, Erk and Fas, and we suppose that their expression
levels determine the values of self-renewal, differentiation and apoptosis rates. Note that these
proteins are present in cells in two forms, activated and inactivated. We are interested in the
activated protein forms. There exist maximum values for Erk and Fas activated forms that cannot
be surpassed. So, we denote by E the ratio of activated Erk form to its maximum value, by F
the ratio of Fas activated form to its maximum value. This guarantees the variables E and F to
be between 0 and 1, that is favorable for mathematical analysis and not limiting for modelling.
To describe the competition between Erk and Fas we consider the following system that has a
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bistable behaviour, ⎧⎪⎨⎪⎩
dE
dt
=(E − a)(b− E − c(F − a)),
dF
dt
=(F − a)(b− F − c(E − a)),
(1.1)
where a, b and c are positive constants, a < b and c > 1. The system has four steady states,
(E1, F 1) = (a, a), (E2, F 2) = (a, b), (E3, F 3) = (b, a), (E4, F 4) =
(
b+ac
1+c
, b+ac
1+c
)
. The
steady states (E2, F 2) and (E3, F 3) are stable. The steady state (E2, F 2) = (a, b) corresponds
to Fas domination, which means that the cell rather chooses differentiation or apoptosis than
self-renewal, and the steady state (E3, F 3) = (b, a) corresponds to Erk prevalence, which means
that the cell undergoes rather self-renewal. Thus (E3, F 3) is associated with cell proliferation,
whereas (E2, F 2) is associated with cell differentiation and apoptosis. The two other steady
states, (E1, F 1) and (E4, F 4), are unstable. A detailed mathematical analysis of a system similar
to the system above can be found in [78].
If in this system we add external sources of activation : the activation of ERK-cascade due
to Epo and GCs denoted by α and FasL-related activation of Fas denoted by γ, then it becomes,
⎧⎪⎨⎪⎩
dE
dt
=(E − a)(b− E − c(F − a)) + α,
dF
dt
=(F − a)(b− F − c(E − a)) + γ.
(1.2)
In the next section we consider a speciﬁc system that describes intracellular protein interac-
tions presented in Figure 7 as a set of chemical reactions.
3.2 From linear behaviour to bistability
Denote by R, M , E, F , A and J the levels of activated forms of Raf-1, Mek, Erk, Fas,
Ask-1 and Jnk/p38, respectively. We describe the reactions of either activation/suppression of
expression or activation by means of linear ordinary differential equations. Enzymatic activa-
tion is expressed by a positive linear term, whereas suppression of expression or suppression
of activation appears as a negative linear term. When modelling intracellular regulation me-
chanisms, external signal sources are considered as constants. We denote by λGC the source
of glucocorticoids stimulating Raf-1 activation, by λEpo the source of erythropoietin activating
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Erk, and by λFL the external source of FasL stimulating Fas activation. Then, the following
system describes the regulatory network summarised in Figure 7,⎧⎪⎪⎪⎪⎪⎪⎨⎪⎪⎪⎪⎪⎪⎩
dR
dt
= λGC + k1E − k2R, dF
dt
= λFL − k8E − k9F,
dM
dt
= k3R− k4M, dA
dt
= k10F − k11A,
dE
dt
= λEpo + k5M − k6E − k7J, dJ
dt
= k12A− k13J.
(1.3)
The last term in each equation stands for degradation. All constants ki, i = 1, . . . , 13, are
positive.
In order to focus on Erk and Fas dynamics, we suppose that all reactions except those for
Erk and Fas are rapid. This allows obtaining equations for Erk and Fas, while keeping all the
information contained in System (1.3). Rapid reactions are then in steady state with respect to
slow reactions, which provides⎧⎪⎪⎨⎪⎪⎩
R =
λGC + k1E
k2
, A =
k10
k11
F,
M =
k3
k4
R, J =
k12
k13
A.
(1.4)
Using values of R, M , J and A in (1.4) in equations for E and F in (1.3), the following linear
system describing interactions between activated Erk and activated Fas is obtained,
⎧⎪⎨⎪⎩
dE
dt
= α + βE − aE − bF,
dF
dt
= γ − cE − dF,
(1.5)
where
α = λEpo +
k3k5
k2k4
λGC , β =
k1k3k5
k2k4
, γ = λFL,
and
a = k6, b =
k7k10k12
k11k13
, c = k8, d = k9.
All coefﬁcients a, b, c, d and α, β, γ are nonnegative. First terms on the right hand side of
System (1.5) account for activation of Erk and Fas by external factors (α and γ) and by self-
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activation (βE). Other terms describe suppression of activation.
System (1.5) is a linear system of ordinary differential equations. It has a unique steady
state, whose stability depends upon the parameter values. We are particularly interested in the
instability of this steady state. Indeed, when it is unstable, either there is an unlimited growth of
activated Erk concentration, and the cell ﬁnally undergoes self-renewal, or an unlimited growth
of activated Fas concentration, and the cell undergoes either differentiation or apoptosis. In
reality, this growth is limited, due to cell division for instance. Hence, this linear system appears
well adapted to the description of Erk and Fas interactions, even if it is biologically limited.
Since we aim at using this system coupled with a description of cell population dynamics,
which is reported in Section 4, and also for the model to be more biologically realistic, we make
some additional assumptions on the dynamics of Erk and Fas concentrations.
First, as described in Figure 7, Fas acts on Erk by suppressing its expression and conversely
Erk suppresses Fas activation. In agreement with mass action law, we assume the rates of these
suppressions, coefﬁcients b and c in System (1.5), are proportional to the concentration of E and
F respectively, so that the terms −bF and −cE become −bEF and −cEF . This assumption
allows, in particular, the Problem (1.5) to be well-posed in the sense that E and F cannot
become negative contrary to the original system.
The second term in the right-hand side of the ﬁrst equation in (1.5), describing Erk self-
activation, is replaced with βEk, where k  1. This considers a nonlinear rate of Erk pro-
duction. The choice of this nonlinearity can be discussed. In particular, as observed in Fi-
gure 7, Erk self-activation is obtained through a kinase cascade, that could be appropriately
ﬁtted with Michaelis-Menten functions (smooth positive increasing s-shaped functions). Quali-
tatively, both assumptions are equivalent. Yet, the choice we make allows an easier analysis of
the ﬁnal System (1.6), and consequently its deeper study.
Third, due to limited resources, we assume there exist maximal values that limit productions
of Erk and Fas. Denote by E0 the maximum value of activated Erk, and by F0 the maximum
value of activated Fas. System (1.5) now reads as
⎧⎪⎨⎪⎩
dE
dt
= (α + βEk)(E0 − E)− aE − bEF,
dF
dt
= γ(F0 − F )− cEF − dF.
(1.6)
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To ﬁnd steady states of System (1.6), we should solve
dE
dt
= 0 and
dF
dt
= 0,
that is
F =
(α + βEk)(E0 − E)
bE
− a
b
and F =
γF0
cE + d + γ
. (1.7)
Depending on the parameter values, (1.7) can have one to three solutions. Indeed, denote by ξ
and χ the following functions,
ξ(E) =
(α + βEk)(E0 − E)
bE
− a
b
and χ(E) =
γF0
cE + d + γ
. (1.8)
Then one easily obtains that χ is a bounded positive decreasing function, mapping the interval
[0, E0] into [γF0/(cE0 + d + γ), γF0/(d + γ)]. The function ξ satisﬁes
lim
E→0
ξ(E) = +∞ and ξ(E0) = −a
b
< 0.
Consequently, System (1.6) has at least one steady state.
The analysis of the variations of function ξ, easy though tedious, shows that for some values
of the parameters ξ is decreasing, hence System (1.6) has only one steady state. For other para-
meter values however, ξ is not monotonous and up to three steady states may exist. In particular,
to obtain existence of three steady states it is necessary that k > 1.
The case of three steady states is shown in Figure 8. The points A and C are stable nodes,
the point B is a saddle. The point A corresponds to high levels of activated Fas and low levels
of activated Erk, whereas the point C corresponds to low levels of activated Fas and high levels
of activated Erk. Hence, the point A is associated with erythroid progenitor differentiation or
apoptosis, the point C with erythroid progenitor self-renewal.
The basins of attraction of the points A and C are separated by the separatrix of the point
B. If the initial condition is chosen in a random way on the plane (E,F ), then the probability
for the trajectory to go to the point A or to the point C depends on the areas of their basins of
attraction. Let us denote these probabilities by pA and pC , respectively. It can be easily veriﬁed
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FIGURE 8 – Curves deﬁned by (1.8). Three intersection points determine steady states of Sys-
tem (1.6). Two of them, A and C, are stable.
that pA increases with the increase of γ and decreases with the increase of α. Moreover,
pA =
⎧⎨⎩ 0, if γ  γ1,1, if γ  γ2,
where γ1 and γ2 are some given values, γ1 < γ2, which depend on α. We note that pA +
pC = 1. Hence, if γ is sufﬁciently large the erythroid progenitor will undergo differentiation or
apoptosis, whereas if γ is sufﬁciently small it will self-renew.
When there is only one steady state, it is asymptotically stable, and corresponds either to a
high level of activated Fas (with low level of activated Erk), or to a high level of activated Erk
(with low level of activated Fas). These situations may be obtained when γ > γ2, for instance,
or γ < γ1. Equivalently, this corresponds to a movement upwards of the curve F = χ(E) in
Figure 8 (γ > γ2) or downwards (γ < γ1).
If α and γ are not constant but dynamically depend on growth factors, then, during a res-
ponse to a stress, values of α and γ can be such that temporarily System (1.6) goes from three
steady states to only one steady state, and all cells undergo either self-renewal or differentia-
tion/apoptosis.
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4 Erythroid progenitor dynamics
Since erythroid cell sensitivity to external signals strongly depends on the maturity, we
consider several erythroid progenitor differentiation stages, called sub-populations, characteri-
sed by their maturity. We suppose there are n erythroid progenitor sub-populations, with n > 1
ﬁxed. Let us denote by Pi, i = 1, . . . , n, the number of progenitors in the i-th sub-population
per μl of blood, and by si, di and ai their rates of self-renewal, differentiation and apoptosis,
respectively. For the sake of simplicity we consider only symmetric cell division. Then, proge-
nitor self-renewal produces two daughter cells with the same maturity as the mother cell, thus,
the two cells belong to the same sub-population. Differentiation produces two cells, which are
more mature, and then belong to the next sub-population, see Figure 9. Dynamics of erythroid
FIGURE 9 – Differentiation scheme of erythroid progenitors. Pi, i = 1, . . . , n, denotes the
number of progenitors in the i-th sub-population per μl of blood, and by si, di and ai their rates
of self-renewal, differentiation and apoptosis, respectively.
progenitors are described by the following system of differential equations,
dP1
dt
= HSC + s1P1 − d1P1 − a1P1, (1.9)
where HSC accounts for the cell inﬂux from the stem cell compartment, and for i = 2, . . . , n,
dPi
dt
= 2di−1Pi−1 + siPi − diPi − aiPi. (1.10)
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Moreover, we denote by M the number of erythrocytes per μl of blood, which satisﬁes
dM
dt
= dnPn − δM, (1.11)
where δ is the natural mortality rate of erythrocytes.
The term red blood cell (RBC) refers to an erythroid cell which circulates in the blood
ﬂow and carries oxygen to tissues. It can be an erythrocyte or a reticulocyte. During normal
erythropoiesis very few reticulocytes circulate in the blood. For this reason and since we do
not consider spatial aspects of erythropoiesis that could allow distinguishing between circu-
lating reticulocytes and reticulocytes in the bone marrow, we assume that RBC count equals
erythrocyte count. RBC count is determinant for the release of various growth factors in the
blood stream. For instance, due to a lack of oxygen, kidneys release Epo. RBCs also induce
the release of glucocorticoids in stress situations [13]. Denote by Epo and GC the blood le-
vels of erythropoietin and glucocorticoids respectively. They are supposed to satisfy ordinary
differential equations [15, 71],
dEpo
dt
= fEpo(M)− kEpo Epo, (1.12)
dGC
dt
= fGC(M)− kGC GC, (1.13)
where kEpo and kGC are degradation constants, and fEpo and fGC are production terms. They
depend on the number of erythrocytes, and are supposed to be positive, bounded, decreasing
functions, since the more erythrocytes the lower erythropoietin and glucocorticoid levels.
In the next section we couple intracellular protein dynamics with cell population dynamics,
and obtain multi-scale models of erythropoiesis.
5 Models of erythropoiesis
5.1 Coupling the two scales
To simplify the modelling, we neglect variations in cell cycle durations, so cell cycle lengths
are supposed to be constant, equal to Tc. Each cell cycle ends up with either self-renewal,
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differentiation or apoptosis. Then, on every time unit
si + di + ai =
1
Tc
.
Since erythroid progenitors perform one cell cycle in about 24 hours [36], and the time unit
considered in this paper is also 24 hours, we suppose Tc = 1 and the above equality becomes
si + di + ai = 1. (1.14)
Let us specify how these rates are deﬁned. This is used later in this section and in Section 6.
Denote by ps the probability of self-renewal provided that the cell does not undergo apoptosis.
Then the probability of differentiation pd, provided that the cell does not undergo apoptosis, is
pd = 1 − ps. Since cell cycle time is ﬁxed and equals one time unit, we can then write s and d
(subscripts are deliberately omitted) as
s = (1− a)ps, d = (1− a)(1− ps). (1.15)
The term 1−a accounts for the rate of survival to apoptosis. Consequently, s denotes the overall
self-renewal rate, which is in fact expressed by the probability of self-renewal of non-apoptotic
cells ps multiplied by the rate of survival 1− a. The same holds for the differentiation rate.
As described in Section 3, self-renewal, differentiation and apoptosis rates depend on one
hand on the intracellular protein regulatory network inherent to each erythroid progenitor, and
on another hand apoptosis is inhibited by Epo. Proteins Erk and Fas have been previously identi-
ﬁed as the main regulators of erythroid progenitor fate, see Section 3. Erk induces self-renewal,
and inhibits differentiation and apoptosis, whereas Fas inhibits self-renewal and induces dif-
ferentiation or apoptosis, depending on Epo blood concentration. In the ﬁrst model, concen-
trations of Erk and Fas, denoted by E and F , satisfy System (1.2), in the second model the
satisfy System (1.6), where constants α and γ account for external sources of Erk and Fas ac-
tivators, respectively. As mentioned in Section 3, the source of Erk activator consists mainly in
erythropoietin and glucocorticoids. Hence, we assume α is an increasing function of Epo and
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GC,
α = α(Epo,GC).
Parameter γ stands for activation of Fas by FasL, which is expressed on surface of reticulocytes.
Hence, we assume γ depends on Pn, which correspond to reticulocytes, and the sensitivity of γ
to Pn decreases with maturity level i, so that
γ = γi(Pn),
and γi is a positive, bounded and increasing function.
Finally, before stating the system veriﬁed by concentrations E and F , let us present the last
assumption. As explained in the previous section, quantities of Erk and Fas are supposed to
have maximum values, denoted by E0 and F0 respectively. Usually, exact quantities of Erk and
Fas in erythroid cells cannot be measured, rather relative levels of activated Erk and Fas are
provided. Hence, in order to render this model more comprehensible, we normalise activated
Erk and Fas quantities, denoting by E and F the ratios E/E0 and F/F0. This guarantees the
variables E and F to be between 0 and 1. Thus, Ei and Fi, the levels of activated Erk and Fas
in the i-th progenitor sub-populations, satisfy the following system, obtained from (1.6),
⎧⎪⎨⎪⎩
dEi
dt
=
(
α(Epo,GC) + βEki
)
(1− Ei)− aEi − bEiFi,
dFi
dt
= γi(Pn)(1− Fi)− cEiFi − dFi,
(1.16)
where β, a, b, c and d respectively stand for βEk0 , aE0, bE0F0, cE0F0 and dF0. Note that all
cells of a sub-population are assumed to express the same levels of activated Erk and Fas. This
is a strong hypothesis, because in reality, different progenitors with the same maturity express
different levels of Erk and Fas indicating stochasticity in protein expression. This stochasticity
certainly plays an important role in erythropoiesis, yet in this model we do not take it into
account.
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The same normalisation can be done for System (1.2),
⎧⎪⎨⎪⎩
dE
dt
=(E − a)(b− E − c(F − a)) + α(Epo,GC),
dF
dt
=(F − a)(b− F − c(E − a)) + γi(Pn).
(1.17)
For example, for the ﬁrst equation of the system, if α = 0, then E < b if initial condition
Einit < E0 = b. If α > 0, then E < E0 = 0.5(a + b +
√
(a− b)2 + 4αmax). So we solve this
system, obtain (E,F ) and do the normalisation to use (E,F ) in the system.
One may observe the complexity of erythropoiesis through the model we propose. Ery-
throid progenitors and erythrocytes contribute to the control of growth factor concentrations in
blood, which in turn regulate intracellular mechanisms of cell fate (self-renewal, differentiation,
apoptosis). We complete the model of erythropoiesis by specifying how intracellular regulatory
mechanisms inﬂuence erythroid progenitor fate.
As described in Section 3, self-renewal, differentiation and apoptosis rates depend on le-
vels of activated Erk and Fas, denoted by Ei and Fi, the subscript i referring to a given sub-
population. Moreover, apoptosis rate is also inhibited by Epo independently of the intracellular
network based on Erk and Fas. Hence, functions si, di and ai are deﬁned as
si = s(Ei, Fi), di = d(Ei, Fi), ai = a(Ei, Fi) faEpo(Epo), (1.18)
where functions s, d and a deﬁne self-renewal, differentiation, and apoptosis rates, respectively,
for given Erk and Fas levels. The function faEpo describes a direct mechanism of apoptosis
inhibition by Epo, which is independent of the intracellular regulatory network. It is assumed to
be bounded, positive and decreasing.
Dynamics of erythroid progenitors, described by Equations (1.9)–(1.10), are then coupled
to protein levels (1.17) in the ﬁrst model (to protein levels (1.16) in the second model) through
erythrocyte dynamics in (1.11), growth factor concentration evolution in (1.12)–(1.13), and self-
renewal, differentiation and apoptosis rates deﬁnitions in (1.14) and (1.18). This set of equations
forms the multi-scale models of erythropoiesis we study below.
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5.2 Existence of steady states
5.2.1 General bistable model
We begin with the analysis of the system consisting of (1.9)-(1.11), (1.1) written for each
cell sub-population and (1.12)-(1.13). Denote this system by Σ1. Once the system is examined,
we establish the correspondence between the steady states of the System Σ1 and the steady
states of the System (1.9)-(1.11), (1.17), (1.12)-(1.13) (denoted by Σ2). This allows us to ﬁnd
steady states of the System Σ2 and their stability.
The System Σ1 is decoupled into three parts (because the System (1.1) does not contain
the terms α(Epo,GC) and γi(Pn)). The ﬁrst one describes Erk-Fas interaction, the second one
describes sub-population dynamics and the third one describes Epo and GCs dynamics. Denote
by (E∗i , F
∗
i ) the values of (Ei, Fi) in a steady state, i = 1, . . . , n, and introduce the notations
s∗i = s(E
∗
i , F
∗
i ), d
∗
i = d(E
∗
i , F
∗
i ), a
∗
i = a(E
∗
i , F
∗
i )faEpo(Epo
∗).
Then (P ∗1 , . . . , P
∗
n ,M
∗), given by
P ∗1 =
HSC
d∗1 + a
∗
1 − s∗1
, P ∗i =
2d∗i−1P
∗
i−1
d∗i + a
∗
i − s∗i
, i = 2, . . . , n, M ∗ =
d∗nP
∗
n
δ
,
is the corresponding steady state of the second subsystem. The condition of the existence of
this steady state, taking into account (1.14), is s∗i < 1/2, i = 1, . . . , n, i.e. during normal
erythropoiesis erythroid progenitors self-renew with a rate less than 50%.
Finally, (Epo∗, GC∗), given by
Epo∗ =
fEpo(M
∗)
kEpo
, GC∗ =
fGC(M
∗)
kGC
,
is the corresponding steady state of the third subsystem. Since System (1.1) has 4 steady states
and we consider n cell sub-populations, we conclude that the System Σ1 has 4n steady states.
To study their stability we linearise the system about a steady state. The resulting matrix is
decoupled into three sub-matrices (one part corresponds to the ﬁrst subsystem, one part to the
second subsystem and one part to the third subsystem, see Figure 10). The second sub-matrix
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FIGURE 10 – Matrix of the System Σ1 linearised about one of its steady states (see text for
details). Symbol x stands for a non-zero element. The matrix has three sub-matrices located on
its diagonal and zeros above. First sub-matrix corresponds to the subsystem describing Ei, Fi
interactions, second sub-matrix corresponds to the cell sub-population dynamics and the third
one corresponds to the growth factor dynamics. Eigenvalues of this matrix are eigenvalues of
the three sub-matrices.
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is a triangle matrix with negative diagonal elements, the third sub-matrix is a diagonal matrix
with negative diagonal elements. So all eigenvalues of the linearised matrix, except maybe the
eigenvalues of the ﬁrst sub-matrix, are negative real numbers. Hence the eigenvalues of the ﬁrst
sub-matrix determine stability of the full System Σ2.
The ﬁrst sub-matrix contains n times the matrix of the System (1.1) linearised about one of
its steady states, once for each cell sub-population. We have noted that the stable steady states
of the System (1.1) are (E∗, F ∗) = (α, β) and (E∗, F ∗) = (β, α). This means that stable steady
states of the System Σ1 are determined by (E∗i , F
∗
i ) = (α, β) and (E
∗
i , F
∗
i ) = (β, α), i =
1, . . . , n. Since only two of four steady states of the System (1.1) are stable, the System Σ1
has 2n stable steady states. Then the System Σ2, like the System Σ1, has also 2n stable steady
states deﬁned by (E˜∗i , F˜
∗
i ), i = 1, . . . , n, that are small perturbations of those mentioned above.
Consequently, some sub-populations are characterised by a domination of Erk, the others by a
domination of Fas. Let us discuss some biological limitations that we have to take into account.
During the process of maturation, erythroid progenitors lose their ability to self-renew [38],
thus immature cells are more inclined to self-renewal and mature ones are more inclined to diffe-
rentiation. Hence, among all possible stable steady states only those which are characterised by a
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certain integer number k, 1  k  n, such that cells in sub-populations P1, . . . , Pk−1 preferen-
tially self-renew (Erk dominates in cells of these sub-populations) and cells in sub-populations
Pk, . . . , Pn preferentially differentiate (Fas dominates in cells of these sub-populations) are bio-
logically reasonable. It reduces the number of biologically meaningful stable steady states to n.
It seems natural to expect that in normal erythropoiesis the number of mature cells is larger than
the number of immature cells, so we impose the conditions P ∗i > P
∗
i−1, that are equivalent to
2d∗i−1
1− 2s∗i
> 1, i = 2, . . . , n.
Thus the multi-scale model has, generally speaking, several (from 1 up to n) stable steady states
that satisfy all biological conditions discussed above.
5.2.2 Model with erythropoiesis-speciﬁc intracellular system
We investigate the existence of steady states for the system formed with (1.9)–(1.14), (1.16)
and (1.18). It should be noted that existence of such solutions is not straightforward. Indeed, de-
note by P ∗i the steady state values of (1.9)–(1.10), M
∗ the steady state value of (1.11), Epo∗ and
GC∗ the steady state values of (1.12)–(1.13), and E∗i and F
∗
i the steady state values of (1.16).
We also introduce the notations
s∗i = s(E
∗
i , F
∗
i ), d
∗
i = d(E
∗
i , F
∗
i ), a
∗
i = a(E
∗
i , F
∗
i )faEpo(Epo
∗).
Then, P ∗i , i = 1, . . . , n, exist if and only if⎧⎨⎩ (d∗1 + a∗1 − s∗1)P ∗1 = HSC,(d∗i + a∗i − s∗i )P ∗i = 2d∗i−1P ∗i−1, i = 2, . . . , n.
Hence, using (1.14), P ∗i exists for i = 1, . . . , n provided that
s∗i <
1
2
,
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and P ∗i is given by
P ∗1 =
HSC
1− 2s∗1
, P ∗i =
2d∗i−1
1− 2s∗i
P ∗i−1, i = 2, . . . , n.
Then, M∗, Epo∗ and GC∗ are uniquely deﬁned by
M∗ =
d∗n
δ
P ∗n , Epo
∗ =
fEpo(M
∗)
kEpo
, GC∗ =
fGC(M
∗)
kGC
.
Yet, implicitly, all the above steady state values, and in particular P ∗n , Epo
∗ and GC∗, are func-
tions of E∗i and F
∗
i , for i = 1, . . . , n, through the steady state values of the different rates s
∗
i , d
∗
i
and a∗i . Since E
∗
i and F
∗
i are solutions of system⎧⎨⎩
(
α(Epo∗, GC∗) + β(E∗i )
k
)
(1− E∗i )− aE∗i − bE∗i F ∗i = 0,
γi(P
∗
n)(1− F ∗i )− cE∗i F ∗i − dF ∗i = 0,
which has been shown to have 1 to 3 solutions when α and γ are constant (see Section 3.2), it
follows that determining steady states for the full model is equivalent to solving a system in the
form ⎧⎨⎩ E∗i = ϕi(E∗1 , . . . , E∗n, F ∗1 , . . . , F ∗n),F ∗i = ψi(E∗1 , . . . , E∗n, F ∗1 , . . . , F ∗n),
for all i = 1, . . . , n. Functions ϕi and ψi are some unknown functions. In a general case such a
system cannot be solved.
For the sake of simplicity, suppose α is given by
α(Epo,GC) = α0 + f(Epo) + g(GC),
where α0 > 0 accounts for Erk activation when erythropoietin and glucocorticoids are low.
Since erythropoietin and glucocorticoids are not the only activators of Erk, this assumption is
biologically reasonable. Functions f and g are bounded nonnegative increasing functions, for
instance, of Michaelis-Menten type, with f(0) = g(0) = 0. Similarly, suppose γi is given by
γi(Pn) = γ0 + μiγ¯(Pn),
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where γ0 is a constant source of Fas activation independent of mature progenitor cell production
of Fas ligand, and μi is a parameter accounting for sensitivity of Fas activation to cell maturity.
The function γ¯ is assumed to be nonnegative, bounded and increasing, with γ¯(0) = 0 and
γ(Pn)  1.
With these assumptions, we can apply the Implicit Function Theorem to ﬁnd steady states of
the full model. Suppose that in the steady state, values of Epo∗ andGC∗ are such that f(Epo∗)+
g(GC∗) is very small, close to zero. Moreover, μi are supposed to be small parameters.
We ﬁrst note that the following system,⎧⎨⎩
(
α0 + β(E
∗
i )
k
)
(1− E∗i )− aE∗i − bE∗i F ∗i = 0,
γ0(1− F ∗i )− cE∗i F ∗i − dF ∗i = 0,
(1.19)
has one to three solutions, depending on the values of α0 and γ0. This has been obtained in
Section 3.2, for α = α0 and γ = γ0, see System (1.7). Denote by (E∗,0, F ∗,0) one of these
potential solutions. Then for every pair (E∗,0, F ∗,0), there exists a unique value of s∗i , d
∗
i and a
∗
i ,
and consequently of P ∗i , i = 1, . . . , n, M
∗, Epo∗ and GC∗.
As μi increases away from zero, the Implicit Function Theorem gives the existence of steady
states for the full model. These steady states are small perturbations of the above mentioned
steady states, based on (E∗,0, F ∗,0). Hence, stability does not change, and steady states of the
full system are stable (respectively, unstable) if steady states of (1.9)–(1.14), (1.18) and (1.19)
are stable (respectively, unstable). And (1.19) has up to 2 stable steady states for all i = 1, . . . , n.
We can then state that full system formed with (1.9)–(1.14), (1.16) and (1.18) has up to 2n
stable steady states. This number may appear large, yet it does not take into account biological
constraints.
During the process of maturation, erythroid progenitors lose their ability to self-renew [38],
thus immature cells are more inclined to self-renewal and mature ones are more inclined to
differentiation. Hence, among all possible stable steady states only those, characterised by a
certain integer j, 1  j  n, such that cells in the ﬁrst j sub-populations (corresponding to
variables P1 to Pj) preferentially self-renew (let us call them self-renewing sub-populations),
and cells in the last n− j sub-populations (corresponding to variables Pj+1 to Pn) preferentially
differentiate (let us call them differentiating sub-populations), are biologically reasonable. It
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reduces the number of biologically meaningful stable steady states to n. Moreover, it seems
natural to expect that in normal erythropoiesis the number of mature cells is larger than the
number of immature cells, so we impose the conditions P ∗i < P
∗
i+1, which are equivalent to
2d∗i
1− 2s∗i+1
> 1, i = 1, . . . , n− 1.
Thus the multi-scale model formed with (1.9)–(1.14), (1.16) and (1.18) has, generally speaking,
several (from 1 up to n) stable steady states, which satisfy the biological constraints discussed
above.
The next section is devoted to numerical simulations. The attention is focused, in particular,
on anaemia situations.
6 Simulations of anaemia
A typical situation of stress erythropoiesis is anaemia : a lack of red blood cells, or haemo-
globin. It can be either induced, for instance by killing erythrocytes, which can be obtained with
phenylhydrazine, or by bleeding, or disease-related. A number of haematological diseases are
characterised by or associated with severe anaemia, such as aplastic anaemia or some leukae-
mias.
6.1 General bistable model
To carry out simulations we have to specify the shape of the functions s(E,F ), d(E,F ),
a(E,F ) and faEpo(Epo) in (1.18). We suppose that α(Epo,GC) = α0 + f(Epo) + g(GC), so
we should specify fE(Epo), fG(GC). We suppose as well that γi(Pn) = μiγ(Pn). We should
specify as well fEpo(M) in (1.12) and fGC(M) in (1.13). To deﬁne the functions s(E,F ) and
d(E,F ) it is sufﬁcient to ﬁx ps(E,F ) and a(E,F ), see (1.15). For simplicity we consider that
the functions ps(E,F ) and a(E,F ) are functions of one variable, ps(E,F ) = ps(F − E) and
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TABLE 1 – Parameters for functions deﬁned by (1.20). Functions of two types (Hill and
Michaelis-Menten) are described in the table. Parameter b expresses the maximum value, para-
meter θ is a threshold value, with the same units as function variable units, parameter n is the
sensitivity (dimensionless quantity). Parameter units are speciﬁed in parenthesis after the value.
function name function type b θ n
f˜aEpo(Epo) Hill 1.2 6.3 (U.ml−1) 3
fE(Epo) Michaelis 0.04 (d−1) 100 (U.ml−1) 6
fG(Epo) Michaelis 0.03 (d−1) 250 (U.ml−1) 10
fF (Pn) Michaelis 1 (d−1) 20 (cells. μl−1) 1
fEpo(M) Hill 7130 (U.ml−1.d−1) 225 (cells. μl−1) 7
fGC(M) Hill 2930 (U.ml−1.d−1) 320 (cells. μl−1) 6
a(E,F ) = a(F − E). We consider
⎧⎪⎪⎨⎪⎪⎩
a(x) = (amax − amin) (x + 1)
na
1 + (x + 1)na
+ amin
ps(x) = (smax − smin) 1
1 + (x + 1)ns
+ smin
, x ∈ [−1, 1],
with amin = 0.1 d−1, amax = 0.48 d−1, smin = 0.1, smax = 0.57 and na = 6, ns = 5.
Functions fE(Epo), fG(GC), fF (Pn) , fEpo(M) and fGC(M) are either Hill or Michaelis-
Menten functions (g1 and g2 in (1.20) respectively) and are deﬁned by three parameters indicated
in Table 1.
g1(x) = b
xn
θn + xn
, g2(x) = b
θn
θn + xn
. (1.20)
Epo cannot suppress apoptosis completely, thus we consider that the function faEpo(Epo) has
a minimum value different from zero, faEpo(Epo) = 0.2 + f˜aEpo(Epo), where f˜aEpo(Epo)
is Hill function with parameters mentioned in Table 1. Erythrocyte lifespan is considered to
be 40 days (average lifespan of an erythrocyte in mice), thus δ = 1/40 d−1. Parameters α =
0.1, β = 0.6, γ = 2.7, μ1 = 0.04, μi = 3μi−1/4, i = 2, . . . , n are dimensionless quantities.
Epo and GCs elimination constants are kEpo = 7.1295 d−1 and kGC = 5.8714 d−1. Parameters
are chosen to describe erythropoiesis in mice.
As discussed above, the model has several, up to n, stable steady states. In the k-th possible
stable steady state, cells in sub-populations P1, . . . , Pk−1 self-renew and in sub-populations
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Pk, . . . , Pn differentiate, thus we can say that a steady state is characterised by a number k. This
number stands for the number of self-renewing sub-populations plus one. Then, for parameters
of the system mentioned above, the steady state value of erythrocyte count in the stable steady
state with k self-renewing sub-populations is about one order larger than the steady state value
of erythrocyte count in the stable steady state with k−1 self-renewing sub-populations. Thus, ta-
king into consideration the realistic proportion between the daily inﬂux of HSC and erythrocyte
count we can choose only one of the possible steady states that would meet this criterion. The
exact proportion between the daily inﬂux of HSC and erythrocyte count cannot be determined,
yet we can estimate the order of the proportion. To our knowledge this proportion is of order
105 [36]. For the parameters mentioned above, the appropriate conﬁguration is four immature
sub-populations with Erk domination and four mature sub-populations with Fas domination.
Anaemia is a critical lack of haemoglobin that can be caused by erythrocyte loss. Thus, to
model an anaemia, as initial conditions in the simulations we take steady state values for all
variables except for erythrocyte count, for which we take an underestimate value (about 30% of
the steady state value).
Left picture in Figure 11 represents cell sub-population dynamics on a logarithmic scale.
We carry out simulations for n = 8 progenitor sub-populations. Four immature progenitor sub-
populations preferentially self-renew (dot lines), four mature ones preferentially differentiate
(solid lines). We can see the ampliﬁcation by about one order from one self-renewing sub-
population to another one, and an overshoot in erythrocyte count following the anaemia. This
has already been noticed in [36]. In the right picture, dynamics of Ei and Fi, i = 1, . . . , n,
perturbed during anaemia, are presented. Erk dominates in self-renewing cells, Fas dominates in
differentiating cells. Figure 12 shows weak self-renewal rate in differentiating sub-populations,
important self-renewal rate in self-renewing sub-populations, apoptosis rate is about 45% for
differentiating cells and about 10% for self-renewing cells. Differentiation rate does not differ
much from one cell sub-population to another, except during the days following the anaemia.
During anaemia mature progenitors self-renew twice more intensively than in normal situation,
with maximum rate about 18%, apoptosis rate is weak for all cells during anaemia. After about
35 days the three rates come back with damped oscillations to their normal values. In Figure 13
growth factor dynamics are presented. We observe elevated levels (Epo levels increase by about
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three orders) during anaemia that come back to the normal state after 5 days.
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FIGURE 11 – Results of anaemia simulations over 45 days. Left : cell sub-population dynamics,
presented on log scale. Right : Ei and Fi dynamics. Parameter n = 8, i.e. the simulations are
carried out with eight progenitor maturation levels. Four immature progenitor sub-populations,
inclined to self-renewal, are described by dot lines, four others, mature cell sub-populations,
are illustrated with solid lines. Dash-dot line represents the dynamics of erythrocytes. Initial
conditions for variables P1, . . . , P8 equal their steady state values, initial condition for erythro-
cyte count is the value that equals 30% of its steady state value. This number is chosen in
accordance with simulations of an anaemia presented in [36]. It takes 6 days to come back to
normal erythrocyte count that is followed by an overshoot. The return after the overshoot to
the steady state is slow because of the small value of erythrocyte elimination constant (erythro-
cyte lifespan, that is equal to 40 days, is assumed to be not modiﬁed during anaemia). Erk and
Fas quantities are importantly modiﬁed during anaemia, and within 15 days they return to their
normal values.
6.2 Model with erythropoiesis-speciﬁc intracellular system
6.2.1 Parameter values
The nature of the induced anaemia can be very different, according to the method used to
urge it. [45] noticed that the way haematocrit evolves following the anaemia induction, and in
particular the speed of the return to the equilibrium, strongly depends on its strength. In other
words, the more red blood cells are removed from the body, the stronger response to anaemia
is. Results of experiments on mice with phenylhydrazine-induced anaemia obtained in [29] are
presented in Figure 14. One can observe that, following the anaemia, the erythrocyte count
6. Simulations of anaemia 59
0 5 10 15 20 25 30 35 40 45
0
10
20
30
40
50
60
70
80
90
100
Time (days)
Se
lf−
re
ne
w
al
 ra
te
 (%
 / d
)
immature progenitors
mature progenitors
0 5 10 15 20 25 30 35 40 45
0
10
20
30
40
50
60
70
80
90
100
Time (days)
D
iff
er
en
tia
tio
n 
ra
te
 (%
 / d
)
0 5 10 15 20 25 30 35 40 45
0
10
20
30
40
50
60
70
80
90
100
Time (days)
A
po
pt
os
is
 ra
te
 (%
 / d
)
FIGURE 12 – Three rates during anaemia simulations. Left : self-renewal rate. Center : differen-
tiation rate. Right : apoptosis rate. Dot lines correspond to immature cell sub-populations, solid
lines describe the three rates in mature cell sub-populations. The rates are almost the same wi-
thin all immature (mature) sub-populations. Feedbacks by Epo and GCs on Erk activation and
feedback by Epo on apoptosis rate modify the self-renewal rate that increases twice in mature
progenitors during anaemia. During anaemia the majority of mature progenitors differentiate
with weak apoptosis rate to gain normal erythrocyte count as fast as possible. The three rates
are strongly perturbed during the ﬁrst 6 days.
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FIGURE 13 – Growth factor dynamics on log scale during anaemia. Left : Epo levels. Right :
GCs levels. Epo concentration increases by about 3 orders due to the lack of haemoglobin
(corresponds to lack of red blood cells) in the blood. After about 5 days it returns to its normal
values. A small undershoot with respect to normal values is observed on day 8.
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quickly increases and, although still not at its equilibrium, decreases once again on day 11
before ﬁnally reaching normal values from day 18 up to the end of experiments. This surprising
decrease (days 11 to 18) will be investigated in Section 6.2.2 : we will look for feedback controls
responsible for it.
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FIGURE 14 – Phenylhydrazine-induced anaemia in mice, adapted from [29]. Two injections
(60mg/kg) are administered intraperitoneally at days 0 and 1. Mean values among six mice are
presented with error bars. Initial value of red blood cell count (before starting the experiment)
is about 107 cells.μl−1.
We consider the model of erythropoiesis that consists of Equations (1.9)-(1.11) describing
immature and mature blood cell dynamics, Equations (1.12)-(1.13) describing growth factors
dynamics, and Equation (1.16) accounting for intracellular regulatory mechanisms.
We determine functions and parameter values of the model. Some parameters are rather ea-
sily accessible, whereas other parameters and most feedback functions are usually unavailable.
We distinguish between these two kinds of values.
Estimations based on existing data. Among easily accessible parameter values, the mortality
rate of erythrocytes (δ in equation (1.11)) is the ﬁrst for which a value can be assigned. Since
erythrocyte average lifespan in mice equals 40 days, we chose δ = 1/40 d−1.
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Let now focus on growth factor dynamics system (1.12)-(1.13). In mice the half-life of ery-
thropoietin is about 180 minutes [85]. The half-life of glucocorticoids ranges in a wide interval,
yet 90 minutes can be considered as reasonable for short-term glucocorticoids [129] (that is
glucocorticoids acting for a short time), like cortisol, which are likely to be involved in stress
erythropoiesis [13]. Using the deﬁnition of half-life, we compute degradation constants : consi-
der a substance that degrades with constant rate ν, then its dynamics can be described by the
equation,
dx
dt
= −νx,
whose solution is x(t) = x0e−νt. The half-life is the time T1/2 such that
x(T1/2) =
x0
2
,
which gives ν = ln(2)/T1/2. Using the above estimations for the half-life of erythropoietin and
glucocorticoids, we obtain the following values for the degradation constants,
kEpo = 5.55 d−1, kGC = 11.1 d−1.
The functions fEpo and fGC in (1.12) and (1.13), accounting for growth factor production
terms, are supposed to be Hill functions [15, 71],
fEpo(M) = f
0
Epo
θqEEpo
θqEEpo + M
qE
, fGC(M) = f
0
GC
θqGGC
θqGGC + M
qG
.
During anaemia Epo blood concentrations increase by 2-3 orders [90]. To our knowledge, va-
riations of glucocorticoids are less important, but exact values are not available. We then chose
parameters of functions fEpo(M) and fGC(M) that allowed us to obtain such variations of Epo
and GCs in anaemia simulations we carried out. All these parameters are listed in Table 2.
As obtained in Section 5.2.2, the model we consider has from 1 up to n stable steady states.
Not all steady states are biologically meaningful and one of these numerous steady states can be
selected by taking into consideration a realistic proportion between the daily inﬂux of haema-
topoietic stem cells (input of the model) and erythrocyte count in mice (output of the model).
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TABLE 2 – Values of the parameters used to numerically compute erythrocyte count and growth
factor levels. N.U means “no unit is relevant”.
Parameter Value Unit
δ mortality rate of erythrocytes 0.025 d−1
kEpo degradation rate of Epo 5.55 d−1
kGC degradation rate of GC 11.1 d−1
f 0Epo maximum value of fEpo 7130 mU.μl
−1
θEpo threshold value of fEpo 4.63× 106 cells.μl−1
qE sensitivity of fEpo 7 N.U.
f 0GC maximum value of fGC 2930 mU.μl
−1
θGC threshold value of fGC 7.69× 106 cells.μl−1
qG sensitivity of fGC 6 N.U.
From [36], the ratio M∗/HSC between normal erythrocyte count and HSC daily inﬂux can be
estimated in the order of 105. The number of self-renewing sub-populations (see discussion at
the end of Section 5.2.2) allows to select the appropriate steady state. We carried out several
simulations with different numbers of self-renewal-inclined sub-populations and we obtained
a correct ratio M∗/HSC for n = 8 and the case of 4 immature preferentially self-renewing
sub-populations, and consequently 4 mature differentiation-inclined sub-populations.
Intracellular regulatory network. Let ﬁrst focus on the part of the intracellular regulatory
system (1.16) independent of feedback functions. Variables E and F are dimensionless and the
parameter values we use are deduced from numerical simulations since no data are available in
the literature. They are
k = 2, β = 40 d−1, a = 2 d−1,
b = 40 d−1, c = 10 d−1, d = 2.5 d−1.
(1.21)
With these values, the intracellular regulatory network may have three steady states for given α
and γ (Figure 8), two steady states being stable.
As mentioned in previous sections, System (1.16), describing intracellular regulatory net-
work, in which α stands for Erk activation by Epo and GCs, and γ stands for Fas activation by
FasL, can have either one or two stable steady states. Thus, primordially bistable system can
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temporarily lose its bistability when values of parameters α and γ change, like in stress situa-
tions. For the parameters of the intracellular regulatory network mentioned in (1.21), we found
numerically the set of (α, γ) values, for which System (1.16) has a bistable behaviour (domain
D1 in Figure 15).
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FIGURE 15 – Intracellular system (1.16) has a bistable behaviour for (α, γ) inside D1. Two
examples of (α, γ) variations are tested numerically, domains D2 and D3, when bistability can
be temporarily lost.
After determining system parameters (see below), we numerically tested two cases : ﬁrst
when intracellular regulatory network always keeps a bistable behaviour during anaemia, in-
dependently of the values of α and γ, and second when for some extreme values of α and γ
the bistability is temporarily lost and the intracellular regulatory network has only one stable
steady state. The ﬁrst case corresponds to variations of α and γ in the rectangular domain D2 in
Figure 15 that is entirely inside the bistability area. The second case corresponds, for instance
(this is what was tested), to variations of α and γ in the domain D3 that partially exits D1. If a
system trajectory goes through these out-of-D1 parts of D3, then the bistability of System (1.16)
is lost for the corresponding values of (α, γ). We investigated the consequences of these two
distinct situations on the response to anaemia.
In the second case the response of the system was stronger but qualitatively the same as
the one obtained in the ﬁrst case. We tried to increase out-of-D1 parts of domain D3 through
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which the trajectory goes and we obtained that beyond certain thresholds (i.e. if the trajectory
stays long enough outside the domain D1), the solution could not come back to its initial state,
the solution changed an attractor and went deﬁnitely to another steady state, or in other words,
the system switched to single stable steady state regimen. The system would then lose its bio-
logical meaning (the balance between self-renewal and differentiation would be broken) and
consequently we decided to focus only on the ﬁrst case (α and γ range in D2) and we present
numerical simulations only for this case.
Let now concentrate ourselves on the choice of functions α and γ.
For the sake of simplicity, we supposed that FasL exerts the same feedback control on Fas
activation for all progenitor sub-populations, which implies that γi(Pn) in (1.16) is independent
of i : γi(Pn) = γ(Pn) for all i = 1, . . . , n.
The system trajectory represented on (α, γ)-plane stays inside domain D2 during erythro-
cyte recovery. The domain D2 is characterised by α ∈ [0.1, 0.6], γ ∈ [0.5, 1.2], see Figure 15.
Recall that α = α(Epo,GC) and γ = γ(Pn). We suppose α(Epo,GC) = α0 + f(Epo) +
g(GC), where α0 is constant and f(Epo), g(GC) are Hill functions,
f(Epo) = fmax
Epoqf
θ
qf
f + Epo
qf
, g(GC) = gmax
GCqg
θ
qg
g + GCqg
. (1.22)
Function γ(Pn) is supposed to be a Hill function, given by
γ(Pn) = γmin + (γmax − γmin) P
qγ
n
θ
qγ
γ + P
qγ
n
. (1.23)
No information could allow us to determine the shape of such functions. The choice of Hill
functions lies on the interest of these functions in describing kinase cascades and, more gene-
rally, biological phenomena with saturation effects. Parameter values of functions α(Epo,GC)
and γ(Pn) are given in Table 3. They were deduced from numerical simulations.
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TABLE 3 – Parameters of the intracellular regulatory network, functions α(Epo,GC) = α0 +
f(Epo) + g(GC) and γ(Pn), deﬁned in (1.22) and (1.23). N.U means “no unit is relevant”.
Parameter Value Unit
k sensitivity of Erk self-activation 2 N.U.
β rate of Erk self-activation 40 d−1
a Erk degradation rate 2 d−1
b suppression of Erk expression rate 40 d−1
c suppression of Fas expression rate 10 d−1
d Fas degradation rate 2.5 d−1
α0 constant Erk activation rate 0.1 d−1
fmax maximum value of f(Epo) 0.25 d−1
qf sensitivity of f(Epo) 6 N.U.
θf threshold value of f(Epo) 100 mU.μl−1
gmax maximum value of g(GC) 0.25 d−1
qg sensitivity of g(GC) 2 N.U.
θg threshold value of g(GC) 49.4 mU.μl−1
γmin minimum value of γ(Pn) 0.5 d−1
γmax maximum value of γ(Pn) 1.2 d−1
qγ sensitivity of γ(Pn) 3 N.U.
θγ threshold value of γ(Pn) 1.14× 106 cells.μl−1
Self-renewal, differentiation and apoptosis rates. From Equations (1.14), (1.15) and (1.18),
self-renewal, differentiation and apoptosis rates are given, for i = 1, . . . , n, by⎧⎪⎪⎪⎨⎪⎪⎪⎩
si = (1− ai) ps(Ei, Fi),
di = 1− si − ai,
ai = a(Ei, Fi) faEpo(Epo).
(1.24)
The dependence upon Erk and Fas is deﬁned through function ps(E,F ), which describes how
the probability of self-renewal depends upon Erk and Fas, and function a(E,F ), which des-
cribes how apoptosis rate depends on Erk and Fas. The direct action of Epo on apoptosis rate
is determined by faEpo(Epo). Hence, the three functions ps, a and faEpo entirely determine the
three rates.
The function faEpo is supposed to be decreasing and bounded. In order to describe the effect
of large Epo variations (quick changes from 5 to 1000 mU.μl−1), we chose a Hill function of
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the logarithm of Epo, given by,
faEpo(Epo) = 0.2 +
0.73× 1.19.2
1.19.2 + (log10(Epo))
9.2
, (1.25)
the parameters being dimensionless, except the threshold value 1.1, which is expressed in
mU.μl−1. Parameters have been chosen so that faEpo(Epo) in the steady state Epo∗ equals
0.9 and numerical simulations ﬁt correctly experimental data from Figure 14.
For the sake of simplicity, we supposed functions ps(E,F ) and a(E,F ) to be functions of
one variable, ps(E,F ) = ps(E − F ) and a(E,F ) = a(F − E). The function ps is supposed to
take larger values when Erk levels are high, whereas the value of a is more important when Fas
levels are high. Consequently, both functions are supposed to be increasing. Moreover, they are
positive and we assumed the following form,
z(x) = zmin +
(zmax − zmin)(x + 1)nz
θnzz + (x + 1)
nz
, x ∈ [−1, 1].
Before giving values of the parameters zmin, zmax, nz and θz associated with functions ps
and a, let us illustrate how the roles of Erk and Fas are investigated through these functions.
Let us recall that we assumed functions γi do not depend on the index i. Hence, from (1.16)
it follows that all sub-populations have the same steady state values (E∗, F ∗), which do not de-
pend on i. Moreover, by assuming that α and γ evolve in the restricted domain D2, we ensure the
existence of two stable steady states for System (1.16), one in which Erk levels are higher than
Fas levels, and the other one with higher Fas levels. These two steady states (E∗, F ∗) provide
two distinct values of the variable F ∗−E∗, one positive and one negative. The positive value is
associated with cell differentiation, whereas the negative one corresponds to cell self-renewal.
Hence, the positive value of F ∗ − E∗ characterises differentiation-inclined erythroid progeni-
tors, that is mature cells, and the negative one self-renewal-inclined erythroid progenitors, that
is immature cells.
During anaemia, concentrations of Erk and Fas vary, therefore values of F − E vary as
well. Carrying out simulations however, we observed that variations of F − E were limited to
neighborhoods of the two stationary points F ∗ − E∗, and did not range in the whole interval
[−1, 1]. This means that variations of functions ps(E − F ) and a(F − E) are only relevant
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on these neighborhoods of F ∗ − E∗. Consequently, in order to determine the roles of Erk and
Fas on the response to anaemia, we considered three cases describing three different ways of
acting on self-renewal, differentiation and apoptosis rates, based on variations of ps and a in the
neighborhoods of the steady state values.
In the ﬁrst case ps(E −F ) and a(F −E) vary slightly on both neighborhoods of the steady
states. In the second case ps(E − F ) (respectively a(F − E)) varies a lot near the steady state
corresponding to Erk prevalence, i.e. F ∗ − E∗ < 0 (respectively, Fas prevalence, i.e. F ∗ −
E∗ > 0), and is almost constant near the other steady state. Biologically it can be interpreted
as follows : in critical situations Erk and Fas importantly modify the progenitor self-renewal
rate of immature but not of mature cells, and apoptosis rate is strongly modiﬁed in mature
cells but not in immature ones. The third case is opposite to the second one. It should be noted
that the assumption on the three rates that conﬁnes them in the interval [0, 1], limits maximum
values of functions ps and a, so the fourth possible case, when the functions vary a lot on both
neighborhoods is ineligible. Simulations indicated that the response obtained in the ﬁrst case is
weak, that is the system takes more time to come back to the equilibrium. Second case seemed
to us biologically more realistic than the third one, hence we chose to use only the second case
for the numerical simulations. Nevertheless, it can be noted that the simulation of the third case
showed a weaker response, i.e. slower erythrocyte count dynamics, though the rates displayed
different dynamics.
In order to obtain a good ﬁt of experimental data, functions ps(E − F ) and a(F − E) used
for the simulations are
ps(x) = 0.1 +
1.2× x40
1.740 + x40
, a(x) = 0.12 +
1.02× x40
1.540 + x40
.
Units of 0.12 and 1.02 for function a are d−1, other parameters are dimensionless values.
Steady state values. Since we are going to confront the simulation results with experimental
data presented in Figure 14, we tried to get equilibrium value of erythrocyte count M∗ = 107
cells.μl−1. This implied HSC = 80 cells.μl−1.d−1. As initial condition for the number of ery-
throcytes we took 30% of its equilibrium value, which corresponds to the anaemia presented in
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Figure 14 (see value of RBC count on day 3). Equilibrium values are taken as initial conditions
for all other system variables. Steady state values of the main system components, obtained
through the simulation, are presented in Table 4.
TABLE 4 – Steady state values of the main variables of the system.
Steady states Value Units
Erythrocyte count M∗ 107 cells.μl−1
Reticulocyte count P ∗8 4.75× 105 cells.μl−1
Erythropoietin level Epo∗ 5.7 mU.μl−1
Glucocorticoids level GC∗ 44.6 mU.μl−1
Fas − Erk level for immature cells F ∗ − E∗ −0.66 N.U.
Fas − Erk level for mature cells F ∗ − E∗ 0.48 N.U.
Activation rate of Erk α(Epo∗, GC∗) α∗ 0.21 d−1
Activation rate of Fas γ(P ∗n) γ
∗ 0.55 d−1
Self-renewal rate of immature cells s∗ 0.44 d−1
Self-renewal rate of mature cells s∗ 0.06 d−1
Differentiation rate of immature cells d∗ 0.45 d−1
Differentiation rate of mature cells d∗ 0.53 d−1
Apoptosis rate of immature cells a∗ 0.11 d−1
Apoptosis rate of mature cells a∗ 0.41 d−1
As shown in Table 4, in normal erythropoiesis reticulocyte count is 20-fold smaller than
erythrocyte count. Progenitor sub-populations P1, . . . , P7 are much smaller than P8 (not shown
here). The model predicts that 44% of immature progenitors self-renew per day (only 6% of ma-
ture progenitors per day), which allows the conclusion that mature progenitors mainly lost their
ability to self-renew. Apoptosis rate is high in mature cells (41% d−1), whereas it is only 11%
d−1 in immature cells. About 53% of mature and 45% of immature progenitors differentiate per
day, providing that the differentiation remains important in all erythroid cells. Thus, in normal
erythropoiesis, immature progenitor sub-populations are characterised by weak apoptosis and
comparable self-renewal and differentiation rates. Mature progenitors, however, preferentially
differentiate with high apoptosis.
The next section is devoted to numerical simulations of phenylhydrazine-induced anaemia.
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6.2.2 Simulation of phenylhydrazine-induced anaemia and comparison with experimen-
tal data
Using parameter values obtained in the previous section, we numerically computed solu-
tions of system formed with Equations (1.9) to (1.13) and Equation (1.16), for an anaemia-
induced situation : it is assumed that at the beginning of the numerical computations (day 0)
the erythrocyte count is lower than its equilibrium value (30% of its equilibrium) due to pre-
vious phenylhydrazine injections. Simulations were carried out using MATLAB and results are
presented in Figures 16 to 20.
First, dynamics of main variables of the system and of some relevant rates are illustrated :
erythrocyte and reticulocyte counts in Figure 16, erythropoietin and glucocorticoid levels in
Figure 17, Erk and Fas levels in Figure 18, self-renewal, differentiation and apoptosis rates in
Figure 19. Explanations on the dynamics of the system are proposed. Then results are confron-
ted to experimental data from Figure 14 in Figure 20.
All simulations start at day zero. For the sake of clarity, equilibrium values are shown on
days -1 to 0.
Erythrocyte and reticulocyte counts. Erythrocyte count (solid line) and reticulocyte count
(dash line) dynamics are presented in Figure 16.
Following the anaemia, erythrocyte count quickly increases and reaches a maximum value
(lower than the equilibrium value) after 7 days, then stays there up to day 10. Afterwards, ery-
throcyte count slowly decreases (days 10 to 17). Quick increase is observed between days 17
to 21, followed by a gradual return to the equilibrium. Although erythrocyte count globally in-
creases between day 0 and day 30, it should be noted that 30 days after anaemia the erythrocyte
count is still below its equilibrium value.
At day 0, the reticulocyte count increases to reach a maximum value that equals approxima-
tely four-fold of its equilibrium value on day 4, then comes back to its steady state and keeps
on decreasing. On day 17, when erythrocyte count is decreasing, the number of reticulocyte
increases once again, though less importantly this time.
The ﬁrst increase of reticulocyte count (up to day 4) is due to a strong increase of mature
progenitor differentiation, see Figure 19.B. Explanations on the behavior of erythrocyte and
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FIGURE 16 – Anaemia simulation. Erythrocyte and reticulocyte count dynamics. Solid curve
represents erythrocyte count, dash curve represents reticulocytes. Equilibrium value of erythro-
cyte count used in the simulation is M∗ = 107cells.μl−1.
reticulocyte counts on day 17 are however less straightforward and will be given later in this
section, when confronting the results with experimental data.
Growth factors dynamics. In Figure 17, erythropoietin and glucocorticoid dynamics are
shown. Growth factor levels are strongly perturbed (large increase) during the ﬁrst ﬁve days
following the anaemia, this perturbation being characterised by a sharp increase of both concen-
trations on day 1, when the organism lacks erythrocytes. Then values of Epo and GCs levels
smoothly return to their equilibria, with small perturbations, in particular they both increase
once again on day 17, due to the fall in erythrocyte count (Figure 16).
As it will be noted in the following sections, two different actions of Epo and GCs appear
in the response to anaemia. First, in the early stages of the response to anaemia (between days
0 and 5) mainly Epo inhibits apoptosis (Figure 19), leading to high proliferation of immature
progenitors. Second, from day 6 up to the end of the response, Epo and GCs levels are closer
to their equilibrium values and they regulate erythropoiesis mainly through Erk-Fas regulation
(Figure 18).
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FIGURE 17 – Anaemia simulation. Dynamics of growth factors, shown on logarithmic scale.
Erk and Fas levels. Dynamics of variable F − E and feedback controls expressed by α and
γ are presented in Figure 18. Values of F −E in all mature (respectively, in all immature) sub-
populations are similar because the feedback by FasL has been supposed to be the same on all
cells (see Section 6.2.1).
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FIGURE 18 – Anaemia simulation. Panel A : Dynamics of F −E for self-renewing (green solid
curve) and differentiating (red dash curve) sub-populations. Panel B : Dynamics of α(Epo,GC)
(blue solid curve) and γ(Pn) (red dash curve).
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On the ﬁrst day following anaemia the quantity F−E decreases. This is more clearly obser-
ved for mature cells (red dash curve), yet it also occurs for immature cells (green solid curve).
This is due to high values of α (Panel B), the feedback function controling Erk production.
Then, F − E increases and reaches its extreme values after 5-6 days following anaemia induc-
tion. As one can observe on Panel A, between days 9 and 19 the difference F − E has values
below its equilibria, which is due to the regulation through α and γ.
Production of Erk, the feedback control expressed by α, is at its maximum during the ﬁrst
four days, while γ (production of Fas) is increasing. Then, α sharply decreases almost down
to its equilibrium, while γ decreases smoothly and reaches its minimum value, where it stays
from day 10 up to day 18. On day 18, a new increase of γ is observed, due to the increase of the
reticulocyte count (Figure 16). Two different behaviors are observed in α and γ dynamics : fast
changes (α on days 1 and 4) and modest variations (γ between days 1 and 8, and days 18 and
25). Fast changes of α are directly due to sharp Epo and GCs dynamics (see Figure 17), while
modest γ dynamics is due to modest evolution of reticulocyte count (see Figure 16).
Self-renewal, differentiation and apoptosis rates. Self-renewal, differentiation and apopto-
sis rates are presented in Figure 19. The three rates exhibit important ﬂuctuations. Their dyna-
mics for immature and mature cell populations are different.
Self-renewal rate varies a lot for all cells. At ﬁrst sight, it seems not to be the case for
mature cells, yet self-renewal equilibrium value is small and the variations represent a two-
fold increase of the equilibrium value. Such important variations are also observed for the two
other rates. Moreover, two different types of changes in values of the rates appear in Figure 19.
First, sharp variations appear between days 0 and 1 : they are strong, for instance, for mature
sub-populations (red dash curves in Figure 19). Then, after day 1, variations are more gradual,
sometimes with large amplitudes.
Taking into account the nature of the feedback controls, we conclude that sudden sharp va-
riations in the three rates right after the induction of anaemia are due to direct inhibition of
apoptosis by Epo, independently of the intracellular network based on Erk and Fas, and gradual
variations that occur later (after day 2) are due to Erk and Fas regulation. During the ﬁrst six
days these gradual variations are observed for the self-renewal rate (Panel A) and the diffe-
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FIGURE 19 – Anaemia simulation. Self-renewal, differentiation and apoptosis rates of immature
self-renewing (green solid curve) and mature differentiating (red dash curve) sub-populations.
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rentiation rate (Panel B) of immature cells. During days 6-32, the three rates keep on varying
gradually, which is due to Erk and Fas variations. These ﬂuctuations are important, suggesting
a strong dependence of the rates on Erk and Fas (which at the same time vary modestly), and
last longtime (40-45 days, not shown here). These conclusions must however be completed by
the fact that the inﬂuence of Epo on apoptosis rate is observed as long as its levels are not back
to equilibrium value, especially for immature self-renewing sub-populations (Figure 19.C).
It should be noted as well that differentiation in our model is a choice by default, i.e. a cell
that is protected against apoptosis and which does not self-renew differentiates.
Confrontation to experimental data. Simulation results and experimental data are presented
in Figure 20. The blue dash curve represents the simulation discussed above (Figure 16), the
black solid line represents the outcome of experiments by [29] (Figure 14).
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FIGURE 20 – Anaemia simulations. Erythrocyte count dynamics obtained by [29] in experi-
ments on induced anaemia in mice (black circled solid line), obtained in simulations carried out
with δ = 1/40 d−1 (blue dash curve) and with δ = 1/30 d−1 (red dash-dot curve).
Let focus on the simulated blue dash curve. First, from day 0 to day 7, the computed erythro-
cyte count increases as fast as observed in the experiments, with only one day delay. From day
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10, simulated erythrocyte count decreases in spite of its low value (lower than equilibrium). Si-
milar phenomenon is observed in the experiments (black solid line) from day 8 to 15. The cause
of such a decrease in cell numbers although the erythrocyte count is still lower than normal is
investigated in the following.
In Figure 16, reticulocyte count starts decreasing at day 4. Figure 19 shows that during ﬁrst
four days apoptosis rate is below its equilibrium for mature cells, whereas both self-renewal
and differentiation rates are above their equilibrium values. This results in an increase of the
number of mature progenitors (not shown here). However, for immature cells the picture is a bit
different, self-renewal rate increases a little bit on the ﬁrst day and then decreases a lot due to
high F−E values (Figure 18.A), differentiation rate is higher than at equilibrium, apoptosis rate
is lower than at equilibrium. This results in a decrease of the number of immature progenitors
(not shown here). Hence, on day 4 the system starts lacking immature cells to maintain the
increase of mature progenitors that triggers a decrease of the latter and, thus, of reticulocytes.
Apoptosis of mature progenitors is high during days 6-8 (Figure 19.C), whereas differentiation
rate is low (Panel B) and self-renewal is about its steady state (Panel A). This makes reticulocyte
count decrease even faster (Figure 16), go below its equilibrium on day 8, where it stays up to
day 19. This, in turn, decreases the supply of mature erythrocytes that results in the reduction
of erythrocyte count observed between day 10 and day 18. Thus, our model suggests that this
decrease of erythrocyte count is a consequence of low self-renewal rate of immature cells during
ﬁrst seven days and of the high apoptosis of mature cells during days 6-8. This, in turn, is due
to a high value of F − E (Figure 18.A) and not to Epo control of apoptosis, which is below
its equilibrium during these days and should, in contrary, decrease apoptosis rate (Figure 21).
Consequently, this decrease (days 10-18) of the erythrocyte count can be explained by Erk-Fas
regulation. It can be compared to the quick increase of erythrocyte count following the anaemia,
which is clearly due to an inhibition of progenitor apoptosis by Epo, independently of Erk-Fas
regulation.
The above analysis enlightens two different and clear mechanisms of erythropoiesis regu-
lation : ﬁrst, inhibition of apoptosis by Epo in the early stages of the response to anaemia,
and second, a more moderate regulation on the long-term of erythroid progenitor self-renewal,
differentiation and apoptosis based on intracellular regulation (Erk and Fas).
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FIGURE 21 – Anaemia simulation. Function faEpo(Epo).
Although close to experimental data, the simulated erythrocyte count (blue dash curve) does
not appear to be the best ﬁt to the data. Focusing on the nature of the anaemia, that is the
consequences of phenylhydrazine use, we can obtain better results.
Phenylhydrazine is known to damage cell membrane, which results in reduced lifetime of
erythrocytes following the injections. We tested this assumption with our model, assuming a
mortality rate of erythrocytes δ = 1/30 d−1, which means the average lifetime of an erythrocyte
is reduced to 30 days under the action of phenylhydrazine. Red dash-dot curve in Figure 20
represents erythrocyte count in this case. It provides a better ﬁt of the data, with a stronger
slope on the ﬁrst days (days 1 to 5), a smaller undershoot afterward and a faster return to the
equilibrium. It should be noted that the current modiﬁcation of the value of δ does not alter
the above analysis and conclusions, it only allows a better ﬁt of the data. For both simulations
presented in Figure 20, one feature of experimental curve is however not well approached :
the undershoot in both simulations (observed around day 18) is slower, occurs later and is also
smaller than the one obtained in the experiments (observed around day 14).
We confronted our model with other experimental data on phenylhydrazine-induced anae-
mia, presented in [36]. In these experiments, haematocrit values were measured during 45 days
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after anaemia induction. The model used in this work does not a priori provide haematocrit, but
only erythrocyte count. Haematocrit H(t) is deﬁned by
H(t) =
vM(t)
vM(t) + Plasma volume
,
where vM(t) represents the volume of erythrocytes in the blood. In [36] we assumed that the
plasma volume was not modiﬁed during the experiments and considering normal haematocrit
H∗ (assumed to equal 50%) and erythrocyte count M∗ we obtained
H∗ =
vM∗
vM ∗ + Plasma volume
,
which provides
Plasma volume =
1−H∗
H∗
vM∗.
Consequently, haematocrit can be deduced from the erythrocyte count,
H(t) =
M(t)
M(t) + (1−H∗)M∗/H∗ .
This is displayed in Figure 22.
To obtain an overshoot on day 5 as presented in Figure 22, it was necessary to modify
functions faEpo(Epo), ps(E −F ) and a(F −E). In particular, the minimum value of faEpo has
been dropped from 0.2 down to 0.1, see (1.25), functions ps(E − F ) and a(F − E) have been
modiﬁed to have smaller variations on the relevant intervals of F − E. One can observe that
experimental results are properly reproduced by the model, although the decrease following the
peak in haematocrit values is slower in the model. Erythrocyte lifespan must be reduced from
40 days to 15 days to obtain these results, similarly to what has been done in [36].
Hence, this model is able to reproduce features of a simpler model, and also leads to more
insights into regulatory mechanisms of erythropoiesis.
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FIGURE 22 – Anaemia simulation. Haematocrit dynamics. Blue solid line represents simulation
results, red dash line represents results of experiments on induced anaemia in mice obtained
in [36]. Normal haematocrit is assumed to equal 50%, lifetime of erythrocytes is 15 days.
7 Discussion
In this chapter we presented two multi-scale mathematical models of erythropoiesis taking
into account several biological aspects known nowadays. The objective of the ﬁrst model was
to bring together all available biological information in a mathematical model. Intracellular
regulatory network has been described by a bistable system. Results of simulations were not
confronted with experimental data. Second model is based on the ﬁrst model. It is more pre-
cise and contains more biological information. Some model parameters have been taken from
the literature, others have been chosen to qualitatively represent erythropoiesis regulation. Se-
cond model has been better studied numerically, i.e. more simulations have been carried out.
The results were confronted with two different experimental data sets on induced anaemia. The
objective of the second model was to study roles of different feedback mechanisms in the regu-
lation of erythropoiesis. The results of the second model were deeper analysed.
In the ﬁrst model intracellular regulatory network, determining cell choice between self-
renewal, differentiation and apoptosis, was supposed to have bistable behaviour. Erk and Fas
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were considered as key proteins determining progenitor fate choice. We considered several
progenitor compartments and erythrocyte compartment that allowed the construction of po-
pulational dynamics with regulation by feedbacks from erythrocyte compartment to progenitor
compartments through two growth factors, Epo and GCs. Epo was supposed to implement two
feedbacks, it controlled Erk levels in cells and regulated apoptosis rate. Reticulocytes imple-
mented feedback on progenitors by means of FasL. An essential feature considered in the model
was the ability of progenitors to self-renew. The resulting mathematical model was analysed, we
found steady states and their stability using Implicit Function Theorem. The considered model
had several stable steady states, but only one among them satisﬁed all biological conditions. We
carried out simulations of anaemia situation. The numerical results were in agreement with our
expectations.
In the second approach, intracellular model was based on the scheme proposed in [96] and
was obtained as a transition from a simple linear model to a non-linear bistable system. Again,
two intracellular proteins, Erk and Fas, were supposed to be determinant for cell fate. Cell
cycles were supposed to be constant and equaled one day. We considered several compartments
of erythroid progenitors and a population of erythrocytes. A new feature, which we took into
account in the model, is self-renewal ability of erythroid progenitors. For each sub-population
of progenitors, we deﬁned self-renewal, differentiation and apoptosis rates. We introduced as
well two growth factors, Epo and GCs. Connections between the two modelling scales were
provided by several feedback controls : Erk and Fas determined self-renewal, differentiation
and apoptosis rates ; Epo and GCs were controlled by erythrocyte count ; Epo directly inhibited
apoptosis rate independently of Erk activation. These feedback controls are turned on in critical
situations. The resulting mathematical model was analysed, we found steady states and their
stability. Then, simulations of anaemia were carried out and the results were confronted with
experimental data. This allowed the evaluation of the roles of the feedback controls in response
to anaemia : feedback by Epo on apoptosis, independently of the intracellular network based on
Erk and Fas, was found to be determinant in the early stage of the response, to quickly increase
the number of erythrocytes, whereas feedback control through the intracellular regulatory net-
work, introduced in Section 3.2, is more important later in the response, when the erythrocyte
count almost reached its equilibrium value, to regulate on a long-term the response to the stress.
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Epo, however, has a permanent inﬂuence on progenitor apoptosis.
An additional feature brought by the model concerns apoptosis rate. The presented simula-
tion provided that the apoptosis rate in mature sub-populations equals a∗ = 0.41 d−1. Thus, the
model suggests that in normal erythropoiesis, 41% of produced mature erythroid progenitors un-
dergo apoptosis daily. The model shows that in stress situations, like anaemia, organism reacts
by temporarily suppressing apoptosis that allows fast recovery of erythrocytes (Figure 19).
Other simulations (not shown here) were carried out as well, to test hypotheses not pre-
sented here. For instance, consequences of the loss of bistability of intracellular network were
investigated. The response of the system in this case was qualitatively the same as the one ob-
tained in the simulations presented in Section 6. As mentioned in the previous section, different
shapes for the probability function ps and the apoptosis function a were considered. The pre-
sented simulation has shown a better ﬁt, other simulations (not presented here) provided weaker
response. We also tried different feedback functions faEpo, to evaluate the role of the feedback
by Epo on apoptosis rate in response to the anaemia (strong or weak sensitivity of apoptosis to
Epo). We also carried out simulations of less severe anaemia, with initial value of erythrocyte
count being equal to 0.7 of steady state value. Obtained dynamics of erythrocyte count was
qualitatively the same.
All the simulations were performed under the assumption that cell cycle durations were
constant, equal to one day. Although there is no evidence that cell cycles vary during response
to a stress, nor that such variations could be important, this assumption appears restrictive. In
particular, it is responsible in part for the delay observed in the ﬁrst days of the response for the
increase of the erythrocyte count. Hence, considering that cell cycles can be shortened during
stress erythropoiesis could enhance the results of the proposed model, by allowing a better ﬁt to
the data, and consequently more relevance of the predicted parameters.
The modelling presented in this chapter is novel and introduce some new insights into ery-
thropoiesis regulation in critical situations.
Deuxième partie
Spatial Models of Erythropoiesis
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8 Spatial distribution of cell populations in the process of
erythropoiesis
Bone marrow has a particular structure. Current research in this ﬁeld provides more and
more insights into its spatial composition. This part of the work is devoted to spatial modelling
of erythropoiesis. We take into account spatial cell distribution inside the bone marrow and
cell motion resulting from cell proliferation. Immature erythrocytes appear and push each other
through the medium formed by other cells and by porous matrix. In the process of this motion,
cells increase their maturity. Mature blood cells are pushed out into blood vessels going through
the marrow, see Figure 23. Thus, normal haematopoiesis implies certain spatial cell organisation
FIGURE 23 – Spatial structure of the bone marrow.
according to their maturity level. There are little experimental results about spatial distribution
of blood cells in the bone marrow. It is known that stem cell can be localised and form a stem
cell niche [75, 81, 84, 99, 110]. One of recent studies of spatial distribution of cells in the bone
marrow was published by Watchman et al. [122]. The authors obtained that haematopoietic
CD34+ cells (stem cells committed to erythroid lineage) were located along a linear spatial
gradient with a maximal areal concentration localised close to the bone surfaces.
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Excessive proliferation of immature cells, which can be related to certain blood diseases in-
cluding leukaemia, changes normal cell distribution in the marrow. If proliferation of malignant
cells is sufﬁciently fast, then the tumour grows and can ﬁll the whole marrow. The propagation
of leukaemic cells corresponds to travelling wave solutions of reaction-diffusion-convection
equations. We study in this model spatial cell distribution for both normal and leukaemic hae-
matopoiesis.
In this work we describe cell concentrations by reaction-diffusion-convection equations and
their motion by Darcy’s law. The difference with the works cited before is related in particular to
some speciﬁc features of cell production in the process of haematopoiesis. A close problem was
studied in [44] in the 1D spatial case. In this work we are particularly interested by propagation
of 2D waves which correspond to leukaemia development in the bone marrow.
The work is organised as follows. In Section 8.1 we present reaction-diffusion equations
in porous media which describe evolution of cell populations. This model is brieﬂy discussed
in the general framework and more speciﬁcally for erythroid progenitors. In Section 8.2 we
prove the existence of a stationary solution in the 1D case. This solution gives a stationary cell
distribution in the cross-section of the bone marrow considered as a 2D rectangular domain. In
the leukaemic case, this 1D solution can become unstable. The region ﬁlled by malignant cells
will propagate and ﬁll the whole domain. We study this phenomenon numerically in Section 8.3.
We give an analytical approximation for the speed of the travelling wave and compare it with
the numerical results.
8.1 Models of cell populations
8.1.1 Equations of continuous mechanics
We consider a cell population in a porous medium. In particular, this can be blood cells in
the bone marrow. Let us denote by ci, i = 1, ..., n the concentrations of different cell types, that
is the mass fraction of cells of the i-th type in a unit volume. Cell population is considered as a
continuous medium. The evolution of the concentrations is governed by the following equation
∂ci
∂t
+∇.(vci) = dΔci + Fi, (2.1)
8. Spatial distribution of cell populations in the process of erythropoiesis 85
where v is the velocity of the medium, d is the diffusion coefﬁcient and Fi is the production rate
of the i-th type of cells. The diffusion terms describes random cell motion. Let φ be the total
cell concentration, that is
φ = c1 + ... + cn. (2.2)
Taking a sum of all equations in (2.1), we obtain that φ satisﬁes the equation
∂φ
∂t
+∇.(vφ) = dΔφ +
n∑
i=1
Fi. (2.3)
Let us consider cells as spherical particles which consist of an external elastic membrane and
which are ﬁlled by an incompressible ﬂuid. Let us suppose for simplicity that all particles have
the same size and denote their diameter by r and the volume by v0. Consider next a sufﬁciently
small cube with the side a and the volume V . Denote by p the pressure, that is the force acting
from the particles on the sides of the cube. Let N be the number of particles inside the cube. If
N < N0 = (a/r)
3, then the particles can be distributed in such a way inside the cube that there
is no repulsion between them and no force on the sides of the cube. The maximal number of
particles can be estimated by Nmax = V/v0. In this case the cube is ﬁlled by an incompressible
ﬂuid. If the number of particles is between N0 and Nmax, then the pressure is a function of N .
Thus, the pressure p is a function of the total cell concentration φ :
p(φ) =
⎧⎨⎩ 0 , φ  φ0p0(φ) , φ0 < φ < φmax ,
where p0(φ) is some given function, φ0 and φmax are positive parameters. If φ = φmax, then
from (2.3) we obtain the following equation
∇.v = 1
φmax
n∑
i=1
Fi. (2.4)
In the case without sources (Fi = 0, i = 1, ..., n), we obtain an incompressible medium.
The pressure-concentration dependence is shown in Figure 24. The equation of state can be
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written as
H(p, φ) = 0, (2.5)
where the function H is such that H(p(φ), φ) = 0.
FIGURE 24 – The pressure-concentration dependence in the equation of state.
If we consider a porous medium, then convective motion is described by Darcy’s law :
ρ

∂v
∂t
= −∇p− μ
K
v, (2.6)
Here p is the pressure, ρ the density,  the porosity of the medium, K the permeability and μ
the viscosity. System of equations (2.1), (2.3), (2.5), (2.6) should be considered in some domain
and completed by appropriate initial and boundary conditions.
8.1.2 Cell proliferation, differentiation, apoptosis
Here we specify the functions Fi used in the previous section. They describe the rates of
production or disappearance of various cell types. Consider a single cell lineage which consists
of n sub-populations with the following properties. The cells in each sub-population Pi are
identical to each other. They can self-renew with the rate si, differentiate with the rate di or
die by apoptosis with the rate ai, see Figure 9. By self-renewal we understand here that two
daughter cells are identical to the mother cell. In the case of differentiation, daughter cells
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belong to the next sub-population Pi+1. We assume that there is an inﬂux of cells to the ﬁrst
sub-population P1 with a constant rate S. These cells can come from stem cell compartment
or from other immature cell populations. Finally, the cells of the last sub-population Pn can
differentiate into other cells or leave the system. This situation corresponds to the development
of erythroid progenitors in the bone marrow, as discussed in previous chapter.
Under these assumptions, homogeneous in space concentrations ci of cell sub-populations
Pi and cD of dead cells are described by the following system of equations :
dc1
dt
= S + (s1 − d1 − a1)c1 ≡ F1, (2.7)
dci
dt
= (si − di − ai)ci + 2di−1ci−1 ≡ Fi, i = 2, ..., n, (2.8)
dcD
dt
= a1c1 + . . . + ancn ≡ FD. (2.9)
The rates of cell self-renewal, differentiation and apoptosis are determined by intracellular
regulatory networks and can be inﬂuenced by surrounding cells, by the whole cell population
and by external regulatory mechanisms based on hormones and growth factors. We do not consi-
der here intracellular regulatory networks (see previous chapter for more detailed discussion)
and suppose that these rates can be only inﬂuenced by surrounding cells. This means that the
coefﬁcients si, di, ai can depend on c1, ..., cn. In particular, we will take into account the limita-
tion on cell proliferation. When the total cell concentration cΣ = c1 + ...+ cn approaches some
maximal value cmax, cells produce signals which reduce their proliferation rate :
si = s
0
i (cmax − cΣ), di = d0i (cmax − cΣ). (2.10)
It is also possible that cells accelerate their own proliferation or proliferation of other cells. In
the case of linear self-acceleration, instead of (2.8) we will have
si = s
0
i ci(cmax − cΣ), di = d0i ci(cmax − cΣ). (2.11)
In this case
F1(c) = S + (s
0
1 − d01) cm1 (cmax − cΣ)− a1c1,
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Fi(c) = (si − di) cmi (cmax − cΣ) + 2di−1(cmax − cΣ)ci−1 − aici, i = 2, ..., n,
where c = (c1, ..., cn), m = 1, 2. We note that the restriction on cell proliferation by the total
number of cells may not take place. In particular, this can be the case for malignant cells. Similar
models can be written for several cell lineages.
8.1.3 Summary of the models
Depending on the value of cell concentration, we obtain the models which differ by the
equations of motion. If cΣ  φ0, then p = 0. From (2.6) it follows that v = 0 and the model is
reduced to reaction-diffusion system (2.1) without convective terms. The condition on cΣ will
be veriﬁed if cmax < φ0.
If cΣ < φmax, then p = p0(φ). The model is given by equation (2.1) and
ρ

∂v
∂t
= −∇p0(cΣ)− μ
K
v.
Under the quasi-stationary approximation, the last equation is replaced by
v = −K
μ
∇p0(cΣ).
If we consider a linear approximation of the function p0, we obtain v = −κ∇(c1 + ... + cn)
(cf. [44]), where κ = K/μ is a positive parameter.
If cΣ = φmax, then the model is given by equations (2.1), (2.4), (2.6). It is possible to have
all three cases cΣ  φ0, φ0 < cΣ < φmax, cΣ = φmax at the same time, each one in some
subdomain. The boundaries between the subdomains can depend on time.
8.2 Incompressible medium
Let us consider the case cΣ = φmax. Then, in the 1D case, we obtain the system of equations
∂ci
∂t
+
∂(vci)
∂x
= d
∂2ci
∂x2
+ Fi(c), i = 1, ..., n, (2.12)
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∂v
∂x
=
1
φmax
(
n∑
i=1
Fi(c) + FD(c)
)
. (2.13)
We consider it in the bounded interval 0  x  L with the boundary conditions
x = 0 : c1 = c
0
1,
∂ci
∂x
= 0, i = 2, ...n, x = L :
∂ci
∂x
= 0, i = 1, ..., n. (2.14)
This problem is supplemented with the condition ∂v
∂x
= 0 at x = 0 and is also supplemented
with some suitable positive initial data. Up to a normalisation of the parameters, we will assume
in the sequel that c01 = 1. Denote
Fi = (si − di − ai)ci + 2di−1ci−1, c0 = 0, i = 1, . . . , n,
F = F1 + . . . + Fn + FD =
n−1∑
k=1
(si + di)ci + (sn − dn)cn.
Then stationary solutions of Problem (2.12)-(2.14) satisfy the following system of equations :
dc′′i − (cip′)′ + Fi(c) = 0, i = 1, ..., n, (2.15)
p′′ = νF, (2.16)
together with the boundary conditions
c1(0) = 1, c
′
i(0) = 0 i = 2, ..., n,
c′i(L) = 0, i = 1, .., n,
p′(0) = 0, p(0) = 0.
(2.17)
Here v = p′, ν = μ/(Kφmax). We obtain the following result.
Theorem 1. Let us suppose that
di + ai − si  0, i = 1, . . . n, and sn − dn  0.
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Then System (2.15)-(2.17) has a solution (c1,0, .., cn,0, p0) ∈ C2([0, L])n+1 such that
ci,0  0, ∀ i = 1, ..., n. (2.18)
Proof. The proof of this theorem is based on the Leray-Schauder method. A similar problem
but with different boundary conditions was considered in [44].
Denote bi = di + ai − si, i = 1, . . . n, ki = si + di, i = 1, . . . n − 1 and kn = sn − dn and
suppose that all bi and ki are positive. With these notations System (2.15)-(2.16) becomes
dc′′i − (cip′)′ + (2di−1ci−1 − bici) = 0, c0 = 0, i = 1, ..., n,
p′′ = ν
n∑
k=1
kici.
Let us consider the system depending on a parameter τ :
dc′′i − τ(cip′)′ + (τ2di−1ci−1 − bici) = 0, c0 = 0, i = 1, ..., n, (2.19)
p′′ = ν|k1c1 + . . . + kncn|, (2.20)
together with boundary conditions (2.17). Here τ ∈ [0, 1] is the homotopy parameter. If τ =
1, then we obtain the previous problem. For τ = 0 we obtain a model problem with known
properties.
Consider a solution of Problem (2.15), (2.16) and (2.17). Show ﬁrst that ci  0. The equation
for c1 is
dc′′1 − τc′1p′1 − (τp′′ + b1)c1 = 0, c1(0) = 1, c′1(L) = 0. (2.21)
Since (τp′′ + b1) is positive, then c1(x) cannot have negative minima. Indeed, let x0 be a point
of a local minimum of the function c1(x). Then, in this point c′′1(x0) > 0 and c
′
1(x0) = 0.
Substituting it into Equation (2.21) we obtain that c1(x)  0. Let us show that the case where
exists x0 ∈ (0, L) such that c1(x)  0 for x ∈ (0, x0) and c1(x) < 0 for x ∈ (x0, L) is not
possible as well. In this case we would have c′′1(L) > 0 that would provide c1(L) > 0. Thus,
c1(x)  0, ∀x ∈ [0, L]. Repeating this reasoning for every i = 2, . . . , n we obtain that ci  0.
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Thus, Equation (2.20) is transformed into the following one :
p′′ = ν(k1c1 + . . . + kncn).
The second step is to obtain a priori estimates of these solutions. Let us multiply Equa-
tion (2.19) by ci and integrate it over (0, L). Then we obtain
L∫
0
dc′′i cidx−
L∫
0
τ(cip
′)′cidx +
L∫
0
(τ2di−1ci−1 − bici)cidx = 0
d
L∫
0
(c′i)
2dx + bi
L∫
0
c2i dx + dc
′
i(0)ci(0) +
τν
2
L∫
0
c2i (k1c1 + . . . + kncn)dx =
= −τ
2
c2i (L)p
′(L) + 2τdi−1
L∫
0
ci−1cidx
Denote by C positive constants that do not depend on the solution. Since p′(L) =
∫ L
0
(c1 + . . .+
cn)dx, then p′(L)  0 and
C‖ci‖2H1  −dc′i(0)ci(0) + 2τdi−1
L∫
0
ci−1cidx  −dc′i(0)ci(0) + 2di−1
L∫
0
ci−1cidx.
For i = 1 we have
C‖c1‖2H1  −dc′1(0), (2.22)
while for i  2,
C‖ci‖2H1  2di−1
L∫
0
ci−1cidx  2di−1‖ci−1‖L2‖ci‖L2  2di−1‖ci−1‖L2‖ci‖H1 ,
and, therefore,
C‖ci‖H1  2di−1‖ci−1‖L2 .
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By induction, we obtain that for i  2 the following estimate holds :
‖ci‖H1  C‖c1‖H1 . (2.23)
In order to estimate c′1(0), let us integrate the equation for c1 over (0, L). We obtain the equality
−dc′1(0) = τp′(L)c1(L) + b1
L∫
0
c1dx.
We have
p′(L) = ν
∫ L
0
(k1c1 + . . . + kncn)dx.
The Hölder inequality provides the following estimate :
p′(L)  C(‖c1‖L2 + . . . + ‖cn‖L2).
Using (2.23), we obtain
p′(L)  C‖c1‖L2 .
The function c1 satisﬁes the problem
dc′′1 − τc′1p′1 − (τp′′ + b1)c1 = 0, c1(0) = 1, c′1(L) = 0.
Since p′′  0, then from the maximum principle we obtain that c1  1, and then c1(L)  1.
This allows obtaining the following estimate :
−dc′1(0)  C‖c1‖L2 .
Finally, due to (2.22) we conclude that ‖ci‖2H1  C for i = 1, . . . , n. This bound provides
an estimate of p in space H3. Due to Sobolev embedding theorem, we obtain an estimate in
C2[0, L] of the function p and due to equation (2.19) we obtain a bound in C1[0, L] for ci.
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Consider now the Banach space Y deﬁned by
Y =
(
C1([0, L])
)n × C2([0, L]),
endowed with the norm
‖(c1, . . . , cn, p)‖Y = ‖c1‖C1([0,L]) + . . . + ‖cn‖C1([0,L]) + ‖p‖C2([0,L]).
Consider the mapping Tτ : Y → Y deﬁned by Tτ ((c˜1, . . . , c˜n), q) = ((c1, . . . , cn), p), where
(c1, . . . , cn, p) is the solution of the linear system
dc′′i − bici = τ((c˜iq′)′ − 2di−1c˜i−1), c0 = 0, i = 1, ..., n, (2.24)
p′′ = ν(k1c1 + . . . + kncn), (2.25)
together with boundary conditions (2.17). From the elliptic regularity it follows that the mapping
Tτ is a compact operator.
Next, from the above a priori estimates it follows that there exists such constant M > 0 that
for any τ ∈ [0, 1], (C, p) is a ﬁxed point of the operator Tτ implies that ‖C, p‖Y < M. Then, if
we consider B = BY (0,M), then the topological degree deg(I − Tτ , B, 0) is well deﬁned and
from the homotopy invariance we have
deg(I − T0, B, 0) = deg(I − T1, B, 0). (2.26)
The operator T0 corresponds to the constant operator
T (C˜, q) = (c01, . . . , c
0
n, p
0),
where c0i ≡ 0, i  2, the function c01 is given by resolution of the equation
dc′′1 − b1c1 = 0, c1(0) = 1, c′1(L) = 0
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and p0(x) =
∫ L
x
∫ s
0
(c01(t))dtds. Thus we obtain that deg(I − T0, B, 0) = 1 and, due to (2.26),
system (2.15)-(2.17) has a solution. This completes the proof of the theorem.

8.3 Numerical simulations
In this section we present numerical simulations of the system considered in the previous
section but in the 2D space. We suppose for simplicity that all parameters ki deﬁned in the proof
of Theorem 1 are equal to each other. We denote them by k. The system of equations
∂ci
∂t
+∇.(civ) = dΔci + k(ci−1 − ci), i = 1, . . . , n, c0 = 0,
ΔP = k(c1 + . . . + cn), ∇P = νv
is considered in the domain
Ω = (0, Lx)× (0, Ly)
with the boundary conditions
∂P
∂x
(0, y) = 0,
∂P
∂y
(x, 0) = 0,
∂P
∂y
(x, Ly) = 0, P (Lx, y) = 0,
c1(0, y) = 1,
∂c1
∂y
(x, 0) = 0,
∂c1
∂y
(x, Ly) = 0,
∂c1
∂x
(Lx, y) = 0,
∂ci
∂x
(0, y) = 0,
∂ci
∂y
(x, 0) = 0,
∂ci
∂y
(x, Ly) = 0,
∂ci
∂x
(Lx, y) = 0,
i = 2, . . . , n.
The boundary conditions for the pressure mean that the vertical component vy of the velocity
vanishes at the top and at the bottom of the rectangular domain. The horizontal component of the
velocity vx equals zero at the left boundary because there is no convective ﬂux. This means that
stem cells are attached to the left boundary and provide a constant concentration of immature
cells c1. Cell proliferation inside the domain results in cell ﬂow outside the domain through the
right boundary where the pressure is zero.
Computer simulations are carried out using COMSOL Multiphysics 3.4 software. This soft-
ware uses ﬁnite element methods. We do not list technical parameters of the calculations for the
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sake of brevity. The simulations are carried out for three cell populations c1, c2 and c3, Lx = 10,
Ly = 20, d = 0.1, k = 15.
Hereafter we present simulations of the stationary solution the existence of which was pro-
ved in the previous section, simulations of wave propagation and the calculation of the wave
speed.
8.3.1 Stationary solution
We ﬁrst present simulations of the stationary problem. Note that the stationary solution does
not depend on the variable y. Hence, the solution of the 2D problem considered as a function of
x coincides with the 1D stationary solution. Its existence is proved in Section 8.2. Left image
of the Figure 25 represents cell population distributions, the right image shows the pressure
distribution.
Recall that the domain Ω represents a bone marrow in which the wall x = 0 is the wall with
stem cells ﬁxed on it, the boundary x = Lx is the boundary between the bone marrow and the
blood stream. Mature cells pass it and leave the bone marrow into the blood stream. Cells of
population ci are considered to be more mature than those of population ci−1. As we can see
from the left image of Figure 25, the majority of cells located on the left boundary x = 0 are
immature cells of population c1, whereas among cells leaving the bone marrow mature cells are
present in bigger quantity.
8.3.2 2D waves
Suppose that malignant cells appear at some moment of time. These cells lose (or decrease)
their ability to differentiate and excessively self-renew. Their distribution in the bone marrow
can be described by the following equation :
∂s
∂t
+∇.(sv) = dsΔs + kss,
with the same boundary conditions as for other cells :
∂s
∂x
(0, y) = 0,
∂s
∂y
(x, 0) = 0,
∂s
∂y
(x, Ly) = 0,
∂s
∂x
(Lx, y) = 0.
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FIGURE 25 – Stationary solution as a function of the variable x (it does not depend on y).
Simulations are carried out for three cell populations. Left : cell population distributions. Right :
pressure distribution.
In this section we present simulations of propagations of the region ﬁlled by malignant cells. As
initial condition for malignant cell population we consider a function that is zero everywhere
in the domain except for a small area inside the domain, the nidus from which malignant cells
start developing. An example of numerical simulations is given in Figure 26. The values of
the parameters are the same as above. We can see that the concentration of malignant cells
gradually grows and propagates along the bone marrow as a travelling wave. At the ﬁrst stage
of the development the tumour propagates along the x-direction (along the ﬂow), at the second
stage along the y-direction (perpendicular to the ﬂow).
Wave propagation occurs if the stationary solution discussed above becomes unstable. The
stability of the stationary solution for a similar problem is studied in [44].
The speed of the propagation depends on the diffusion coefﬁcients d and ds of normal and
malignant cells, and on the parameters k and ks. We study the speed of propagation in the
section.
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FIGURE 26 – Propagation of malignant cells in the bone marrow. Their concentration at times
t = 0, 0.02, 0.2, 0.6, 1.2 and 1.8. Malignant cells propagate and ﬁnally occupy the whole bone
marrow.
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8.3.3 Wave speed
From mathematical point of view, wave propagation should be studied in the inﬁnite strip
Ω = (0, L)× R. We consider the system of equations
∂ci
∂t
+∇.(civ) = dΔci + k(ci−1 − ci), i = 1, .., n, c0 = 0. (2.27)
∂s
∂t
+∇.(sv) = dsΔs + kss, (2.28)
∇.v = k(c1 + ... + cn) + kss, ∇p = νv, (2.29)
in this domain together with boundary conditions
c1(0, y) = 1, ∂xs(0, y) = ∂xci(0, y) = 0 for y ∈ R and i = 2, .., n, (2.30)
∂xs(L, y) = ∂xci(L, y) = 0 for y ∈ R and i = 1, .., n, (2.31)
∂p
∂x
(0, y) = 0, p(L, y) = 0 for y ∈ R. (2.32)
In order to ﬁnd an analytical approximation of the wave front speed we suppose ﬁrst that
there exists a one-dimensional disease free stationary solution
(ci,0, s0, p0, v0) = (ci,0(x), 0, p0(x), v0(x)).
It corresponds to solutions of the stationary problem in the interval (0, L) :
(ci,0v0)
′ = dc′′i,0 + k(ci−1,0 − ci,0), i = 1, .., n, c0 = 0
v′0 = k(c1,0 + ... + cn,0), p
′
0 = νv0
c1,0(0) = 1, c
′
i,0 = 0 for i = 2, .., n
c′i,0(L) = 0, p
′
0(0) = 0, p0(L) = 0.
This stationary solution is supposed to be stable with respect to the system without malignant
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cells. This means that the eigenvalue problem : ﬁnd λ ∈ C, c1, .., cn and v satisfying
λci + (ci,0v)
′ + (civ0)′ = dc′′i + k(ci−1 − ci), i = 1, .., n, c0 = 0
v′ = k(c1 + ... + cn), p′ = νv
c1(0) = 0, c
′
i(0) = 0 for i = 2, .., n
c′i(L) = 0, p
′(0) = 0, p(L) = 0,
(2.33)
has solutions only with a negative real part, 
λ < 0.
We now consider travelling wave solutions of Problem (2.27)-(2.32), that are solutions in
the form
(c1, .., cn, s, p,v) (t, x, y) = (c˜1, .., c˜n, s˜, p˜, v˜) (x, y − ct),
where c > 0 is the wave speed. In order to simplify the notations, we omit the tilde. Setting
z = y − ct, we obtain that the travelling wave solution satisﬁes the following problem in the
moving frame :
dΔci + c
∂ci
∂z
−∇.(civ) + k(ci−1 − ci) = 0, i = 1, .., n, c0 = 0.
dsΔs + c
∂s
∂z
−∇.(sv) + kss = 0, (2.34)
∇.v = k(c1 + ..cn) + kss, ∇p = νv,
together with the boundary conditions
c1(0, z) = 1, ∂xs(0, z) = ∂xci(0, z) = 0 for z ∈ R and i = 2, .., n,
∂xs(L, z) = ∂xci(L, z) = 0 for z ∈ R and i = 1, .., n,
∂p
∂x
(0, z) = 0, p(L, z) = 0 for z ∈ R.
We are looking for a travelling wave that connects the disease free stationary state when unstable
(with respect to the complete model) to what we expect to be a stationary solution, which
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corresponds to the disease, that is
lim
z→+∞
(c1, .., cn, s, p,v)(x, z) = (c1,0(x), .., cn,0(x), 0, p0(x), v0(x)), (2.35)
∂yp(x,±∞) = 0 for x ∈ (0, L),
and we assume that
∂y(c1, .., cn)(x,±∞) = 0 for x ∈ (0, L).
To ﬁnd the wave speed, we assume that the solution has an exponential behaviour as z →
+∞. More precisely we suppose that
s(z, x) ≈ e−μzs(x) z → +∞.
Since the function s(z, x) is assumed to be positive, one obtains the conditions
μ ∈ (0,∞), s  0.
We substitute the solution in this form into (2.34) and using condition (2.35), we obtain that
(dsμ
2 − cμ)s + ds∂2ys− (sv0(x))′ + kss = 0,
s′(0) = 0, s′(L) = 0.
Consider the operator
Ls = ds∂2ys− (sv0(x))′ + kss, s′(0) = 0, s′(L) = 0. (2.36)
Then, s is its eigenvector and cμ − dsμ2 is an associated eigenvalue. Since s  0, then we
conclude that it is an eigenvector associated with the principal eigenvalue λp > 0 of the operator
L, i.e., Ls = λps, and μ satisﬁes
cμ− dsμ2 = λp, μ > 0.
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This equation has a real and positive solution if and only if c2 − 4dsλp  0, that is for any c
such that
c  c∗ with c∗ = 2
√
dsλp. (2.37)
Finally, we expect that c∗ corresponds to the spreading rate of the malignant cells.
Numerical computations of c∗ for n = 3 and Lx = 1 and direct numerical computations
of the speed of front propagation of malignant cells cnum are presented in Table 5. Wave speed
obtained by the analytical approximation is in a good agreement with the wave speed found by
direct numerical calculations.
TABLE 5 – Comparison between analytical approximation of the wave speed and numerical
simulations. The values of the parameters are d = 0.1, k = 15 and ds = 0.8. Analytical
approximation is obtained through linearisation of the equation.
ks 8 10 12 14 16 18 20
c∗ 2.06 3.26 4.13 4.84 5.46 6.02 6.53
cnum 1.98 3.20 4.06 4.80 5.49 6.15 6.83
Since λp is the principal eigenvalue of the operator L deﬁned by (2.36), one can conclude
that λp depends linearly on ks. Then from (2.37) we obtain that (c∗)2 linearly depends on ks.
We verify this dependence for analytical and numerical computations. For the values given
in Table 5, we test this linear dependence between ks and c2num. The results are presented in
Figure 27.
8.4 Discussion
We studied a spatial model of erythropoiesis. The model consisted of a system of reaction-
diffusion-convection equations in the porous medium described by Darcy’s law. We proved the
existence of a 1D solution. If we introduce malignant cells, which have a higher proliferation
rate than normal cells, then one-dimensional cell distribution can lose its stability. This corres-
ponds to the appearance of tumour. We carried out numerical simulations of tumour growth,
that is of malignant cell propagation. This propagation has a form of a two-dimensional travel-
ling wave. The speed of the wave was calculated in two ways. Firstly, we linearised the system
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FIGURE 27 – Dependence of c2 on ks. Circles : analytical approximation, asterisks : direct
numerical simulations.
and obtained an eigenvalue problem. It allowed us to ﬁnd the minimal wave speed from the
condition of positivity of the corresponding eigenfunction. Secondly, we found the wave speed
in direct numerical simulations. These two approaches are in a good agreement, see Table 5.
9 Nonlocal reaction-diffusion equation
In this section we study a nonlocal reaction-diffusion equation arising in population dyna-
mics. We prove the existence of travelling wave solutions using the Leray-Schauder method.
In order to do this we deﬁne topological degree and obtain a priori estimates of solutions in
weighted Hölder spaces.
9.1 Introduction
We study the integro-differential equation
∂u
∂t
=
∂2u
∂x2
+ J(u) u(1− u)− αu, (2.38)
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where
J(u) =
∫ ∞
−∞
φ(x− y)u(y, t)dy,
φ(x) is a non-negative function with a bounded support and
∫∞
−∞ φ(x)dx = 1. If we replace φ
by a δ-function, then instead of (2.38) we obtain the reaction-diffusion equation
∂u
∂t
=
∂2u
∂x2
+ u2(1− u)− αu. (2.39)
In population dynamics it describes evolution of a population density. The reproduction term
u2(1 − u) is proportional to the square of the density (sexual reproduction) and to available
resources (1− u). The last term in the right-hand side describes mortality of the population. In
some cases the interaction of the individuals in the population can be nonlocal. This can be for
example plants that can distribute their pollen in some area around their location or biological
cells which can send signalling molecules stimulating other cells to proliferate. In this case,
instead of the reaction-diffusion equation we should consider the integro-differential equation
(2.38).
The properties of the reaction-diffusion equation (2.39) are well-known. If 0 < α < 1/4,
then the nonlinearity
F (u) = u2(1− u)− αu
has three zeros :
w+ = 0, w0 =
1
2
−
√
1
4
− α, w− = 1
2
+
√
1
4
− α .
In this case equation (2.39) has a travelling wave solution, that is solution of the form u(x, t) =
w(x− ct), with the limits w(±∞) = w± at inﬁnity. It is unique up to translation in space, and
globally stable.
We study the existence of waves for equation (2.38). In the other words, we look for solu-
tions of the problem
w′′ + cw′ + J(w)w(1− w)− αw = 0. (2.40)
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lim
x→±∞
w(x) = w±. (2.41)
This particular equation represents, for example, cell communitation during the process of hae-
matopoiesis. The main result is stated in the following theorem.
Theorem 2. There exists a monotone travelling wave, that is a constant c and a twice conti-
nuously differentiable monotone function w(x) satisfying (2.40), (2.41).
In the case of the scalar reaction-diffusion equation, the proof of the wave existence is
simple. It is sufﬁcient to reduce the equation
w′′ + cw′ + F (w) = 0
to the system of ﬁrst order equations and to prove the existence of a heteroclinic trajectory. For
obvious reasons, this method is not applicable for the integro-differential equation. The proof
becomes much more involved and requires a rather sophisticated mathematical construction. It
is based on the Leray-Schauder method which implies the existence of a topological degree for
the corresponding operators and a priori estimates solutions.
Topological degree for elliptic operators in unbounded domains is constructed using the
properties of Fredholm and proper operators with the zero index [117, 119, 120]. The same
construction can be used for the nonlocal reaction-diffusion operators. We discuss this question
in Section 9.2. We need to use here weighted spaces. Otherwise the degree may not be deﬁned.
The method to obtain a priori estimates of solutions is similar to the method developed for
monotone reaction-diffusion systems [119]. It is based on the maximum principle which appears
to be applicable for the equations under consideration. This is an important point which should
be emphasised. If the integral enters the nonlinearity in a different way, for example u(1 − J),
as it is the case for the nonlocal Fisher equation, then the maximum principle is not applicable.
In this case, the properties of the equation become quite different. It possesses an interesting
nonlinear dynamics [23, 52] but the wave existence can be proved only in the case of functions
φ with a small support where the perturbation methods are applicable [9, 10]. Here we do not
assume that the support is small. A priori estimates of solutions are proved in Section 9.3.
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9.2 Operators, spaces, topological degree
9.2.1 Operators and spaces
We recall that the Leray-Schauder method, which is used here to prove the existence of
waves, implies that the topological degree for the corresponding operators is deﬁned. If it is the
case, a homotopy of a given operator to some model operator with known properties should be
constructed, and a priori estimates of solutions in the process of this deformation of the operator
should be obtained.
When we consider unbounded domains, we should use some specially chosen weighted
spaces. Otherwise, the degree with the usual properties may not exist. Here we use weighted
Hölder spaces Ck+αμ (R) with the norm
‖u‖Ck+αμ (R) = ‖uμ‖Ck+α(R),
where k is a non-negative integer, 0 < α < 1, Ck+α(R) is the usual Hölder space. Parame-
ter α here is different from constant α introduced in (2.38). The weight function μ(x) has a
polynomial growth at inﬁnity. We take μ(x) = 1 + x2.
Obviously, any function u ∈ Ck+αμ (R) tends to zero at inﬁnity. On the other hand, we look
for solutions of equation (2.40) with the limits (2.41). Therefore, we introduce an inﬁnitely
differentiable function ψ(x) such that ψ(x) = w+ for x  1 and ψ(x) = w− for x  −1 and
put w = u + ψ. Hence we can write equation (2.40) in the form
(u + ψ)′′ + c(u + ψ)′ + J(u + ψ)(u + ψ)(1− u− ψ)− α(u + ψ) = 0. (2.42)
Consider the operator A(u) corresponding to the left-hand side of the previous equation,
A(u) = (u + ψ)′′ + c(u + ψ)′ + J(u + ψ)(u + ψ)(1− u− ψ)− α(u + ψ) (2.43)
and acting in weighted Hölder spaces, A : C2+αμ (R) → Cαμ (R).
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9.2.2 Homotopy
In [10] the authors have proved the existence of solutions in the form of monotone tra-
velling waves for a similar integro-differential equation, in which function φ had a small sup-
port [−ε0, ε0]. In this section we construct a homotopy that relies equation (2.40) to the equa-
tion with function φ having a small support. Let us introduce a family of operators Aτ :
C2+αμ (R)× [0, 1] → Cαμ (R) :
Aτ (u) = (u + ψ)
′′ + c(u + ψ)′ + Jτ (u + ψ)(u + ψ)(1− u− ψ)− α(u + ψ) (2.44)
with
Jτ (u) =
∫ ∞
−∞
φτ (x− y)u(y)dy, (2.45)
where
φτ (x) =
(ε0 − 1)τ + 1
ε0
φ
(
((ε0 − 1)τ + 1)x
ε0
)
. (2.46)
We study the following equation,
w′′ + cw′ + Jτ (w)w(1− w)− αw = 0 (2.47)
If τ = 0 then we obtain operator A0 with function φ(x), which has a small support, and,
thus, the existence of a solution of equation A0(u) = 0 is known [10]. When τ = 1 we obtain
equation (2.40).
Linearised near function u1(x) operator Aτ , introduced in (2.44), is
Lτu = lim
t→0
Aτ (u1 + tu)− Aτu1
t
= u′′ + cu′ + Jτ (w1)(1− 2w1)u + w1(1− w1)Jτ (u)− αu,
(2.48)
where w1 = u1 + ψ. Let us introduce limiting operators of operator L,
Lτ±u = u′′ + cu′ + w±(1− 2w±)u + w±(1− w±)Jτ (u)− αu. (2.49)
Let us recall the deﬁnition of a proper operator and of Condition NS.
Deﬁnition 3 (Properness). Operator A(u) : E0 → E is proper if intersection of an inverse
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image of a compact set with any bounded closed ball B ∈ E0 is compact.
Deﬁnition 4 (Condition NS). We say that the operator L satisﬁes Condition NS if the limiting
equations L±u = 0 do not have nonzero solutions. in C2+α(R).
Lemma 5 (Schauder estimate). For any solution u of equation Lτu = f ∈ Cα(R), the following
estimate holds :
‖u‖C2+α(R)  K(‖Lτu‖Cα(R) + ‖u‖C(R)) (2.50)
where K is a constant.
Proof. The proof of this lemma for similar integro-differential operator can be found in [10].

9.2.3 Fredholm operator with zero index
We recall that an operator satisﬁes the Fredholm property if it is normally solvable, its
kernel has a ﬁnite dimension and the codimension of its image is also ﬁnite. Elliptic operators
in unbounded domains are normally solvable with a ﬁnite dimensional kernel if the Condition
NS is satisﬁed [116]. Invertibility of limiting operators provides the Fredholm property.
The operator Lτ acting from C2+α(R) into Cα(R) satisﬁes the Fredholm property and
has the zero index. The proof of this assertion follows the same lines as for elliptic operators
(cf. [10]). We should verify that the Fredholm property remains valid in the weighted spaces,
Lτ : C
2+α
μ (R) → Cαμ (R), and the index equals zero. From Lemma 2.24 in [119] it follows that
it is sufﬁcient to verify that the operator
Ku = μLτu− Lτ (μu), K : C2+αμ (R) → Cα(R)
is compact. Consider a sequence {ui} such that ‖ui‖C2+αμ (R)  M. We should prove that from
the sequence {Kui} we can ﬁnd a convergent in Cα(R) subsequence. Put vi = uiμ. Then
‖vi‖C2+α(R)  M. From the sequence {vi} we can ﬁnd a subsequence, denoted again by {vi},
convergent locally in C2 to some function v0. Denote zi = vi − v0, then
‖Kui −Ku0‖Cα(R) = ‖Kzi
μ
‖Cα(R),
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where ‖zi‖C2+α(R)  M1, zi → 0 in C2 locally. Denote yi = K(zi/μ). We should prove that
‖yi‖Cα → 0. The deﬁnition of the operator K gives
yi = μLτ (zi/μ)− Lτzi =(
−ziμ
′′
μ
− 2z′i
μ′
μ
+ 2zi
(
μ′
μ
)2
− cziμ
′
μ
)
+ w1(1− w1)(μJ(zi/μ)− J(zi)). (2.51)
We have
μJ(zi/μ)− J(zi) =
∫ ∞
−∞
φ(ξ)zi(x− ξ)
(
μ(x)
μ(x− ξ) − 1
)
dξ.
Both terms in the right-hand side of (2.51) uniformly tends to zero at inﬁnity. From this and
from the local convergence zi → 0 in C2, it follows that yi converges to zero in Cα(R).
9.2.4 Properness
In this section we show that operator Aτ , deﬁned in (2.44), is proper. First, let us prove the
following lemma.
Lemma 6. For any u, u0 ∈ C2+αμ and τ, τ0 ∈ [0, 1] the following representation holds
Aτ (u)− Aτ0(u0) = A′τ0(u0)(u− u0) + ϕ(u, u0, τ, τ0), (2.52)
where A′τ0(u0)(u− u0) = Lτ0(u0)(u− u0) and
ϕ(u, u0, τ, τ0) = Jτ (w)w(1− w)− Jτ0(w)w0(1− w0)− Jτ0(w0)(1− 2w0)(w − w0),
where w = u + ψ and w0 = u0 + ψ. Moreover
ϕ(u, u0, τ0, τ0) = (u− u0)(Jτ0(w)(1− w − w0)− Jτ0(w0)(1− 2w0)). (2.53)
Proof. Let us denote the difference Aτ (u)−Aτ0(u0)−Lτ0(u0)(u− u0) by ϕ(u, u0, τ, τ0), then
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using (2.44) and (2.48) we obtain
ϕ(u, u0, τ, τ0) = (u− u0)′′ + c(u− u0)′ + Jτ (w)w(1− w)− Jτ0(w0)w0(1− w0)− α(u− u0)−
(u− u0)′′ − c(u− u0)′ − Jτ0(w0)(1− 2w0)(w − w0)− w0(1− w0)Jτ0(w − w0) + α(u− u0) =
Jτ (w)w(1− w)− Jτ0(w0)w0(1− w0)− Jτ0(w0)(1− 2w0)(w − w0)− w0(1− w0)Jτ0(w − w0) =
Jτ (w)w(1− w)− Jτ0(w)w0(1− w0)− Jτ0(w0)(1− 2w0)(w − w0).
Simple transformation of ϕ(u, u0, τ0, τ0) gives (2.53). The lemma is proved.

Theorem 7 (properness of operator Aτ ). If the operator Lτ , deﬁned in (2.48), satisﬁes Condi-
tion NS, then the operator Aτ (u), deﬁned in (2.44), is proper with respect to both u and τ.
Proof. Consider a convergent in Cαμ (R) sequence {fn} → f0 and solutions of the equations
Aτn(un) = fn (2.54)
bounded inC2+αμ (R)×[0, 1], ‖un‖C2+αμ (R) M.We should prove the existence of a subsequence
{umn} that is convergent in C2+αμ (R) to a function u0 ∈ C2+αμ (R).
Since {un} is bounded in C2+αμ (R), it admits a subsequence {unm}, which is convergent
to a function u0, uniformly on any bounded interval I ⊂ R. By diagonalisation process we
prolong u0 to all R. The limit function u0 ∈ C2+αμ (R). Passing to the limit m →∞ in equation
Aτnm (unm) = fnm we obtain
Aτ0(u0) = f0. (2.55)
We know that unm → u0 uniformly on any bounded interval I. Let us show that the convergence
is uniform with respect to x on the whole axis, unm → u0 in C(R).
Let us write the subscript n instead of nm and denote
vn = unμ, v0 = u0μ, zn = vn − v0, gn = fnμ, g0 = f0μ. (2.56)
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Subtracting (2.55) from (2.54) and multiplying it by μ we obtain
(Aτn(un)− Aτ0(un))μ + (Aτ0(un)− Aτ0(u0))μ = gn − g0. (2.57)
Denote
rn = (Aτn(un)− Aτ0(un))μ, (2.58)
then we have
‖rn‖Cα(R) → 0, n →∞.
Injecting (2.56), (2.58), operator deﬁnition (2.44) into (2.57) and taking into account Lemma 6
we obtain
z′′n+z
′
n + Jτ0(w0)(1− 2w0)zn + w0(1− w0)Jτ0(un − u0)μ− αzn+(
−znμ
′′
μ
− 2z′n
μ′
μ
+ 2zn
(
μ′
μ
)2
− cznμ
′
μ
)
+ ϕ(un, u0, τ0, τ0)μ = gn − g0 − rn.
(2.59)
We should prove that there exists a subsequence {znk} convergent uniformly on the whole
axis, znk → 0 in C(R). Suppose that it is not true. Then there exists an unbounded sequence
{xm}, such that |zm(xm)|  ε > 0. Let us introduce shifted functions,
z˜m(x) = zm(x + xm).
Since ‖z˜m‖C2+α(R) M, from sequence {z˜m} we can choose a subsequence {z˜mk(x)} conver-
ging to a limiting function z˜0 ∈ C2+α(R) in C2 uniformly on any bounded interval I ⊂ R (the
same reasoning as above). We have |z˜0(0)|  ε > 0. Functions z˜mk(x) with shifted arguments
satisfy equation (2.59). From deﬁnition of weight function μ we obtain
μ′(x + xm)
μ(x + xm)
→ 0, μ
′′(x + xm)
μ(x + xm)
→ 0 as xm →∞.
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From (2.53) :
ϕ(um(x + xm), u0(x + xm), τ0, τ0)μ =
z˜m(x)(Jτ0(wm(x + xm))(1− wm(x + xm)− w0(x + xm))− Jτ0(w0(x + xm))(1− 2w0(x + xm))).
Since w0(x + xm), wm(x + xm) → w±0 as m →∞, we obtain that
‖ϕ(um(x + xm), u0(x + xm), τ0, τ0)μ‖Cα → 0 as m →∞.
By deﬁnition of gm and g0, ‖gm − g0‖Cα(R) → 0 as m → ∞. In the limit m → ∞, equa-
tion (2.59) becomes
L̂z˜0 = 0,
which means that limiting operator L̂ admits a nonzero solution. This contradicts Condition
NS. Thus, convergence zm → 0 is uniform in C(R). Using this convergence and Schauder
estimate (Lemma 5) we obtain convergence zm → 0 in C2+α(R), which means the convergence
um → u0 in C2+αμ (R). This completes the proof.

9.2.5 Functionalisation of parameter c
We recall that parameter c in (2.40) is an unknown constant that should be found along
with function w(x). Note that solutions of (2.40) are invariant with respect to translation, i.e. if
w(x) = u(x) + ψ(x) is a solution of (2.40), then w(x + h) = u(x + h) + ψ(x + h) is also a
solution of this equation for all h ∈ R. Then the weighted norm ‖u(x + h)μ(x)‖C2+α tends to
inﬁnity as h → ±∞. Hence the set of solutions of the equation A(u) = 0 is not bounded in the
space C2+αμ (R), and the topological degree cannot be applied.
To get rid of the invariance of solutions with respect to translation, we apply functionali-
sation of parameter c ﬁrst used for travelling waves in [117, 118]. We introduce a functional
c = c(u) that satisﬁes the following properties :
1. c(u) satisﬁes Lipschitz condition on every bounded set in C2+αμ (R) and has a continuous
Fréchet derivative,
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2. function c˜(h) = c(u(x + h)) is a decreasing function of h, such that c˜(−∞) = +∞ and
c˜(+∞) = −∞,
3. the solution w = u + ψ of equation (2.40) satisﬁes
〈c′(u), w′〉 = 0.
We introduce the following function
c(u) = ln
∫
R
(u(x) + ψ(x)− w+)2σ(x)dx,
where σ(x) is an increasing function, with σ(−∞) = 0, σ(+∞) = 1 and
∫ 0
−∞
σ(x)dx < ∞.
The function c(u) introduced in this way satisﬁes the conditions enumerated above, the proof
can be found in [117]. Equation (2.40) is equivalent to the equation
(u + ψ)′′ + c(u)(u + ψ)′ + J(u + ψ)(u + ψ)(1− u− ψ)− α(u + ψ) = 0. (2.60)
9.2.6 Construction of topological degree
Consider an operator A acting from a Banach space E into another Banach space F . By
deﬁnition, topological degree is an integer number γ(A,D) which depends on the operator
and on the domain D in the function space E. Topological degree for elliptic operators in
unbounded domains is constructed in [119, 120] on the basis of the theory of Fredholm and
proper operators. The results on the Fredholm property and properness of the integro-differential
operators presented above allow us to use the same construction.
One of the main applications of the topological degree is related to the Leray-Schauder
method widely used to prove existence of solutions of various problems. We brieﬂy recall the
main ideas of this method. If the operator Aτ continuously depends on the parameter τ and
Aτ (u) = 0, u ∈ ∂D, τ ∈ [0, 1], (2.61)
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then the value γ(Aτ , D) of the degree does not depend on τ . This property is called homotopy
invariance. If we can reduce the operator A = A1 by a continuous deformation to a model
operator A0 for which γ(A0, D) = 0 and (2.61) is satisﬁed, then γ(A,D) = 0. Another property
of the degree, nonzero rotation, ensures that the equation A(u) = 0 has a solutions in the domain
D.
Let us take as a domain D a ball B of the radius R. Then condition (2.61) will be satisﬁed
if all solutions of the equation Aτ (u) = 0 satisfy the inequality ‖u‖  R. These are a priori
estimates of solutions. They play a crucial role in the proof of the existence of solutions. We
discuss them in the next section.
9.3 A priori estimates
A priori estimates of travelling wave solutions have some speciﬁc features. We note ﬁrst
of all that they imply not only the estimate of the function w(x) but also of the wave velocity.
Moreover, the function w(x) should be estimated in the weighted space. We consider in fact the
function u(x) = w(x)−ψ(x) with the zero limits at inﬁnity. It decays exponentially at inﬁnity,
so its weighted norm with a polynomial weight is limited. The difﬁculty is to estimate it "far"
from inﬁnity.
To explain the origin of this difﬁculty, let us consider the following geometrical interpreta-
tion. Travelling wave is a heteroclinic trajectory of some ﬁrst order ordinary differential system
of equations. Suppose that this trajectory approaches some intermediate stationary point during
the deformation of the system. In the limit we can obtain two heteroclinic trajectories which
connect consecutively three stationary points.This situation corresponds to loss of a priori esti-
mates in the weighted space. Thus, we need to prove that the trajectory, which corresponds to
the travelling wave, cannot approach intermediate stationary points or other invariant manifolds.
We will follow here the method developed in [117, 118] for monotone reaction-diffusion
systems. It consists of two steps. First of all, we separate monotone and non-monotone solu-
tions w(x) of problem (2.40), (2.41). This means that two sequences of solutions, wjM(x) and
wjN(x), where the former are monotone with respect to x and the latter non-monotone, can-
not converge in C2(R) to the same limiting function. This result allows us to deal only with
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monotone solutions. At the second step, we obtain a priori estimates of monotone solutions.
According to the geometrical interpretation given above, we prove that the trajectory cannot be
attracted by an intermediate stationary point. This will follow from the sign of the wave velo-
city. Here we use the monotonicity of solutions. Otherwise, the intermediate manifold can have
a more complex structure, and the method is not applicable.
9.3.1 Monotonicity
In this section we show that monotone solutions of equation (2.47) are strictly monotone. We
begin with an auxiliary result on the positiveness of solutions of the linear parabolic equation
∂v
∂t
=
∂2v
∂x2
+ a(x, t)J(v) + b(x, t)v (2.62)
in x ∈ R assuming that a(x, t) and b(x, t) are continuous functions, a(x, t)  0. We cannot
directly use the classical positiveness theorems here because of the integral term in the right-
hand side.
Lemma 8. Suppose that a(x, t) + b(x, t) < 0 for |x|  N , 0  t  T with some positive N
and T . If v(x, 0)  0 and v(x, 0) ≡ 0, then v(x, t) > 0 for 0  t  T .
Proof. Suppose that the assertion of the lemma does not hold. If there exists such (x0, t0) that
v(x0, t0) = 0, v(x, t0)  0 for all x ∈ R, and v(x, t) > 0 for all x ∈ R and 0 < t < t0, then
we obtain a contradiction with the classical positiveness theorem [48]. Indeed, we can write
equation (2.62) in the form
∂v
∂t
=
∂2v
∂x2
+ b(x, t)v + c(x, t),
where c(x, t) = a(x, t)J(v)  0 for all x and 0  t  t0. Since v(x, 0) is non-negative and not
identically zero, then v(x, t0) should be strictly positive.
Otherwise, the solution becomes negative for some t1 > 0. Then there exists such t0, 0 
t0  t1 that v(x, t0)  0 for all x ∈ R and v(xk, tk) < 0 for some sequences xk and tk > t0,
tk → t0 as k →∞. If the sequence xk is bounded, then we can ﬁnd a convergent subsequence.
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Denote its limit by x0. Then v(x, t0)  0 for all x and v(x0, t0) = 0. As above, we obtain the
contradiction with the positiveness theorem.
Hence, the sequence xk does not have bounded limiting points. Without loss of generality
we can assume that xk → +∞. For each ﬁxed t we have v(x, t) → 0 as x →∞. Therefore, the
function v(x, t) has a negative minimum that we denote by xmk . As before, x
m
k → +∞.
Let us choose k sufﬁciently large such that xmk > N . Put z = v +  where  = |v(xmk , tk)|.
Then z satisﬁes the equation
∂z
∂t
=
∂2z
∂x2
+ a(x, t)J(z) + b(x, t)z − (a(x, t) + b(x, t)). (2.63)
Moreover, z(x, tk)  0 for all x, 0  t  tk and z(xk, tk) = 0. We obtain a contradiction in
signs in the last equation. Indeed, the time derivative at the point x = xk, t = tk is non-positive,
while all all terms in the right-hand side are non-negative. The last term is strictly positive. The
lemma is proved.

Lemma 9. If w0(x) is a non-constant solution of equation (2.47) such that w′0(x)  0 for all
x ∈ R, then w′0(x) < 0.
Proof. Denote v = −w′. Differentiating equation (2.47) and taking into account that J ′(w) =
J(v), we obtain
v′′ + cv′ + a(x)J(v) + b(x)v = 0,
where
a(x) = w(1− w), b(x) = J(w)(1− 2w)− α,
a(x) + b(x) < 0 for |x| sufﬁciently large. We should prove that solution of this equation, which
satisﬁes v  0, is strictly positive. This follows from Lemma 8 if we take function v(x) as
initial condition.

Lemma 10. If wj(x) is a sequence of solutions of problem (2.47), (2.41) such that wj → w0 in
C1(R), where w′0(x)  0, x ∈ R, then for all j sufﬁciently large 0 < wj(x) < 1 and w′j(x) < 0,
x ∈ R.
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Proof. Let us ﬁrst prove the inequality 0 < wj(x) < 1. The right inequality holds for j sufﬁ-
ciently large because of the uniform convergence wj → w0 and 0 < w0(x) < w− < 1. We now
verify that wj(x) is positive for all x. If this is not the case, then each of these functions has a
negative minimum xj . From the uniform convergence wj → w0 it follows that xj → +∞ and
J(wj(xj)) → 0. Hence,
w′′j (xj)  0, w′j(xj) = 0, J(wj(xj))(1− wj(xj))− α < 0, wj(xj) < 0.
This gives a contradiction in signs in the equation
w′′j + cw
′
j + (J(wj)(1− wj)− α)wj = 0.
Next, we prove that the functions wj are decreasing. Suppose that this assertion does not
hold and there exists a sequence xj such that w′j(xj) = 0. If it is bounded, then there exists a
subsequence converging to some point x0. Hence w′0(x0) = 0. We obtain a contradiction with
Lemma 9.
Consider now the case where xj → +∞. Denote v = −w′. Differentiating equation (2.47)
and taking into account that J ′(w) = J(v), we obtain
v′′ + cv′ + a(x)J(v) + b(x)v = 0,
where
a(x) = w(1− w), b(x) = J(w)(1− 2w)− α.
If vj(x)  0 for all x, then the existence of xj such that vj(xj) = 0 contradicts Lemma 9.
Therefore, there exist negative values of this function for each j. On the other hand, from the
convergence w′j → w′0 it follows that vj is positive in each given interval for j sufﬁciently large.
Finally, note that vj(x) → 0 as x → ±∞. Hence, there exists a sequence xˆj → ∞ such that it
is a negative minimum of the function vj(x). The uniform convergence w′j(x) → w′0(x) implies
that vj(xˆj) → 0 as j →∞.
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Put  = vj(xˆj) for some j sufﬁciently large and z(x) = vj(x) + . Then
z′′ + cz′ + a(x)J(z) + b(x)z − (a(x) + b(x)) = 0. (2.64)
Moreover, z(x)  0 for −∞ < x < ∞, z(xj) = 0. Hence z′′(xj)  0, z′(xj) = 0, J(z)(xj) 
0. Since 0 < wj(x) < 1, then a(xj) > 0. It remains to note that a(xj) + b(xj) < 0 for j
sufﬁciently large. Indeed, if xj → +∞, then a(xj) → 0, b(xj) → −α. If xj → −∞, then
a(xj) → α, b(xj) → w−(1− 2w−)− α, that is
a(xj) + b(xj) → w−(1− 2w−) < 0.
We obtain a contradiction in signs in equation (2.64). The lemma is proved.

9.3.2 Estimates of derivatives
In this section we obtain estimates in C(−∞,+∞) of the derivatives w′(x) and w′′(x) of the
solution w(x) of equation (2.47). We will use the notation R2 = max|w|R
|Jτ (w)w(1− w)− αw|.
Lemma 11. Let solution w(x) of equation (2.47) satisfy inequality |w(x)|  R for all x. Then
the derivatives w′(x) and w′′(x) can be estimated in C(−∞,+∞) by a constant, depending
only on R and R2.
Proof. Let us ﬁrst obtain an estimate for the ﬁrst derivative w′(x). We consider two cases,
|c|  1 and |c| < 1. Suppose that |c|  1. The second derivative w′′(x) equals zero when w′(x)
is at its extremum point, which we denote by x0. Then from equation (2.47) we obtain
|w′(x)|  |w′(x0)|  |Jτ (w(x0))w(x0)(1− w(x0))− αw(x0))|  R2, ∀x ∈ R.
Suppose now that |c| < 1. Consider an interval [α, β] where |w′(x)|  1. Integrating equa-
tion (2.47) over the interval [α, x], we obtain
w′(x)− w′(α) + c(w(x)− w(α)) +
x∫
α
(Jτ (w(x))w(x)(1− w(x))− αw(x))dx = 0.
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This provides
|w′(x)|  1 + |c||w(x)− w(α)|+ R2(β − α)  1 + 2R + R2(β − α).
The mean-value theorem gives
|w(β)− w(α)| = |w′(x0)|(β − α)  (β − α),
which provides that β − α  2R and thus ﬁnally we obtain
|w′(x)|  1 + 2R + 2RR2.
So we have estimated the ﬁrst derivative of the function w(x). Let us now estimate the second
derivative. From equation (2.47) we obtain
|w′′(x)|  |cw′(x)|+ R2.
The ﬁrst term in the right-hand side has its maximum when w′(x) reaches its extremum, that is
w′′(x) = 0 at this point. Therefore, from equation (2.47)
|cw′(x)|  R2.
Hence
|w′′(x)|  2R2,
which completes the proof of the lemma.

9.3.3 A priori estimates of the speed
In this section we obtain a priori estimates of the speed c of monotone waves. Suppose that
there exists a solution w(x) of equation (2.40) for some c = c0 with the limits (2.41) at inﬁnity.
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Let us estimate the value c0 of the speed. For this purpose we consider the evolution equation
∂u
∂t
=
∂2u
∂x2
+ c0
∂u
∂x
+ J(u)u(1− u)− αu. (2.65)
So that w(x) is a stationary solution of this equation. Let u(x, t) be a solution of equation (2.65)
and v = u− w0, where w0 < 1/2 satisﬁes w0(1− w0) = α. Then v satisﬁes the equation
∂v
∂t
=
∂2v
∂x2
+ c0
∂v
∂x
+ J(v)(1− w0)u− J(u)uv. (2.66)
Suppose that 0 < u < 1 and v > 0. Then
J(v)(1− w0)u− J(u)uv  J(v). (2.67)
Next, consider the equation
∂z
∂t
=
∂2z
∂x2
+ c0
∂z
∂x
+ Jη(z), (2.68)
where
Jη(z) =
∫ ∞
−∞
η(x− y)z(y, t)dy,
η(x) is a piece-wise constant function equal M = supx φ(x) in the support of the function φ(x)
and zero otherwise. Let the support of the function η(x) be [−N,N ]. Let us look for a solution
of the equation
w′′ + cw′ + Jη(w) = 0 (2.69)
for some c possibly different from c0 in the form of the exponential w(x) = e−λx. We obtain
λ2 − cλ + M
λ
(
eλN − e−λN) = 0.
For any M and N , if c is sufﬁciently large, then this equation has a solution λ. Let us take
these values of c and λ and consider the corresponding solution w(x) of equation (2.69). Then
z(x, t) = w(x − (c − c0)t) is a solution of equation (2.68), which has a constant proﬁle and
moves to the right with the speed (c − c0). The function uˆ(x, t) = z(x, t) + w0 satisﬁes the
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FIGURE 28 – The estimate of the speed of the travelling wave solution of equation (2.38). The
wave w propagates with the speed c0, the solution uˆ with the speed c. The wave remains below
the solution. If it touches it, this will contradict the comparison of solutions. Hence c > c0.
equation
∂uˆ
∂t
=
∂2uˆ
∂x2
+ c0
∂uˆ
∂x
+ Jη(uˆ− u0) (2.70)
Let us now compare the solution u(x, t) of equation (2.65) and the solution uˆ(x, t) of equa-
tion (2.70) (Figure 1). We recall that u(x, t) → w± as x → ±∞ for each t  0 and uˆ(x, t) is
a strictly decreasing function converging to w0 as x → +∞ and exponentially growing at −∞.
Hence, we can choose a constant h such that u(x, 0) < uˆ(x− h, 0) for all x ∈ R. We are going
to prove that u(x, t) < uˆ(x − h, t) for all x ∈ R and t  0. Suppose that this is not true. Then
there exists t0 > 0 such that u(x, t0)  uˆ(x− h, t0) for all x ∈ R and u(x0, t0) = uˆ(x0 − h, t0)
for some x0. Since uˆ(x0 − h, t0) > w0, then v(x0, t0) > 0. This inequality holds in some
neighborhood δ(x0) of x = x0. Moreover, 0 < u(x, t) < 1, J(u) > 0. Hence, by virtue of
(2.67),
J(u)u(1−u)−αu = J(v)(1−w0)u−J(u)uv  J(v) = J(u−w0)  Jη(uˆ−w0), x ∈ δ(x0).
We obtain a contradiction with the positiveness theorem. Thus, if there exists a stationary solu-
tion w(x) of equation (2.65), then we put u(x, 0) = w(x) and obtain w(x) ≡ u(x, t) < uˆ(x, t).
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Therefore, c0 < c, where c is the value of the speed chosen above.
In order to estimate the speed c from below, we repeat a similar construction with a solution
w(x) such that w(x) → w0 as x →∞ and exponentially decreasing as x → +∞. It propagates
to the left with a certain speed (c− c0). We thus have proved the following theorem.
Theorem 12. For any arbitrary solution (c, w) of problem (2.47), (2.41), where w(x) is mono-
tonically decreasing function, there exists an estimate of the speed c independent of τ.
9.3.4 Sign of the speed
In this section we consider behaviour of solutions of equation (2.47) as x → ±∞. The
subscript τ is omitted. We prove that the waves connecting a stable point with an unstable point
can exist only with the speed of a certain sign. This will be used below in order to obtain a priori
estimates of solutions. We begin with an auxiliary result.
Lemma 13. Suppose that v(x) is a decreasing positive function, φ(x) is even and non-negative.
Then for any N
∫ ∞
N
dx
∫ ∞
−∞
φ(x− y)v(y)dy 
∫ ∞
N
dx
∫ ∞
−∞
φ(x− y)v(x)dy. (2.71)
If v is a positive and increasing function, then
∫ N
−∞
dx
∫ ∞
−∞
φ(x− y)v(y)dy 
∫ N
−∞
dx
∫ ∞
−∞
φ(x− y)v(x)dy. (2.72)
It is assumed that all these integrals exist.
Proof. We have
∫ ∞
N
dx
∫ ∞
N
φ(x− y)v(y)dy =
∫ ∞
N
dx
∫ ∞
N
φ(x− y)v(x)dy.
If v is decreasing, then
∫ ∞
N
dx
∫ N
−∞
φ(x− y)v(y)dy 
∫ ∞
N
dx
∫ N
−∞
φ(x− y)v(x)dy
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since y  N  x in the domain of integration and, consequently, v(y)  v(N)  v(x). Taking
a sum of the last two relations, we obtain (2.71).
Consider now the second case. From the equality
∫ N
−∞
dx
∫ N
−∞
φ(x− y)v(y)dy =
∫ N
−∞
dx
∫ N
−∞
φ(x− y)v(x)dy
and inequality
∫ N
−∞
dx
∫ ∞
N
φ(x− y)v(y)dy 
∫ N
−∞
dx
∫ ∞
N
φ(x− y)v(x)dy,
which takes place since in the domain of integration x  N  y and v(x)  v(N)  v(y), we
obtain (2.72). The lemma is proved.

Let w0 < 1/2 be a solution of the equation u(1 − u) = α. Suppose that there exists a
decreasing solution u(x) of equation (2.47) such that u(x) → w0 as x → +∞. Put u(x) =
w0 + v(x). Then
v′′ + cv′ + (J(v)(1− w0)− (w0 + J(v))v)(w0 + v) = 0. (2.73)
Consider ﬁrst the linear equation
v′′ + cv′ + (J(v)(1− w0)− w0v)w0 = 0 (2.74)
and integrate it from N to +∞ :
−v′(N)− cv(N) + I+(N) = 0, (2.75)
where
I+(N) = w0(1− w0)
∫ ∞
N
dx
∫ ∞
−∞
φ(x− y)v(y)dy − w20
∫ ∞
N
dx
∫ ∞
−∞
φ(x− y)v(x)dy.
Since 1− w0 > w0, then by virtue of Lemma 13, I+(N) > 0 for any N. We recall that v(x) is
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positive and decreasing. Therefore, equality (2.75) can take place only if c > 0.
The corresponding integral remains positive for equation (2.73) since J(v) → 0 as x → +∞
and for any  > 0, w0 + J(v)  w0 + , x  N for N sufﬁciently large. Therefore, integrating
(2.73), we obtain, as before, that c > 0.
Suppose now that there exists a decreasing solution u(x) of equation (2.47) such that u(x) →
w0 as x → −∞. Put v(x) = w0 − u(x). Then v(x) is a positive increasing function. As above,
we obtain equation (2.74). Integrating it from −∞ to N , we obtain
v′(N) + cv(N) + I−(N) = 0, (2.76)
where
I−(N) = w0(1− w0)
∫ N
−∞
dx
∫ ∞
−∞
φ(x− y)v(y)dy − w20
∫ N
−∞
dx
∫ ∞
−∞
φ(x− y)v(x)dy.
It follows from (2.72) that I−(N)  0. Then from (2.76), c < 0. Thus, we have proved the
following lemma.
Lemma 14. If there exists a decreasing solution of equation (2.47) with the limits w(−∞) =
w−, w(+∞) = w0, then c > 0. If such solution has the limits w(−∞) = w0, w(+∞) = w+,
then c < 0.
9.3.5 A priori estimates of solutions
In this section we obtain a priori estimates of monotone solutions of equation (2.47) with
conditions (2.41). We begin with the lemma which states exponential behaviour of solutions at
inﬁnity.
Lemma 15. There exists a constant ε > 0 such that the following estimates of monotone solu-
tions wτ (x) of problem (2.47), (2.41) hold
|wτ (x)− w+|  Ke−ax (2.77)
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for such x that |wτ (x)− w+|  ε, and
|wτ (x)− w−|  Ke−bx (2.78)
for such x that |wτ (x)−w−|  ε. Moreover, constants K > 0, a > 0 and b > 0 are independent
of τ and of solution wτ (x).
Proof. Consider ﬁrst behavior of solutions of equation (2.47) as x →∞. Since wτ → w+ = 0,
and it is monotonically decreasing, then for sufﬁciently large x we can estimate the integral
Jτ (w) by a small constant β > 0 such that β < α,
Jτ (w(x))  β, ∀x > x0,
which provides
Jτ (w(x))w(x)(1− w(x))− αw(x)  (β − α)w(x), ∀x > x0.
We can now compare solutions of equation (2.47) with the equation
v′′ + cv′ + (β − α)v = 0, β < α
Exponential behaviour of solutions of this equation is well known. It remains to prove that
monotone solutions w(x) of equation (2.47) can be majorated by solutions v(x) of the previous
equation, i.e.
w(x)  v(x), ∀x > x0. (2.79)
To do so, consider the difference z(x) = v(x)− w(x). It satisﬁes the following equation :
z′′ + cz′ + (β − α)z + ((β − α)w − Jτ (w)w(1− w)− αw) = 0.
It can be rewritten as
z′′ + cz′ + (β − α)z + g(x) = 0, (2.80)
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where g(x)  0 for all x > x0. Consider this equation on the half-axis [x0,+∞) with the
boundary conditions z(x0) = 0 and z(x0) → 0 as x → 0. If we prove that solutions of this
problem satisfy z(x)  0 for all x  x0, then estimate (2.79) will be proved. Let us assume that
this is not true. Hence z(x) has negative values. Since it converges to zero at inﬁnity, then there
exists a point x2 > x0 where the function z(x) attains its negative minimum. At this point we
have z′′(x2)  0, z′(x2) = 0, (β − α)z(x2) > 0 and g(x2) > 0. We obtain a contradiction in
signs in equation (2.80). Estimate (2.77) follows from (2.79). Estimate (2.78) can be proved in
a similar way.

Lemma 16. There exists a constant χ > 0 such that outside of the ε-neighbourhoods of the
points w+ and w− the following estimate holds |w′τ (x)|  χ for arbitrary monotone solution
wτ (x) of the problem (2.47), (2.41). Constant χ is independent of the parameter τ and of solu-
tion wτ (x), constant ε is deﬁned in Lemma 15.
Proof. Let us assume that the assertion of the lemma does not hold. Then there exist sequences
{τk}, {wτk}, {xk} such that w′τk(xk) → 0 and points xk do not belong to ε-neighbourhoods of
points w− and w+. We can assume that τk → τ0 and ck → c0, where τ0 ∈ [0, 1], c0 is a constant,
and ck is the speed of the wave wτk .
Since solutions of equation (2.47) are invariant relative to translation with respect to x, we
can assume that |wτk(0) − w−| = ε. We can also assume that the sequences {wτk(0)} and
{w′τk(0)} are convergent with limits y and z, respectively. Denote by v(1)(x) the solution of
equation (2.47) for c = c0, τ = τ0 with initial conditions v(1)(0) = y, v(1)′(0) = z. It is clear
that v(1)(x) → w− as x → −∞.
Let us suppose that v(1)(x) → w+ as x → ∞. Then, outside of the ε-neighbourhoods of
the points w−, w+, function v(1)(x) exists on a ﬁnite interval with respect to x. Since solutions
wτk(x) converge to v
(1)(x), then, for some x = x0, we have v(1)′(x0) = 0, and the point v(1)(x0)
lies outside the ε-neighbourhoods of the points w−, w+. This contradicts Lemma 9. Thus v(1)(x)
is a monotone (not necessarily strict) function not tending towards w+. Then v(1)(x) tends to
w0 as x →∞, where w0 is such that w0(1− w0)− α = 0.
In a similar way we may prove existence of function v(2)(x) having limits w0 as x → −∞
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and w+ as x → ∞. Thus we have simultaneously two solutions of equation (2.47) with the
same wave speed c = c0. This contradicts Lemma 14, which completes the proof of the lemma.

Lemma 17. LetMr (r  0) be the set of all monotone solutions of problem (2.47),(2.41) for
all τ such that for x0 deﬁned by
wτ (x0) = w0
holds the estimation |x0|  r. Then there exists such a constant Mr that for all w ∈ Mr the
following estimate holds,
‖w − ψ‖C2+αμ (R) Mr. (2.81)
Proof. Let w be fromMr and points x1 and x2 be deﬁned by the equalities
|w(x1)− w−| = ε, |w(x2)− w+| = ε,
where the constant ε is deﬁned in Lemma 15, ε < w0. Then
x1 < x0 < x2, |x0|  r. (2.82)
Let χ be the constant in the estimate of w′(x), presented in Lemma 16. Then
0 < x2 − x1 < (w− − w+)/χ := N. (2.83)
We suppose that χ < 1. From (2.82) and (2.83) we obtain that
|x1|  N + r, |x2|  N + r.
From Lemma 15 we conclude that solutions w(x) approach ψ(x) exponentially outside the
interval [x1, x2]. Thus we conclude that
‖w − ψ‖C2+αμ (R) = ‖w − ψ‖C2+αμ ([x1,x2]).
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This norm, in turn, is
‖w − ψ‖C2+αμ ([x1,x2]) = ‖(w − ψ)μ‖C2+α([x1,x2]).
The estimate of the norm in the right-hand side follows from the estimate of the Hölder norm
of the functions w and μ. The former follows from Lemma 11 for the function itself and its ﬁrst
two derivative. The norm Cα of the second derivative can be obtained from the equation. The
estimate of the Hölder norm of μ follows from the boundedness of the interval.

Proposition 18. Consider the homotopy deﬁned in Section 9.2.2 and the equation
w′′ + cw′ + Jτ (w)w(1− w)− αw = 0, (τ ∈ [0, 1]).
1) The following estimate holds for all monotone solutions w(x) of problem (2.47), (2.41),
‖w − ψ‖C2+αμ  R,
where R > 0 is some constant.
2) For some r > 0 we have the estimate
‖wM − wN‖C2+αμ  r,
where wM and wN are, respectively, an arbitrary monotone and a nonmonotone solution of
problem (2.47), (2.41).
Proof. Up to now we considered c as a constant, now we consider it as a functional c(u) intro-
duced previously, u(x) = w(x) − ψ(x). Let us denote the solution of equation w(x) = w0 by
x0 and prove that there exists a constant r > 0 such that |x0| < r for all monotone solutions
of our problem and for all τ ∈ [0, 1]. Let us assume the contrary. Then there exists a sequence
{xk} such that |xk| → ∞ with k → ∞ and a sequence of solutions {wk(x)} with c = c(uk),
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uk(x) = wk(x)− ψ(x) are such that wk(xk) = w0. Let
vk(x) = wk(x + xk)− ψ(x),
so that vk + ψ ∈M0 (see Lemma 17), and, thus, we have the estimate
‖vk‖C2+αμ M0.
From functionalisation of parameter c we have
ρ(u) =
(∫
R
(u(x) + ψ(x)− w+)2σ(x)dx
)1/2
,
which provides
ρ(uk) =
(∫
R
(vk(x) + ψ(x)− w+)2σ(x + xk)dx
)1/2
.
Further we show that c(uk) = ln ρ(uk) is unbounded, which leads to a contradiction with the
a priori estimates of the speed obtained in Section 9.3.3. When xk → ∞, σ(x + xk) → 1 and
|vk| → 0. Function ψ(x) is different from w+ when−x is big, thus ρ(xk) →∞ as xk →∞. We
should consider as well the case when xk → −∞. From the deﬁnition of the norm in Hölder
spaces we obtain that |vk(x)|  N(μ(x))1/2. Thus there exists square summarible function y(x)
such that |vk(x)| < y(x). This allows the conclusion that ρ(uk) → 0 as xk → −∞.
Thus we have shown that all monotone solutions of problem (2.47),(2.41), in which c =
c(u), belong toMr for some r > 0 and validity of the ﬁrst part of the proposition follows from
Lemma 17.
Let us now prove the second part of the proposition. Introduce the notation,
uM = wM − ψ, uN = wN + ψ.
Assume that the assertion of the second part of the proposition does not hold. We can then ﬁnd
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sequences of solutions of equation (2.47) {u(k)M } and {u(k)N } such that
‖u(k)M − u(k)N ‖C2+αμ −−−→k→∞ 0. (2.84)
Since all the functions u(k)M are in the ball of radius R of the space C
2+α
μ (R), we obtain the
strong convergence of {u(k)M } to some u(0)M ,
‖u(k)M − u(0)M ‖C2 −−−→
k→∞
0
We let w(0) = u(0)M + ψ. Then function w
(0) is a solution of problem (2.47),(2.41) for some τ
and c and
‖w(k)M − w(0)‖C2 −−−→
k→∞
0 (2.85)
Then from (2.84) and (2.85) we have
‖w(k)N − w(0)‖C2 −−−→
k→∞
0 (2.86)
Applying Lemma 10 to sequence {w(k)N } we obtain a contradiction, which completes the proof
of the proposition.

Consider a ball ‖u‖C2+αμ  R of spaceC2+αμ (R), in which all solutions of equation (2.47) are
contained. We set R1 = R+1 and select r, 0 < r < 1, such that for solutions of equation (2.47)
in the ball ‖u‖C2+αμ  R1 we have the inequality
‖wM − wN‖C2+αμ  r.
In Theorem 7 we have proved that operator Aτ (u) is proper with respect to both τ and u. This
means that the set of solutions of equation Aτ (u) = 0 is compact in the ball ‖u‖C2+αμ  R1. For
a ﬁxed solution uM(x) we construct the ball K(uM) of radius r and center at the point uM . By
virtue of compactness of the set of solutions uM , we can select from a covering of this set by
balls K(uM) a ﬁnite subcovering. We denote by Gk, k = 1, . . . , N, the set of domains formed
by the union of the balls from this subcovering, Γk are boundaries of these domains.
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It is obvious that any uN /∈
⋃N
k=1[Gk + Γk] and all solutions uM belong to
⋃N
k=1 Gk for
all τ ∈ [0, 1]. We thus have separated all monotone solutions from all nonmonotone solutions,
which allows us to prove the main result of this work stated in Theorem 2.
Proof. Consider the homotopy (2.45)-(2.47). As it is shown in Section 9.2, the topological de-
gree can be introduced for the operator Aτ . By virtue of a priori estimates obtained in this
section we can use the Leray-Schauder method. As shown in [10], equation (2.47) with condi-
tions (2.41) has a solution in the form of monotone travelling wave when τ = 0. Thus topolo-
gical degree for the operator Aτ (u), introduced in (2.44), equals 1 for τ = 0. Consequently, the
topological degree for operator A1, corresponding to the initial equation (2.40) also equals 1,
whence the existence of a solution follows.

Troisième partie
Individual Based Modelling Approach
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Cell-to-cell communications are very important for the erythropoiesis regulation. One of
the appropriate approaches that allows taking into account this communication is the indivi-
dual based modelling. This considers each cell as an independent element of the whole system
and, thus, allows considering communications of every single cell with its neighbours that can
provide additional insights into the behaviour of cell populations.
In Section 10 a multi-agent software that describes such a communication is presented. It
allows us to numerically study spatial distribution of erythroid progenitors in the bone marrow,
see Section 11. Using this software we demonstrate that cell division can generate random cell
motion (Section 12). Random cell motion, in turn, can be described by a diffusion term when
dealing with continuous models.
10 Description of “Cell Dynamics” software
“Cell Dynamics” is an original software developed by N. Bessonov [21]. Several versions of
the software are available. In this section some features of version BC.v27c, which was released
in spring 2009, are presented. The software can be used to study various types of cell-to-cell in-
teractions. For instance, cell interactions that occur in the bone marrow during haematopoiesis.
10.1 User interface
In Figure 29 the main window of the application is shown. It consists of the plot area and
several buttons. The plot area is a domain of calculation, cells that leave this domain are removed
from the calculation. Several buttons of the interface are used to set up model parameters. Panels
presented in Figure 30 are accessible through the button "Tree". An example can be saved or
opened using the menu "File". The button "Data" allows to deﬁne some parameters determining
cell-to-cell interaction. In the current version only mechanical interaction is taken into account.
Note that this version does not take into account the exchange of chemical signals. Button
"Output" allows to determine a representation of output results. Other buttons are interface
related and ease the usage of the software.
Panels presented in Figure 30 are used to deﬁne domain settings and cell types. Domain
dimensions are deﬁned in Panel A. Button "Create" creates the domain. To restart calculation,
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FIGURE 29 – Software description. Main window.
A B C
FIGURE 30 – Software description. The genealogical tree.
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all current cells and segments can be removed using button "Clean". "Get segment" button
allows to create obstacles in the domain, which cells cannot overpass. For example, in Figure 29
the top and bottom borders of the calculation area are such obstacles. This option can also be
used to model ﬁbres of the bone marrow, which represent obstacles for cell motion. Several cell
types (generations), describing maturation process are deﬁned in Panel C. Lifetime of cells is
deﬁned in Panel B, edit-box "t0" deﬁnes average lifetime, edit-box "+/-" deﬁnes an interval of
stochasticity. The Panel C shows genealogical tree of cell generations. Letter "F" means that
cells of this type are ﬁxed and do not move. A user can choose a color and a name for every cell
type. At the end of the cell cycle the cell makes a choice, which is described in the tree. Let us
explain how this tree is organised. Cells of type "p3" (Figure 30.C, blue discs) are produced by
cells of type "p2". In turn, a "p3" cell produces two daughter "p3" cells with probability 0.45
(self-renewal), two daughter cells of type "p4" with probability 0.44 (differentiation) and with
probability 0.11 one cell of type "ap". Cells of type "ap", which do not have children, are used
to model apoptosis, i.e. a "p3" cell produces an apoptotic cell that will die at the end of its cell
cycle with probability 0.11. Cell type "HSC" models haematopoietic stem cells. A cell of this
type gives birth to two daughter cells, one of the same type as mother cell, which replaces it,
and one cell of another type (an immature progenitor).
Cells push each other out of the domain that results in the cell motion. Stochastic cell divi-
sion results in homogeneous diffusion. This aspect is discussed in detail in Section 12.
An example of simulation can be found in Figure 31. Panel A represents conﬁguration of
the plot area and stem cells inside (yellow discs in the middle) before starting the calculation.
Panel B shows the computational domain after some time. Stem cells (yellow discs) are ﬁxed
and do not move. They give birth to their offsprings. The offsprings, in turn, proliferate and
move. After some time the domain is partially ﬁlled with cells of different types as shown in
Panel B.
The software can be used as well to model the appearance of malignant cells and their pro-
pagation. This is demonstrated in Figures 32 and 33. The probability of appearance of malignant
cells (yellow) is small, equals 0.001 (Figure 32), which models a rare genetic mutation. Once
such a cell appears, it proliferates and, if it survives producing enough daughter cells, then ma-
lignant cells propagate and ﬁnally ﬁll the whole domain. Such application of the software can
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A B
FIGURE 31 – Software description. An example of simulation.
FIGURE 32 – Demonstration of the software. Propagation of malignant cells. Genealogical tree.
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FIGURE 33 – Demonstration of the software. Propagation of malignant cells (yellow).
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be done in order to study leukaemias. In the next section we present how the software can be
used to study spatial aspects of erythropoiesis.
10.2 Cell displacement
Each cell is considered as a disk in the plane. Cells of different types are shown with dif-
ferent colors. Cell behaviour is characterised by its interactions with other cells, its proliferation,
differentiation and apoptosis properties.
Interaction of two neighboring cells is determined by the interaction potential. The sum of
forces acting on each cell from other cells determines the cell motion according to Newton’s
law with a possible damping because of the friction with other cells. Thus, we use an approach
similar to molecular dynamics simulations even though the potential is different. We have
x
′′
i − x
′
i +
1
m
∑
i =j
fij = 0,
where xi is the coordinate of the center of the i-th cell, m is its mass,  is the damping coefﬁcient,
fij is the force acting between the cells i and j. We put
fij = −φ(|xi − xj|),
where the function φ(r, t) equals zero for r  ri + rj and it goes to inﬁnity as r decreases. Here
ri and rj are the radii of the cells i and j, respectively (which can depend on time). Thus, two
cells push each other when the distance between their centers is less than the sum of their radii.
11 Simulations of erythropoiesis
In this section we present simulations of normal erythropoiesis. In the part I, devoted to
multi-scale modelling of erythropoiesis, we assumed that 8 maturity levels of erythroid pro-
genitors can be distinguished. That modelling provided values of self-renewal, differentiation
and apoptosis rates in normal erythropoiesis. Here we consider 8 cell types with the rates of
self-renewal, differentiation and apoptosis as obtained in Section 6.2. The objective of the si-
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mulations presented hereafter is to study spatial distributions of erythroid cells in the bone
marrow.
The multi-agent approach implies calculations for every single element of the system, i.e.
for every single cell, which is very resource-demanding. The number of individual elements in
the simulations is about 80 000. The number of primary cells in the domain that give birth to all
other cells is 9 with daily inﬂux equals 2 cells per day (each primary cell divides every 4.5 days).
These cells are called "HSC" that means haematopoietic stem cells. The hierarchic tree of cell
generations is presented in Figure 34. Cell types "p1",...,"p8" model erythroid progenitor sub-
A B
FIGURE 34 – Genealogical tree of cell types for a model of erythropoiesis.
populations, "ap" – apoptotic cells, "er" – population of mature erythrocytes. Sub-populations
"p1",...,"p4" are self-renewing (means inclined preferentially to the self-renewal, discussed in
detail in Section 6), "p5",...,"p8" are differentiating. All progenitors are supposed to have ave-
rage lifetime of 1 day, erythrocytes have average lifetime of 40 days. This particular number
describes average lifetime of erythrocytes for mice. Progenitor volume decreases with matura-
tion from 0.015 to 0.01 units.
The calculation domain has the same form as that presented previously in Figure 31 with
two closed borders (top and bottom) and two others (left and right), through which cells leave
the domain. This domain is a schematic representation of bone marrow, cells leaving the domain
are supposed to get into the blood stream. To calculate cell densities, the domain is divided into
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11 vertical stripes, with one stripe in the middle of the domain, where stem cells are located.
All stripes have the same dimensions. We calculate the total number of cells as well as percen-
tages of erythrocytes, reticulocytes and of apoptotic cells in every stripe. These calculations are
carried out for several time moments. The results of spatial distributions of cells with respect to
the stripes are presented in Figure 35.
A B
C D
FIGURE 35 – Simulations of normal erythropoiesis. Cell distributions in the bone marrow, which
is divided into 11 vertical stripes, x = 6 is the center stripe that contains stem cells. Panel A :
total cell count in the bone marrow, Panel B : percentage of erythrocytes, Panel C : percentage
of reticulocytes, Panel D : percentage of apoptotic cells.
Horizontal axis x denotes the stripe number, x = 6 corresponds to the middle stripe with
stem cells, x = 1 and x = 11 correspond to the stripes located closely to open borders of the
domain. Since the domain and all model conditions are homogeneous (no preferred direction is
introduced), the distributions should be symmetric with respect to x = 6. It should be noted that
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the approach implies stochasticity, that is why the obtained results do not possess this symmetry.
Figure 35.A demonstrates that cell count decreases from the center to the exit borders with a
maximum value in the second or third stripe. The modelling provides that among erythroid cells
of the bone marrow 55% − 70% are mature erythrocytes, 4.5% − 7% are reticulocytes, 7% −
12% are apoptotic cells and others are immature progenitors. The percentage of erythrocytes is
maximal near open borders of the bone marrow.
12 Cell division and displacement in individual based model-
ling
We show the existence of random motion due to cell division and of directed motion due
to cell pressure. The contribution of each of these two factors can be different. In particular,
if the cell density is low, then their random motion prevails over directed motion. In this case
we can use reaction-diffusion systems of equations in order to describe the evolution of cell
populations.
Spatial cell distribution in the bone marrow should be taken into account in order to specify
the conditions of leukaemia development. This distribution is closely related to cell division
and displacement. In this section we investigate both cell division and displacement with the
individual based modelling approach. We also use it to explain the origin of random cell mo-
tion due to division. This justiﬁes the usage of reaction-diffusion systems in the next section.
Simulations are performed using the software “Cell dynamics”, version “Soft sphere model”,
presented in Section 10.
As presented in Section 10.2, each particle moves according to the equation
x¨i + νx˙i +
∑
j =i
f(rij) = 0, (3.1)
where the second term in the left-hand side of this equation describes the friction of the particle
by the medium, the last term represents the force acting on the particle by all other particles.
This is one of possible models in the approach called dissipative particle dynamics [21]. The
force f(rij) between the i-th and the j-th particle depends on the distance rij between them. In
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molecular dynamics this is the Van der Waals force, which is nonlocal and usually described
by the Lennard-Jones potential. In the case of cell dynamics, the force between two particles is
nonzero only when they touch each other, that is when the distance between the centers of the
spherical particles is less than the sum of their radii.
Equation (3.1) allows us to determine the position of each cell in time. In addition, the
process of cell division, which changes the number of cells and the forces acting between them,
must be speciﬁed. This is done hereafter.
12.1 Cell division
When haematopoietic cells in the bone marrow divide, they push each other resulting in
their displacement. This mechanism determines motion of immature red blood cells, which are
the most represented cells in the bone marrow. Therefore, in order to study cell motion, we need
to begin with cell division.
When a cell divides, it is replaced by two other cells. If we neglect the mechanical interaction
with other cells, then the center of mass of the body composed by the two daughter cells does not
change in comparison with the center of mass of the mother cell. Hence, after each division, each
daughter cell is shifted with respect to its mother cell. Figure 36 shows several ﬁrst consecutive
divisions simulated with the software “Cell dynamics”, version “Soft sphere model”. Cell size
and the frequency of division are given as parameters of the model.
There is one more parameter which should be speciﬁed in order to describe cell division : the
direction of division, that is the direction of the straight line connecting the centers of the new
cells. In some cases, the direction of division can be determined by the position of the mother
cell with respect to the surrounding cells. In particular, this can be the case in embryogenesis
or in plant growth. However, in the case of haematopoiesis, we can assume that this direction
is arbitrary. Therefore the angle of the straight line connecting the centers with respect to the
x-axis is chosen in a random way with a uniform distribution.
Let now focus on cell motion. Consider the following division process A → A + B (Figure
36) under the assumptions formulated above. After each division the cell A gives one cell, which
is identical to itself (self-renewal), and another cell which is different (differentiation). Hence,
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FIGURE 36 – Successive cell divisions simulated with the software “Cell dynamics”, version
“Soft sphere model”. Every division gives birth to two daughter cells (green for a self-renewing
division, purple for differentiating division). The direction of division is not speciﬁed.
there will always be one cell of the type A and a growing number of cells B. After each division
the cell A moves in a random direction at the distance equal to its radius. This means that the
cell A moves along the plane in a random way. In the case where there are many such cells and
we can consider them as a continuous medium, this motion becomes similar to diffusion and
can be described in a similar way. We discuss this question in more detail in the next section.
Each cell deﬁned in the individual-based model must be able to divide, change its type,
or die (either by apoptosis or necrosis). Hence probabilities for such events are provided by the
user, for each type of cell deﬁned. These probabilities are determined by intracellular regulatory
networks. In the case of erythroid progenitors they are discussed in Section 3.
In the example shown in Figure 37 (left), there is one stem cell (green) that divides in two
cells at each division, one cell is identical (this is self-renewal) and the other cell is of another
type (red). In turn, the red cell can self-renew with the probability 0.57, differentiate with the
probability 0.39, or die by apoptosis with the probability 0.04 (this probability does not appear
on Figure 37, it is obtained from the two other probabilities). In the ﬁrst case, it divides giving
two cells identical to itself. In the second case, it gives two different cells (violet). If the cell
dies, it is removed from the computational domain. Red cells can also mutate with the proba-
bility 0.001. When this happens, a mutated cell (yellow) appears. Its properties are different in
comparison with the original cell (red). It self-renews with the probability 0.7, differentiates
with the probability 0.3, and does not die by apoptosis. These assumptions correspond, for ins-
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tance, to properties of malignant cells. Their self-renewal ability is greater than for normal cells,
while differentiation and apoptosis abilities are lower (or absent). Therefore, we can expect that
after some time malignant cells will appear and will take over the normal cells. It is numerically
observed that malignant cells push out normal cells and gradually ﬁll the whole computational
domain (Figure 37, right). This replacement corresponds to reaction-diffusion waves discussed
in Section 14.2.1, Theorem 19. Cell division occurs according to the algorithm described above,
presented in Figure 36.
FIGURE 37 – Simulation obtained with the software “Cell dynamics”. Left : Properties of the
different cells involved in the computations are listed, as self-renewing (same color), differentia-
ting (different color) and mutation (yellow) probabilities. Right : Computational domain, ﬁlled
with cells deﬁned on the left panel.
12.2 Cell displacement
There are various mechanisms of cell displacement in the bone marrow. We discuss here
random cell motion, which is to some extent similar to diffusion, and directed cell motion, si-
milar to convection. Since biological cells are macroscopical objects, the usual Fickian diffusion
is not applicable for them. However they can move in a random way due to division.
Let us discuss the motion of a single dividing cell when it is surrounded by other cells.
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Obviously, cells push each other and create a preferential direction of motion. It is easier for a
cell to move in the direction where there are less cells. In order to study this phenomenon, we
consider the following numerical experiment. The cell A is placed at the bottom of an empty
rectangular box (Figure 38, left). It divides reproducing itself and some other cells which ﬁll
the box. These latter cells do not divide and do not move unless they are pushed by other cells.
What will be the position of the cell A in time ? If it moves in a random way, its distance from
the initial position will grow proportionally to
√
t (with random perturbations). However, when
there are many other cells around it, they will inﬂuence its motion pushing it to the direction
where cell concentration is lower. If we introduce pressure, that is the force exerted by cells
on the unit surface, then, similar to Darcy’s law, cell velocity will be determined by pressure
gradient [27]. It can be veriﬁed on model examples that the cell will move in this case with a
constant speed, that is its displacement will be proportional to t.
FIGURE 38 – Trajectory and displacement of a cell A dividing according to the process A →
A + B + 2C. Left : Rectangular domain, center : cell trajectory, right : cell displacement.
We can vary the ratio of the directed and random motion. In order to do this, let us consider
the division scheme in the form A → A + B + 2C and assume that the cells A and B have
the same radius, the radius of the cell C is twice less, the cell B is located on one side of the
cell A after the division, and the cells C on the diametrically opposite side. The cell A is shown
in yellow in Figure 38, B and C in blue. Clearly, such a cell division is not realistic from the
biological point of view. We consider it in order to explain the mechanisms of cell motion.
We use here the advantage of mathematical modelling, which allows us to consider idealised
models, in order to study a symmetric division where the center of the cell A does not shift after
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cell division, and various asymmetric divisions where this center displaces due to division. In
the real biological situation, division is asymmetric. We will see below that it results in a random
cell motion. However, if cell density is sufﬁciently high, convective cell motion becomes also
important. To study it more precisely and independently of the random motion, we need to
consider a symmetric division.
With the division scheme shown in Figure 38, the center of the cell A before and after the
division remains at the same place. In fact, we consider here not the center of mass of the system
of cells but its geometrical center. Hence, cell division in this case does not provide random
motion. Figure 38 shows the cell trajectory and its displacement from the initial position. We
can see that its displacement is close to a linear function. Therefore, it is a directed motion with
a weak random component.
FIGURE 39 – Trajectory and displacement of a cell A dividing according to the process A →
A + B + C, where B and A have the same radius, and the radius of C equals one half of the
radius of A. Left : Rectangular domain, center : Cell trajectory, right : Cell displacement.
Figure 39 shows another scheme of cell division, A → A+B+C, where B and C are from
the opposite sides of A. Since the radius rC of C is twice less than the radius rB of B, then the
center of the cell A moves at rC/2 after each division. The cell displacement remains practically
linear. However its trajectory essentially changes in comparison with the previous case. The
projection of the cell speed on the vertical direction remains the same since it is determined by
the frequency of its division. In other words, by the rate with which it ﬁlls the box with other
cells. However, its local mobility becomes higher because of the increased random motion.
The cell motion has two components : small random displacements and large scale sinusoidal
motion from one side to another and upwards. This horizontal motion of the cell is caused by the
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pressure difference. Since the box is sufﬁciently large, the cell ﬁrst ﬁlls one side, then another
side of the box. Its increased mobility makes it more sensitive to the pressure difference.
FIGURE 40 – Cell trajectory (left) and displacement (right) in the case of a strong random
component.
If we increase even more the random component of the cell motion by appropriately choo-
sing division scheme, then the directed component of its motion is not visible any more (Figure
40). Another parameter which determines the relative contribution of the random and directed
components of the cell motion is their concentration. If it is low, then mechanical interaction
with the surrounding cells will be negligible.
In Section 8 we modelled the evolution of cell populations by reaction-diffusion-convection
equations. We took into account their random motion described by the diffusion-terms and their
directed motion. Directed or convective motion should be taken into account if the density of cell
population is sufﬁciently high. In this case it can be described by reaction-diffusion equations
coupled with ﬂuid dynamics in a porous medium. Such a model has been studied in previous
works [21, 44].
We note ﬁnally that the diffusion coefﬁcient depends on the cell adhesion to the extracel-
lular matrix. In particular, leukaemic cells have a weaker adhesion and, consequently, a bigger
diffusion coefﬁcient.
13 Discussion
In this part we presented the software which is based on the individual based modelling
and which can be applied to study cell interaction processes. The presented version of the soft-
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ware considers mechanical cell-to-cell interactions. Using this software we studied spatial cell
distributions of erythroid progenitors in bone marrow.
Models of cell populations are often semi-empiric and based on some intuitive assumptions,
which seem in agreement with biological observations. We attempted to give here some more
rigorous justiﬁcation of one of such assumptions about cell displacement. Although there are
different mechanisms of cell motion in the bone marrow, we did not discuss here biologically
active mechanisms such as chemotaxis but concentrated only on pure mechanical cell interac-
tion. Since new cells appear due to proliferation, cells push each other creating random motion,
which can be described by diffusion, and directed motion determined by pressure difference.
We carried out some analysis of this motion with individual based modelling.
Quatrième partie
PK/PD Modelling of AML Treatment with
AraC
149
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Acute myeloid leukaemia (known also as non-lymphocytic or myelogenous) is a type of
leukaemia characterised by abnormal proliferation of myeloid cells. One of the most common
and effective chemotherapeutic agents against AML is AraC (cytosine arabinoside, cytarabine),
which is used in combination with other drugs. Pharmacokinetics-pharmacodynamics approach
is one of modern ways to study drug outcome on the disease. The last part of my work is devoted
to the PK/PD modelling of AML treatment with AraC.
We consider dynamics of normal and malignant cells, which are determined by AraC concen-
tration. We built a mathematical model of AraC distribution in the body and of its action. The
model consists of two parts. First part describes pharmacokinetics of AraC, that is drug delivery
to the bone marrow, penetration through cell membrane and its metabolism, which is a set of
interactions between the drug and intracellular proteins, its degradation, phosphorylation and
deamination. Then we describe AraC action on cells, that is pharmacodynamics.
We consider AraC distribution between two compartments, blood and bone marrow. Trans-
membrane transport is described as a process of passive diffusion that goes until concentrations
of AraC inside and outside cells are equal. Metabolism of AraC is described as a set of chemical
reactions and is modelled using Michaelis-Menten kinetics. Drug action on DNA synthesis and
thus on cell proliferation is presented as a dependance of proliferation rates and apoptosis on
AraCTP concentrations. This constitutes pharmacodynamics part.
14 Cell population dynamics
14.1 Normal erythropoiesis
In Section 4 we considered several erythroid progenitor sub-populations denoted by P1, . . . , Pn.
Each of them consists of identical cells with given rates of self-renewal si, differentiation di and
apoptosis ai, i = 1, . . . , n. As discussed in Section 3, these rates and their dependence on the
parameters are determined by the Erk/Fas regulatory system (see Figure 7). In the framework
of the model described in Section 3, they are determined by the basins of attraction of the cor-
responding stationary points.
Evolution of these population densities is described by the ordinary differential system of
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equations ⎧⎪⎨⎪⎩
dP1
dt
= H + (s1 − d1 − a1)P1,
dPi
dt
= (si − di − ai)Pi + 2di−1Pi−1, i = 2, . . . , n,
(4.1)
where H denotes a constant ﬂux of haematopoietic stem cells differentiating in erythroid pro-
genitors, the coefﬁcients si, di and ai depend on the values of the concentrations of intracellular
proteins Erk and Fas, Ei and Fi. These concentrations are regulated by intracellular networks
(see Section 3). In this section we do not take into account the external control feedback by hor-
mones (glucocorticoids or erythropoietin) discussed in Section 5. Hence, the source term α in
System (1.6) is assumed to be constant. Fas-ligand, the main external source for Fas activation
is produced by mature cells [39], hence we assume γ, in (1.6), is a function of Pj , j = 1, . . . , n.
Consequently, the protein concentrations are governed by the equations
⎧⎪⎨⎪⎩
dEi
dt
= Φ(α,Ei, Fi),
dFi
dt
= Ψ
(∑n
j=1 μijPj, Ei, Fi
)
,
(4.2)
where the functions Φ and Ψ are deﬁned in (1.6), and μij are constant parameters accounting
for the weight of mature cell populations in the production of Fas-ligand.
We now introduce spatial cell distribution. We consider a one-dimensional problem with
the space variable x and assume cells can move in space in a random way. This motion can be
described by diffusion (see Section 12). The intracellular concentrations Ei and Fi are supposed
to be the same for all cells in the i-th population, therefore they do not depend on the space
variable, but can depend on time.
We also take into account a limitation of cell proliferation when cell density exceeds some
threshold level, by means of a chemical cell interaction. Let P0 be the maximal cell density. Then
System (4.1) can be rewritten in order to take into account both diffusion and the dependence
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of cell proliferation (self-renewal and differentiation) on P0 − P¯ , where P¯ =
∑n
i=1 Pi,
∂P1
∂t
= D
∂2P1
∂x2
+ H + (s1 − d1)P1(P0 − P¯ )− a1P1,
∂Pi
∂t
= D
∂2Pi
∂x2
+ (si − di)Pi(P0 − P¯ )− aiPi + 2di−1Pi−1(P0 − P¯ ), i = 2, . . . , n.
(4.3)
In order to be able to analyse the model, we ﬁrst assume intracellular reactions are fast in the
time scale related to cell motion. Then, instead of System (4.2), we can consider the stationary
equations
Φ(α,Ei, Fi) = 0, Ψ
(
n∑
j=1
μijPj, Ei, Fi
)
= 0. (4.4)
Therefore, Ei and Fi can be expressed as functions of Pj , j = 1, . . . , n. As a consequence,
coefﬁcients si, di, ai in (4.1) also become functions of Pj .
System (4.3) and (4.4) describes erythroid progenitor dynamics in normal erythropoiesis
under the assumption of fast intracellular reactions. Consider ﬁrst the case of a single cell po-
pulation P1. Then System (4.3) is reduced to the ﬁrst equation where P¯ = P1 :
∂P1
∂t
= D
∂2P1
∂x2
+ H + (s1 − d1)P1(P0 − a1
s1 − d1 − P1). (4.5)
Equation
H + (s1 − d1)P1(P0 − a1
s1 − d1 − P1) = 0
has a unique positive solution P1 = P ∗1 if s1 − d1 > 0. It is a globally asymptotically stable
stationary solution of equation (4.5), that satisﬁes P ∗1  max{0, P0 − a1/(s1 − d1)}.
If P0 > a1/(s1 − d1), then P ∗1  P0 − a1/(s1 − d1), and P ∗1 is positive even if H = 0.
This means that even in the absence of haematopoietic stem cells, erythroid progenitors keep a
positive concentration due to self-sustained proliferation. This case seems to be unrealistic from
the biological point of view. Therefore, we assume in what follows P0  a1/(s1 − d1).
In the next section, we introduce a population of leukaemic cells and investigate the dy-
namics of the model. In particular, the attention is focused on the existence of a leukaemic
equilibrium.
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14.2 Erythroleukaemia
Consider two cell lineages, normal and mutated. The lineage of mutated cells will differ
by the rates of self-renewal, differentiation and apoptosis. Denote by Pi cells from the normal
lineage and by Qi cells from the mutated lineage. Both of them are described by the same model
(4.3) as in the previous section. However, we should take here into account that the total number
of cells include both lineages,
P¯ = P1 + · · ·+ Pn + Q1 + · · ·+ Qn.
In what follows we restrict ourselves to the case where each of these two lineages consists of
a single cell type. This is equivalent to the assumption that we neglect in the previous equality
all cell densities except for P1 and Q1. Then equations for P1 and Q1 become independent of
other equations and can be written in the form :⎧⎪⎪⎨⎪⎪⎩
∂P
∂t
= DP
∂2P
∂x2
+ H + (s− d)P (P0 − P −Q)− aP,
∂Q
∂t
= DQ
∂2Q
∂x2
+ (sm − dm)Q(P0 − P −Q)− amQ,
(4.6)
where the subscripts are omitted for simplicity of notation, and sm, dm, am denote the rates
of self-renewal, differentiation and apoptosis of mutated cells, respectively. In particular, since
there is only one generation of erythroid progenitors, denoted by P , the inﬂuence of progenitor
densities on the activation of Fas is neglected, so that (4.4) becomes
Φ(α,E, F ) = 0, Ψ(γ,E, F ) = 0,
with α > 0 and γ > 0 constant. Consequently, E and F no longer depend on P and, si-
milarly, the different rates do not depend on cell densities. This assumption has then strong
consequences, yet it allows drawing comprehensive conclusions on the existence of a leukae-
mic equilibrium and treatment of the disease (see below).
The constant source H is absent in the second equation of (4.6) because it is assumed in
the case of erythroleukaemia there is no permanent inﬂux of mutated cells from the stem cell
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compartment. Different assumptions could of course be considered.
14.2.1 Existence of a Leukaemic Equilibrium
In order to analyse reaction-diffusion System (4.6), we ﬁrst consider the system without
diffusion, ⎧⎪⎨⎪⎩
dP
dt
= H + (s− d)P (P0 − P −Q)− aP,
dQ
dt
= (sm − dm)Q(P0 − P −Q)− amQ,
(4.7)
and we assume s−d > 0, sm−dm > 0, and am/(sm−dm) < P0 < a/(s−d). The assumption
am/(sm − dm) < P0 ensures the possibility to have a leukaemic equilibrium (see (4.8)), as
shown below.
Zero lines of the right-hand side of (4.7) are given by the equalities
H + kP (−b− P −Q) = 0, kmQ(bm − P −Q) = 0, (4.8)
where
k = s− d, km = sm − dm, b = −P0 + a
k
, bm = P0 − am
km
.
According to the above assumptions, all parameters, k, km, b and bm are positive.
From the ﬁrst equation in (4.8),
Q = −b− P + H
kP
, (4.9)
and from the second equation
Q = 0 or Q = bm − P. (4.10)
System (4.9)–(4.10) can have one or two stationary points (Figure 41). If we put Q = 0 in
(4.9), and denote by P ∗ the positive solution of this equation, then we ﬁnd
P ∗ =
b
2
(√
1 +
4H
kb2
− 1
)
.
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FIGURE 41 – Graphical solution of System (4.9)–(4.10). Case 1 corresponds to the existence of
two stationary points, A and B, the case 3 to the existence of only one stationary point, B. In
case 2, the points A and B have the same location.
The stationary solution (P,Q) = (P ∗, 0) always exists.
On the other hand, from (4.9) and the second equation in (4.10), we obtain
P ∗m + Q
∗
m = −b +
H
kP ∗m
and P ∗m + Q
∗
m = bm.
If bm > P ∗, then we have the case 1 in Figure 41. There exist two stationary points : A with the
coordinates (P ∗m, Q
∗
m), and B with the coordinates (P
∗, 0). If bm < P ∗, then we have the case 3
in Figure 41, there exists a unique stationary point B = (P ∗, 0). It follows that leukaemia may
develop only if bm > P ∗.
Condition bm > P ∗ can be written as
bm(bm + b) >
H
k
or equivalently (
μ− P0k
a
)
(μ− 1) > Hk
a2
, (4.11)
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where
μ =
am
a
k
km
=
am
a
s− d
sm − dm . (4.12)
We call the inverse parameter 1/μ the strength of mutation. If a malignant mutation decreases
the rate of apoptosis and differentiation and increases the rate of proliferation, then μ < 1. This
means that the strength of mutation is greater than 1.
We recall that the assumption b > 0 implies that P0k/a < 1. Moreover, from (4.12) and
the assumption bm > 0, one deduces μ < P0k/a. Consequently, the left-hand side of (4.11) is
positive. Furthermore, it is straightforward that inequality (4.11) is satisﬁed if and only if
P0 >
H
a
. (4.13)
This condition means that (4.11) is true for μ = 0. Indeed, the set of values of μ satisfying
(4.11) is an interval in the form [0, μ∗) with μ∗ < P0k/a < 1. If (4.13) is not satisﬁed, then
leukaemia will not develop, independently of the strength of mutation. This occurs if the inﬂux
of normal cells from the stem cell compartment is sufﬁciently large.
If (4.11) is satisﬁed, that is the mutation is sufﬁciently strong and the inﬂux is not strong
enough, then System (4.7) has two stationary points A and B (Figure 41). It can be veriﬁed
that A is stable while B is unstable. This means that the disease will develop. The values of
the concentrations P ∗m and Q
∗
m in the leukaemic equilibrium depend on μ. In particular, the
concentration Q∗m of malignant cells can be rather low if μ is close to the critical value. If (4.11)
is not satisﬁed (weak mutation or strong inﬂux), then there exists a unique stable stationary
point B, which corresponds to the disease free situation.
The analysis of the ordinary differential system of equations (4.7) allows us to do some
conclusions about the behaviour of solutions of (4.6). More precisely, classical results on mo-
notone systems allow to conclude the existence of a travelling wave providing a transition from
the unstable disease free equilibrium B to the leukaemic equilibrium A, when (4.11) is satis-
ﬁed. The existence and stability of travelling waves for monostable monotone reaction-diffusion
systems are well known [117]. The existence result is stated in the next theorem.
Theorem 19. Let condition (4.11) be satisﬁed. Then the endemic equilibrium (P ∗m, Q∗m) of
System (4.6) considered on the whole axis is globally asymptotically stable in the sense that
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any solution with the initial condition (P0(x), Q0(x)), where P0(x)  , Q0(x)  ,  is a
positive constant, converges uniformly to (P,Q) = (P ∗m, Q
∗
m) as t → ∞. The disease free
solution (P ∗, 0) is unstable.
Moreover there exists a minimal speed c0 such that for all speeds c  c0 there exist travelling
wave solutions of System (4.6), that is solutions of the form P (x, t) = p(x − ct), Q(x, t) =
q(x− ct). The functions p(x) and q(x) are monotone with respect to x and satisfy the system
DP p
′′ + cp′ + H + (s− d)P (P0 − P −Q)− aP = 0,
DQ q
′′ + cq′ + (sm − dm)Q(P0 − P −Q)− amQ = 0
and the conditions at inﬁnity :
p(−∞) = P ∗m, q(−∞) = Q∗m, p(+∞) = P ∗, q(+∞) = 0.
For c < c0 such solutions do not exist.
The proof of the theorem is based on the reduction of System (4.6) to a monotone system
and on the application of the comparison principle. The interested reader may refer to [117] for
details.
It is known that the appearance of malignant cells is due to several rare consecutive mu-
tations. Once this event occurs, malignant cells start proliferating. If malignant cells appear
then they persist and spread in the whole bone marrow in the form of a travelling wave. Their
existence is stated in Theorem 19.
15 Pharmacokinetics modelling
Pharmacokinetics study drug distribution in the body and its delivery to target organs. Three
stages can be distinguished, delivery to target organs, transport inside cells and drug metabo-
lism.
To describe drug distribution in the body, several anatomical compartments should be cho-
sen. In [31] the authors suggest that it can be gastrointestinal tract, blood, liver, non eliminating
15. Pharmacokinetics modelling 159
tissue, efﬁcacy and toxicity compartments. Efﬁcacy compartment in leukaemic case is the bone
marrow. Considering many compartments introduce more complexity because of many unk-
nown parameters that should be estimated. In [54] the authors proposed methods of model
reduction, which can be used in PK/PD modelling. They presented how some compartments
can be removed without loosing relevant information in the model. In order to render our mo-
del simpler with a few parameters to estimate, we choose two compartments, blood and bone
marrow, and consider drug concentrations inside them (Section 15.1). Drug distribution in other
organs can be introduced, for example, as clearance from the blood.
Second step, membrane penetration, is very drug-speciﬁc, different drugs go through mem-
brane by different transport mechanism. AraC is brought into cells by nucleoside transporters
and can be considered as passive diffusion. A simple model of the transport is presented in
Section 15.2. For other drugs transmembrane transport can be due to different mechanisms.
Metabolism scheme is also drug-speciﬁc. Nevertheless, some similarities can be found for
certain drugs, for example for AraC and gemcitabine. This last stage of pharmacokinetics is
often described as a set of chemical reactions. Each reaction can be described using Michaelis-
Menten mechanism, the law of mass action or by other methods depending on the concrete
chemical reactions. We use Michaelis-Menten mechanism to describe the scheme of metabolism
of AraC, which is presented in Section 15.4. In Section 15.3 we explain this mechanism on three
example chemical reactions.
15.1 Drug distribution
In this section we propose a simple model of drug distribution in the body. We distinguish
two compartments, blood and bone marrow, see Figure 42. Let us denote by ab(t) and am(t)
respectively extracellular concentrations of AraC in the blood and in the bone marrow at time
t. Then their dynamics can be described by the following equations,
a˙b = I(t)− kbm(ab − am)− γbab, (4.14)
a˙m = kbm(ab − am)− g(am, ami)− γmam. (4.15)
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FIGURE 42 – Two compartment model of AraC distribution in the body is considered in the
modelling.
The term I(t) describes drug administration protocol, last term in each equation describes AraC
clearance, i.e. its destruction. The term kbm(ab − am) describes AraC transition between the
two compartments, in which constant kbm determines the rate of the distribution. The term
g(am, ami) describes AraC transmembrane transport inside the bone marrow and is discussed
in Section 15.2.
15.2 Transmembrane transport of AraC
In Section 15.1 we considered a model that describes drug distribution in the body. We inclu-
ded two compartments, blood and bone marrow. The term g(am, ami) described transmembrane
transport.
AraC penetrates inside a cell by a mechanism relayed essentially by human equivibrative nu-
cleoside transporter-1 (hENT1), which can be considered as facilitated diffusion, see Figure 43.
The process does not need energy and goes in accordance with the gradient of concentration up
FIGURE 43 – Transmembrane transport of AraC is implemented by hENT1 transporter.
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to the equilibrium between intracellular and extracellular concentrations of AraC [62, 125].
For weak AraC plasma concentrations (less than 0.5–1μM), obtained after administration of
a standard dose of AraC (100–200 mg/m2) the transmembrane transport is a limiting factor for
AraCTP formation. In case of strong AraC plasma concentrations (more than 10μM), obtained
after administration of a strong dose of AraC, the transmembrane transport is no more a limiting
factor. In this case intracellular processes such as phosphorylation, deamination, nucleoside
half-life and AraCTP incorporation into DNA determine drug efﬁcacy.
We propose the following simple model of the transmembrane transport. The rate of intra-
cellular AraC accumulation due to transmembrane transport is
g(am, ami) = khENT1(am − ami),
where ami is intracellular concentration of AraC, am is extracellular concentration of AraC,
khENT1 is a constant that describes the rate of transmembrane penetration and is determined
by the activity of hENT transporter. If extracellular concentration is greater than intracellular
concentration (am > ami), then intracellular concentration increases, extracellular decreases
and vice versa. When both concentrations are equal, the transport stops.
Hence, Equations (4.14), (4.15) describing dynamics of extracellular concentrations of AraC
in the blood and in the bone marrow become
a˙b = I(t)− kbm(ab − am)− γbab, (4.16)
a˙m = kbm(ab − am)− khENT1(am − ami)− γmam. (4.17)
This simple model allows us to take into account the transmembrane transport.
In Section 15.4 we describe kinetics of intracellular AraC, determined by the scheme of
metabolism, using Michaelis-Menten kinetics presented in the next section.
15.3 Michaelis-Menten kinetics
The Michaelis-Menten mechanism for the catalysis of biological chemical reactions is one
of the most common approaches in biochemistry. Catalysis is a process in which the rate of
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a chemical reaction is either increased or decreased by a catalyst. Enzymes are large protein
molecules that are natural catalysts. The vast majority of chemical reactions that keep living
systems alive are too slow without a catalyst to sustain life and it becomes rapid in presence of
a catalyst. Let us demonstrate this mechanism on several example chemical reactions.
15.3.1 Enzyme without inhibitor
Consider a chemical reaction,
E + S
k1−−→
k−1
ES
k2−→ E + products, (4.18)
where E is the enzyme, S is the "substrate" (the molecule on which the enzyme does its work),
and ES is an enzyme-substrate complex. It is presumed that the substrate binds somehow to the
enzyme before the enzyme can do its work. The step of complex formation of [ES] goes very
fast with respect to the product formation. Constants k1, k−1 denote rates of reaction in both
directions.
Let us show how the approach is generally used in chemical kinetics. The rate of formation
of product, called the reaction rate, v, is deﬁned as
v =
[product]
dt
= k2[ES]. (4.19)
The enzyme-substrate complex, ES, is an intermediate complex. A steady-state approximation
provides
d[ES]
dt
= k1[E][S]− k−1[ES]− k2[ES] ≈ 0, (4.20)
where [E] is the concentration of free (uncomplexed) enzyme, which is usually unknown. The
concentration of the substrate is deﬁned by [S]. From Equation (4.20) we obtain
[ES] =
k1[E][S]
k−1 + k2
=
[E][S]
KM
, (4.21)
where
KM =
k−1 + k2
k1
.
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This constant is called the Michaelis-Menten constant. Substitute (4.21) into Equation (4.19),
v =
d[product]
dt
= k2
[E][S]
KM
. (4.22)
Total concentration [E]0 of the enzyme, which is supposed to remain constant, is
[E]0 = [E] + [ES] = [E] +
[E][S]
KM
= [E]
(
1 +
[S]
KM
)
.
Deriving from this equation [E] and substituting it into (4.22) we obtain
v = k2
[E]0[S]
KM + [S]
. (4.23)
The reaction velocity, v, is zero when [S] is zero and it increases if [S] increases. It reaches its
maximum when [S] becomes very large. Deﬁne the maximal velocity, vmax, as
vmax = lim
[S]→∞
k2
[E]0[S]
KM + [S]
= k2[E]0.
Then Equation (4.23) can be written as
v =
vmax[S]
KM + [S]
.
The kinetics of the reaction are characterised by two parameters, vmax and KM . These are
the parameters that are usually given in the literature in studies of the kinetics of biochemical
reactions.
15.3.2 Enzyme with inhibitor
Let us suppose now that for the chemical reaction deﬁned in (4.18), an inhibitor I interferes
with enzyme E but not with the complex ES,
E + I
k′1−−→
k′−1
EI.
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The condition of quasi-steady state for the complex [EI] provides
d[EI]
dt
= k′1[E][I]− k′−1[EI] ≈ 0,
which gives
[EI] =
k′1
k′−1
[E][I]. (4.24)
Expression (4.22) remains valid in this case, the only difference that should be introduced
in the reasoning presented in the previous section is that now the total quantity of the enzyme is
[E]0 = [E] + [ES] + [EI]. (4.25)
Substituting (4.21), (4.24) into (4.25) we obtain
[E]0 = [E]
(
1 +
[S]
KM
+
k′1
k′−1
[I]
)
.
Resolve [E] from this equation and substitute it into (4.22),
v = k2
[E0][S]
KM + [S] + KM
k′1
k′−1
[I]
.
The maximal velocity vmax = k2E0 in this case remains the same as in the previous section,
then
v =
vmax[S]
KM + [S] + KM
k′1
k′−1
[I]
.
15.3.3 Mixed inhibition
Consider the same chemical reaction (4.18) and the case when inhibitor can bind to both [E]
and [ES],
E + I
k′1−−→
k′−1
EI,
ES + I
k′′1−−→
k′′−1
ESI.
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Conditions for quasi steady states for complexes [EI] and [ESI] are
d[EI]
dt
= k′1[E][I]− k′−1[EI] ≈ 0,
d[ESI]
dt
= k′′1 [ES][I]− k′′−1[ESI] ≈ 0,
which provide
[EI] =
k′1
k′−1
[E][I], (4.26)
[ESI] =
k′′1
k′′−1
[ES][I]. (4.27)
The total quantity of the enzyme is
[E]0 = [E] + [ES] + [EI] + [ESI]. (4.28)
Substituting (4.21), (4.26) and (4.27) into (4.28) we obtain
[E]0 = [E]
(
1 +
[S]
KM
(
1 +
k′′1
k′′−1
[I]
)
+
k′1
k′−1
[I]
)
.
Resolve [E] from this equation and substitute it into (4.22),
v = k2
[E0][S]
KM + [S]
(
1 +
k′′1
k′′−1
[I]
)
+ KM
k′1
k′−1
[I]
.
When [S] tends to inﬁnity very small amount of free inhibitor remains, thus [I] → 0. The
maximal velocity is then as before vmax = k2E0, so
v =
vmax[S]
KM + [S]
(
1 +
k′′1
k′′−1
[I]
)
+ KM
k′1
k′−1
[I]
.
We demonstrated how Michaelis-Menten mechanism is applied to describe kinetics of che-
mical reactions. In the next section we describe the metabolism of AraC using this approach.
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15.4 Metabolism of AraC
Metabolism scheme of AraC is presented in Figure 44. The enzymatic paths of AraC me-
FIGURE 44 – The metabolism of AraC, adapted from [76].
tabolism are the same as that of deoxycytidine dC [73]. AraC should pass through three steps
of phosphorylation to form its active metabolite AraC triphosphate (AraCTP), which arrests the
DNA synthesis and thus prevents cells from proliferating.
Let us brieﬂy present the most important components of the metabolism. Monophospho-
rylation is catalysed by deoxycytidine kinase (dCK). This step of AraC phosphorylation is
rate determining. The activity of dCK is inhibited by dCTP (regulation by retroinhibition) and
AraCTP. The phosphate is taken from ATP (adenosine triphosphate) and UTP (uridine triphos-
phate), see [11, 101] for more details. The diphosphorylation and triphosphorylation are ca-
talysed by other kinases and the phosphate is taken from ATP. These two stages go fast with
respect to the monophosphorylation. Dephosphorylation AraCMP → AraC is catalysed by 5’-
nucleotidases [6]. Deamination AraC→ AraU is catalysed by cytidine deaminase (CDA). Dea-
mination AraCMP → AraUMP is catalysed by deoxycytidilate deaminase (dCMPDA). This
step of the deamination is of secondary importance and is not introduced in the model. The
phosphorylation AraU → araUMP is observed in vitro. In human leukaemic cells this phos-
phorylation is not observed, the only source of AraUMP, which accumulates in cells, is due to
deamination of AraCMP by dCMPDA.
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First step of AraC phosphorylation, which is catalysed by dCK, is of particular importance.
Its mixed kinetics for AraC phosphorylation appears in Figure 45. Deoxycytidine kinase is
FIGURE 45 – The monosubstrate kinetics of deoxycytidine kinase and AraC at saturating le-
vels of ATP. The equilibrium constants are given here in the mixed inhibition notation used
commonly in enzyme kinetics. The ﬁgure is adapted from [76].
inhibited by both dCTP and AraCTP. Normal substrate, deoxycytidine (dC), is also an inhibitor
of the enzyme with respect to AraC phosphorylation. dCTP and AraCTP form a complex with
dCK that interferes with AraC.
Let us describe the ﬁrst step of phosphorylation using Michaelis-Menten kinetics for mixed
inhibition as explained in Section 15.3. Introduce the following notations,
– ami – intracellular AraC concentration ;
– ap3 – intracellular AraCTP concentration ;
– ap1, ap2 – AraCMP and AraCDP concentrations respectively ;
– c – dCTP (deoxycytidine triphosphate) concentration ;
– dC – deoxycytidine concentration ;
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Then phosphorylation rate of AraC is given by
r˙p ≡
[
d(ap1 + ap2 + ap3)
dt
]
p
=
Vk
1 + Km
ami
(
1 + c
Ki
+ dC
KI
+ ap3
K′i
)
+ Km
(
c
KiK′m
+ ap3
K′iK′′m
) ,
(4.29)
where KI is the deoxycytidine inhibitor constant, Km is the competitive Michaelis-Menten
constant, Ki, K ′i, K
′
m, K
′′
m are mixed inhibition constants, Vk is the kinase activity. It should be
noted that in the left part of (4.29) we should write the sum of all three forms of AraC. This is
because two other steps of phosphorylation go very fast with respect to the ﬁrst step and, thus,
a part of obtained by phosphorylation AraCMP is transmitted rapidly to AraCDP and AraCTP.
We can suppose that the fractions ap3/ap2 and ap2/ap1 are constant,
ap3
ap2
= α1,
ap2
ap1
= α2,
which provides
r˙p =
(
1 +
1
α1
+
1
α1α2
)
d ap3
dt
.
The 5′-nucleotidase is the most important enzyme that catalyses the dephosphorylation of
AraCMP→ AraC. We do not consider mixed inhibition for this enzyme, hence the dephospho-
rylation rate of intracellular AraC is given by a simple Michaelis-Menten equation,
r˙dp ≡
[
d(ap1 + ap2 + ap3)
dt
]
dp
=
(
1 +
1
α1α2
+
1
α1
)[
d ap3
dt
]
dp
=
Vdp
1 +
α1α2Kdp
ap3
, (4.30)
where Kdp is the Michaelis constant, Vdp is the nucleotidase activity, ap3α1α2 = ap1.
The last component, which we take into account, is deamination AraC→AraU. We consider
the deamination only by cytidine deaminase (CDA) and other mechanisms are omitted due to
their minor effects. To describe it we use a simple Michelis-Menten equation,
r˙da =
da
dt
=
Vda
1 + Kda
ami
, (4.31)
where Kda is the Michaelis constant and Vda is CDA activity.
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The overall kinetics of intracellular AraC is then described by the following equation,
dami
dt
= −r˙p + r˙dp − r˙da.
Taking into account transmembrane transport (see Section 15.2) of AraC this equation becomes
dami
dt
= khENT1(am − ami)− r˙p + r˙dp − r˙da, (4.32)
where am is extracellular AraC concentration in bone marrow. Denote for brievity,
α˜ =
(
1 +
1
α1
+
1
α1α2
)
. (4.33)
Then, dynamics of intracellular AraCTP (ap3) is described by the following equation,
dap3
dt
= (r˙p − r˙dp)/α˜. (4.34)
Hence Equations (4.29)-(4.34) describe intracellular kinetics of AraC and AraCTP inside
bone marrow cells. Let us note that AraCTP consumption due to its incorporation into DNA is
not included into the model, which can slightly modify AraCTP kinetics.
15.5 Resistances
Several mechanisms of resistance to AraC are known nowadays, deﬁciency of transmem-
brane transport, problems with dCK kinase and high CDA activity, which deaminate AraC to
its inactive form AraU. It has been demonstrated that relapsed leukaemia patients show decrea-
sed dCK mRNA expression [59]. In addition, reduced dCK mRNA expression and a deﬁciency
of functional dCK have often been associated with resistance to AraC [82]. The deamination
of AraC into AraU by CDA prevents the formation of AraCTP and decreases the cytotoxicity
of AraC. In [60] the authors concluded that decreased hENT-1 expression and function is res-
ponsible for the acquisition of Ara-C resistance. In Section 17.2 we study numerically these
mechanisms of resistance.
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16 Pharmacodynamics modelling
Pharmacodynamics describes what drug does to organism. In Section 14 we introduced
System (4.7) that describes a model of cell populations, in which a population of malignant and
a population of normal cells are considered. We introduced self-renewal, differentiation and
apoptosis rates for each cell population. AraCTP exerts cytotoxic effect on all dividing cells
arresting DNA synthesis. This results in increased apoptosis rate and reduced proliferation rate.
We describe drug action as a dependence of the three rates on AraCTP concentration,
s = s(ap3), d = d(ap3), a = a(ap3), (4.35)
where s(ap3) and d(ap3) are decreasing bounded functions. Hill functions can be used to des-
cribe such dependencies. Let us denote rates of self-renewal, differentiation and apoptosis by
s∗, d∗, a∗ for population of normal cells and by s∗m, d
∗
m, a
∗
m for population of malignant cells in
non-treated case, which provides,
s(0) = s∗, d(0) = d∗, a(0) = a∗.
17 Simulations
In previous sections of this chapter we constructed WBPBPK/PD model that consists of
cell population dynamics (4.7), AraC distribution in the body (4.16)-(4.17), Equations (4.29)-
(4.34) describing AraC metabolism inside bone marrow cells and drug action described by
Equation (4.35). In Section 17.1 we present simulations of the Whole Body Physiologically
Based PharmacoKinetic (WBPBPK) model. The simulations demonstrate AraC distribution in
the body and kinetics of AraCTP (AraC active form) under some protocols of administration,
including high-dose and standard dose AraC. We introduce the notions of minimal cytotoxic
and cytostatic AraCTP concentrations and study the efﬁcacy of treatment with respect to them.
In Section 17.2 we present simulations of WBPBPK model within resistant cells. Then, in
Section 17.3 we present PK/PD model of AraC, which provides the dynamics of malignant as
well as of normal bone marrow cells under chemotherapy treatment.
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17.1 WBPBPK model
Let us ﬁrst introduce parameters of metabolism scheme, their values are taken from [76]
and correspond to AraC metabolism in mice, see Table 6. In Section 15.4 we introduced two
TABLE 6 – Parameter values of the metabolism scheme of AraC.
Parameter Value Unit
Vk deoxycytidine kinase activity 1.28 μM.min−1
Km 27.0 μM
Ki 1.0 μM
K ′i 17.9 μM
KI 0.84 μM
K ′m 309 μM
K ′′m 101.9 μM
Vdp nucleotidase activity 300 μM.min−1
Kdp Michaelis-Menten constant 900 μM
Vda CDA activity 16.45 μM.min−1
Kda Michaelis-Menten constant 1011.7 μM
parameters, α1 and α2 which denote proportions between concentrations AraCTP/AraCDP and
AraCDP/AraCMP respectively. We took the following values for them, α1 = 7.83 and α2 =
5.67, which provided α˜ = 1.30, see (4.33). Deoxycytidine triphosphate (dCTP) concentration
was supposed to equal 10μM and deoxycytidine concentration (dC) equals to 4μM.
Two phases of AraC distribution in the body can be distinguished. Each stage is charac-
terised by its own half-life and different processes interfere into its fate. Once administered
in the blood, AraC is distributed between different compartments and penetrates into cells.
Clearance is also present during this initial phase, but is less important than physiological
processes. On the second phase, when drug concentrations are equalised in different com-
partments and inside cells, clearance becomes important. Secondary half-life, which represents
AraC clearance, is known to equal one to three hours. We choose two hours, which provides
γb = 0.0058min−1. We suppose that AraC clearance in the blood and in the bone marrow is the
same, γm = 0.0058min−1. In Section 6.2.1 we presented how to obtain clearance constant γ of
a degradating substance if its half-life is known.
Let us now describe transmembrane transport. To determine the rate of transmembrane pe-
netration, we introduce the notion of half-exchange. Let us explain it. Consider a substrate that
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is able to penetrate through cell membrane. Suppose that its transmembrane transport rate is
constant and equals k. The exchange stops when intracellular and extracellular concentrations
are equal, otherwise it goes from the compartment with greater concentration to that with lower
concentration. Denote by ce(t) and ci(t) respectively its extracellular and intracellular concen-
trations at time t. Then, the substrate behaviour can be described by the following equations,
dci(t)
dt
= k(ce(t)− ci(t)), dce(t)
dt
= k(ci(t)− ce(t)). (4.36)
The total concentration of the substrate remains constant, denote it by cT . Then, ce(t) = cT −
ci(t). Substitute it into the ﬁrst equation of (4.36),
dci(t)
dt
= k(cT − 2ci(t)).
The solution is given by
ci =
cT
2
− ci0
2
e−2kt, ce =
cT
2
+
ci0
2
e−2kt.
This provides ce(t)− ci(t) = ci0e−2kt. At time t0 = 0 the difference is ce(0)− ci(0) = ci0. We
call the half-exchange time, the time T2 such that
ce(T2)− ci(T2) = 1
2
(ce(0)− ci(0)) ,
i.e. the time after which the difference between intracellular and extracellular concentrations is
decreased twice. This provides
k =
ln 2
2T2
.
This formulae allows the estimation of constant khENT1 in Equation (4.17). We suppose that
the difference between intracellular and extracellular concentrations decreases twice in a half
an hour, i.e. half-exchange time equals 30 minutes. Then, we obtain khENT1 = 0.0116min−1.
In [76] the authors determined limits of cytotoxic and cytostatic effects of AraCTP. As mi-
nimum cytotoxic level of AraCTP concentration, below which AraCTP is no more cytotoxic,
they determined 1μM. As minimum cytostatic level of AraCTP concentration 0.1μM was deter-
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mined. With this concentration, AraCTP is supposed to inhibit 50% of DNA synthesis. Thus for
the simulations, we assume that AraC treatment kills cells when intracellular AraCTP concen-
tration is above 1μM. Cytostatic effect is not included in the model.
Results of simulations of different regimens of AraC administration are presented in Fi-
gure 46 and Figure 47. Figure 46 demonstrates kinetics of AraC in blood, bone marrow and
inside bone marrow cells as well as kinetics of intracellular AraCTP concentrations. For stan-
dard protocol (200mg/m2), AraC is cytotoxic during about 7 hours (Panel A), for high-dose
protocol (3g/m2), AraC is cytotoxic during about 14 hours (Panel B). Let us note that high dose
of AraC represents 15-fold standard dose of AraC. Panel C demonstrates that similar cytotoxic
effect can be obtained through two standard dose injections of AraC, one at the beginning and
another after 7 hours after the ﬁrst dose. Similar cytotoxic effect can be obtained through three
injections of 100mg/m2 at hours 0, 4 and 10, which divides the amount of administered drug
by 10 with respect to high-dose. Hence, our model suggests that high-dose regimen can be not
beneﬁt for patients, taking into account many side effects that emerge during chemotherapy. Fi-
gure 47 demonstrates another treatment protocol, with continuous infusion of AraC, that allows
obtaining similar cytotoxic effect as high-dose treatment.
Standard protocol used in induction therapy on patients diagnosed with AML consists of
100-200mg/m2/day given in bolus (impulse doses) or as continuous intravenous infusion during
ﬁrst 7 days. AraC is generally given in combination with daunorubicin. Results of simulations
of standard protocol are presented in Figure 48.
17.2 Pharmacokinetics of AraC within resistant cells
As discussed in Section 15.5, three mechanisms of resistance are known nowadays, decrea-
sed dCK activity, problems with transmembrane transport and high deamination rate of AraC
to its inactive form AraU. In this section we carry out simulations which describe these mecha-
nisms.
In normal cells we use the following parameter values, dCK activity is V nk = 1.28μM.min
−1,
half-exchange time equals 30 minutes, which provides knhENT1 = 0.0116min
−1 and cytidine
deaminase activity equals V nda = 16.45μM.min
−1. We consider the three sources of resistance
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FIGURE 46 – WBPBPK modelling of AraC. Panel A : Standard dose treatment (200mg/m2),
Panel B : High dose treatment (3g/m2). Panel C : Two injections of standard dose of AraC
(200mg/m2) at hours 0 and 7. Panel D : Three injections of low dose of AraC (100mg/m2)
at hours 0, 4 and 10. Parameters of metabolism are taken for murine L1210 cell line. Red
solid lines represent AraCTP concentration, green dash-dot lines represent extracellular AraC
concentration in blood, blue dash lines represent extracellular AraC concentration in bone mar-
row, magenta dash lines represent intracellular AraC concentration in bone marrow cells.
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FIGURE 47 – WBPBPK modelling of AraC. Standard dose injection at the beginning
(200mg/m2), followed by continuous infusion of 150mg/m2 administered during hours 4-13.
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FIGURE 48 – Simulations of AraC/AraCTP kinetics during standard protocol of induction the-
rapy. Panel A : in bolus intravenous injection of standard dose (200mg/m2) of AraC, Panel B :
continuous infusion of standard dose (200mg/m2) of AraC. Parameters of metabolism are ta-
ken for murine L1210 cell line. Red solid lines represent AraCTP concentration, green dash-dot
lines represent extracellular AraC concentration in blood, blue dash lines represent extracellular
AraC concentration in bone marrow, magenta dash lines represent intracellular AraC concen-
tration in bone marrow cells.
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separately. We suppose that dCK activity within resistant cells is twice lower than in normal
cells, V rk = V
n
k /2 = 0.64μM.min
−1, half-exchange time is doubled, to equal one hours, which
provides krhENT1 = k
n
hENT1/2 = 0.0058min
−1 and and deaminase activity is doubled and
equals V rda = 2V
n
da = 32.9μM.min
−1. Below we compare AraCTP kinetics within normal cells
and within defected cells with three sources of resistances.
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FIGURE 49 – Kinetics of AraCTP within normal cells (blue solid line) and resistance cells.
Three types of resistance are considered separately, resistance due to low dCK activity (green
dash line), to problems with transmembrane transport (violet dash dot line) and due to high
cytidine deaminase activity (red dot line).
Results of simulations for standard dose of AraC are presented in Figure 49. As shown in
this Figure, all the three mechanisms of resistance decrease cytotoxic time of AraC and, thus,
its efﬁcacy. We can conclude that mechanism of resistance due to dCK deﬁciency is stronger
than the two others, reducing almost twice the period when AraC is cytotoxic.
17.3 PK/PD model
Dynamics of cell sub-populations are deﬁned in (4.7), where rates s, d, a and sm, dm, am de-
pend on AraCTP concentration. We should then introduce functions s(ap3), d(ap3), a(ap3) and
sm(ap3), dm(ap3), am(ap3). As said above, s(ap3), d(ap3) are decreasing bounded functions.
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We use Hill functions to describe these dependencies,
s(ap3) = s
∗ θ
ns
s
θnss + ap
ns
3
, d(ap3) = d
∗ θ
nd
d
θndd + ap
nd
3
, (4.37)
where s∗ and d∗ represent self-renewal and differentiation rates of untreated bone marrow cells.
Hence, greater AraCTP concentrations in the body, smaller self-renewal and differentiation
rates. Cells killed by AraCTP increase apoptosis rate, which provides
a(ap3) = a
∗ + s∗
apns3
θnss + ap
ns
3
+ d∗
apnd3
θndd + ap
nd
3
, (4.38)
where a∗ represents apoptosis rate of untreated bone marrow cells. The rates for malignant
cell population are deﬁned by similar functions, denoted respectively by sm(ap3), dm(ap3) and
am(ap3). In previous section we obtained that even during high-dose AraC treatment, intracellu-
lar AraCTP concentration does not exceed 10μM. Hence, we assume that functions s(ap3) and
d(ap3) are only relevant on the interval ap3 ∈ [0, 10]. Plots of functions s(ap3), d(ap3), a(ap3)
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FIGURE 50 – Functions s(ap3), d(ap3), a(ap3) as well as sm(ap3), dm(ap3), am(ap3) describing
self-renewal, differentiation and apoptosis rates of normal and malignant cells as a function
of intracellular AraCTP concentration. Panel A : the three rates in sub-population of normal
cells, Panel B : the three rates in sub-population of malignant cells. Green solid lines represent
self-renewal rates, red dash lines represent differentiation rates, black dash-dot lines represent
apoptosis rates.
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and sm(ap3), dm(ap3), am(ap3) can be found in Figure 50, their parameter values are indicated
in Table 7. Dynamics of cell populations are presented in Figure 51.
TABLE 7 – Parameters that deﬁne how self-renewal, differentiation and apoptosis rates depend
on AraCTP concentrations, see (4.37)-(4.38), their plots can be found in Figure 50.
Parameter Value Unit
s∗ normal self-renewal rate 0.3 d−1
ns sensitivity of s(ap3) 5 N.U.
θs threshold value of s(ap3) 0.5 μM
d∗ normal differentiation rate 0.4 d−1
nd sensitivity of d(ap3) 5 N.U.
θd threshold value of d(ap3) 0.5 μM
a∗ normal apoptosis rate 0.3 d−1
s∗m normal self-renewal rate 0.7 d
−1
nsm sensitivity of sm(ap3) 5 N.U.
θsm threshold value of sm(ap3) 0.5 μM
d∗m normal differentiation rate 0.2 d
−1
ndm sensitivity of dm(ap3) 5 N.U.
θdm threshold value of dm(ap3) 0.5 μM
a∗m normal apoptosis rate 0.1 d
−1
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FIGURE 51 – Dynamics of cell populations during standard dose treatment (Panel A) and high
dose treatment (Panel B). Blue solid line represents normal cell population, red dash line repre-
sents malignant cell population. Kinetics of AraCTP concentrations for these two examples are
presented in Figure 46.A-B.
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One can notice, even the high-dose protocol does not allow killing all malignant cells. This
can be due to the parameter values which are not well estimated. Nevertheless, the dynamics of
populations demonstrates that if the administered dose of AraC is increased then all malignant
cells are killed and some of the normal cells remain alive (not shown here). On the contrary, if
not all malignant cells are removed, then they recover much faster than normal cells, once the
chemotherapy effect is over.
18 Discussion
In this chapter we presented a PK/PD model of AML treatment with AraC. We ﬁrst introdu-
ced a model of cell populations, in which we considered a population of normal and a population
of malignant cells. We studied steady states of this system and found conditions when leukaemic
steady state is stable. Dynamics of cell populations were described by their self-renewal, dif-
ferentiation and apoptosis rates. Pharmacodynamics was modelled as the dependence of these
rates upon AraC active form.
Pharmacokinetics model consists of several parts. We introduced a model of drug distribu-
tion between two compartments, blood and bone marrow. Drug penetration through cell mem-
brane was described as passive diffusion. We explained the Michaelis-Menten mechanism on
several model reactions and then applied it to describe the AraC metabolism scheme.
We carried out simulations of pharmacokinetic model of the whole body. Several treatment
protocols were studied. The values of parameters were chosen to describe AraC metabolism in
mice. Simulations have shown different kinetics of AraC and AraCTP concentrations. AraCTP
remains longer within cells than AraC. We tested standard dose treatment and high dose treat-
ment. Simulations demonstrated that high dose treatment is not advantageous and can be re-
placed by several injections of standard dose in order to reduce the overall administered dose
and thus its toxicity to organism. We carried out several simulations, in which the total dose is
reduced with respect to high-dose and which have similar effect on malignant cells. This allows
stating an optimal control problem, to ﬁnd a treatment protocol with a given administered dose
to maximise its efﬁcacy.
We also studied numerically AraC distribution within resistant cells. We considered sepa-
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rately three possible mechanisms of resistance (due to transmembrane transport, due to dCK
deﬁciency and due to increased CDA activity). We concluded with simulations of PK/PD mo-
del.
Thus, the model presented in this chapter can serve as a basis of the modelling of AML
treatment with AraC. It can be used to describe treatment of humans. To do so, the values of
parameters should be experimentally estimated.
Cinquième partie
Conclusions and Perspectives
181

183
This PhD thesis is devoted to mathematical modelling of haematopoiesis and blood diseases.
We investigated several models, which consider different aspects of blood production process.
First we studied a multi-scale model of erythropoiesis in which we coupled intracellular
protein interactions, which determine cell behaviour, with dynamics of cell sub-populations.
The model allowed the evaluation of the roles of different feedback mechanisms in response to
stress erythropoiesis.
We studied spatial distribution of cells in bone marrow, using a system of reaction-diffusion-
convection equations. We demonstrated the existence of a solution of this system and computed
the speed of propagation of malignant cells. Bone marrow cells exchange different signals that
regulate cell behaviour. We considered an integro-differential equation which describes cell
communication. We proved the existence of travelling wave solutions using topological degree
and the Leray-Schauder method. Individual based approach was used to study mechanical cell
interactions and cell distributions in bone marrow. Using this approach we demonstrated that
cell division can result in random cell motion.
Erythropoiesis can sometimes exhibit disorders, such as excessive proliferation of immature
cells, as observed in acute leukaemias. We then considered a physiologically based pharmacoki-
netics-pharmacodynamics model of treatment of acute myeloid leukaemia with AraC. We in-
vestigated numerically pharmacokinetics of AraC and efﬁcacy of several treatment protocols.
Below we discuss possible perspectives for this work.
Multiscale modelling of haematopoiesis. The intracellular regulatory network studied
in this work is simpliﬁed. A more sophisticated model can be considered (Figure 52). Every
protein-protein interaction can be presented as a chemical reaction. Taking into account parti-
cular conditions of these interactions, they could be described by different chemical kinetics
mechanisms (Michaelis-Menten kinetics, law of mass action, etc.). However, such a regulatory
network would necessitate to go deeper in the nature of proteins involved in erythropoiesis
regulation and their interactions. Although meaningful, such an approach will also add com-
plexity to the model. It is however expected to obtain in a future work a more precise model of
intracellular regulatory mechanisms.
In this work we assumed that all erythroid progenitors with the same maturity had similar
184
FIGURE 52 – Intracellular regulatory network that controls erythroid progenitor fate. Red
ﬂashes represent fast reactions, blue ﬂashes represent slow reactions. For notations, see Sec-
tion 3.
concentrations of Erk and Fas. Thus, our model does not take into account stochasticity in these
expressions, which can play an important role in the regulation of erythropoiesis. One of the
appropriate approaches that would allow taking into account the stochasticity is the individual
based modelling, presented in Chapter III. It considers each cell as an independent element of
the whole system and, consequently, every cell can have its own properties and protein concen-
trations.
It is known that Epo level rises due to the lack of haemoglobin. In this work we did not
consider haemoglobin and we assumed that erythrocyte count alters Epo levels (thus impli-
citly supposing that erythrocyte count and haemoglobin are linearly dependent). Nevertheless,
as shown in [29], there is no linear dependence between haemoglobin and erythrocyte (or red
blood cell) count during anaemia. This point can be relevant for the modelling of the response
to anaemia. Studies like [5, 115] can clarify dependencies between haemoglobin, erythrocyte
count and reticulocyte count in stress erythropoiesis. It should be noted as well that during
anaemia there is no clear distinctions between erythrocytes and circulating reticulocytes, both
circulate in the blood and fulﬁl functions of red blood cells. Here, we only considered erythro-
cytes to be red blood cells, which is not exact. Reticulocytes also contain haemoglobin but in
smaller volumes. Another point is that no information is currently available about how sensiti-
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vity to Epo evolves with maturation. All these aspects of Epo regulation should be investigated
to improve erythropoiesis modelling.
Spatial modelling of haematopoiesis. Spatial models of haematopoiesis considered in
this work are generic from the mathematical point of view but do not take into account detailed
biological mechanisms. In the future we will consider more speciﬁc models that allow taking
into account more biological information.
Individual based modelling. The software presented in this work takes into account me-
chanical cell interactions. Nevertheless, it is well known that chemical interactions between
cells can play an important role for cell population behaviour. Moreover, cell proliferation is
controlled by certain extracellular substances, such as nutrients, oxygen, growth factors, etc.
Thus, introducing chemical interactions between cells into the modelling as well as cell interac-
tions with extracellular substances will allow approaching the biological reality of the processes
under consideration.
One of the applications of the software is modelling of haematopoiesis and, in particular, of
erythropoiesis. As we demonstrated in Chapter I, during erythropoiesis cell behaviour crucially
depends on the intracellular regulatory network. This regulatory network is controlled by growth
factors, which are extracellular substances, and by some enzymes which are expressed on the
surface of mature cells. This means that cell fate depends also on neighbouring cells. Conside-
ring the intracellular regulatory network for every single cell would additionally improve the
individual based modelling.
PK/PD modelling. The considered PK/PD model of AML treatment with AraC consisted
of two parts, drug pharmacokinetics and pharmacodynamics. In order to describe the pharma-
codynamics, we introduced two interacting between each other cell populations, a population of
normal and a population of malignant cells. Drug action on cell proliferation was modelled by
a simple dependence of the proliferation and apoptosis rates on the concentration of drug active
form. This is a simpliﬁed pharmacodynamics model. Considering several sub-populations of
malignant and of normal cells depending on the cell cycle phase (including quiescent cells) will
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allow introducing a cell cycle model. In this more precise model, we can take into account that
the considered drug is a cycle active agent and kills only cells that are in S-phase.
The metabolism scheme is well described in the model. To carry out simulations, we consi-
dered the values of parameters that describe murine metabolism. Although the scheme of me-
tabolism remains similar for humans, chemical constants are not the same, they should be es-
timated experimentally. Thresholds of cytotoxic and cytostatic effects will also change. In the
present model we did not consider cytostatic effect of the drug, which should also be taken into
account.
When we describe drug distribution in the body, in order to reduce the number of constants
to estimate, we considered two compartments, blood and the bone marrow. To study a more
precise model of drug distribution we can introduce additional compartments. To estimate all
the necessary constants, experimental data will be needed.
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Re´sume´
Cette the`se est consacre´e a` la mode´lisation mathe´matique de l’he´matopo¨ıe`se et des maladies sanguines.
Plusieurs mode`les traitant d’aspects diﬀe´rents et comple´mentaires de l’he´matopo¨ıe`se y sont e´tudie´s.
Tout d’abord, un mode`le multi-e´chelle de l’e´rythropo¨ıe`se est analyse´, dans lequel sont de´crits a` la fois le
re´seau intracellulaire, qui de´termine le comportement individuel des cellules, et la dynamique des populations
de cellules. En utilisant des donne´es expe´rimentales sur les souris, nous e´valuons les roˆles des divers me´canismes
de retro-controˆle en re´ponse aux situations de stress.
Ensuite, nous tenons compte de la distribution spatiale des cellules dans la mœlle osseuse, question qui
n’avait pas e´te´ e´tudie´e auparavant. Nous de´crivons l’he´matopo¨ıe`se normale a` l’aide d’un syste`me d’e´quations de
re´action-diﬀusion-convection et nous de´montrons l’existence d’une distribution stationnaire des cellules. Puis,
nous introduisons dans le mode`le les cellules malignes. Pour certaines valeurs des parame`tres, la solution
”disease-free” devient instable et une autre solution, qui correspond a` la leuce´mie, apparaˆıt. Cela me`ne a` la
formation d’une tumeur qui se propage dans la mœlle osseuse comme une onde progressive. La vitesse de
cette propagation est e´tudie´e analytiquement et nume´riquement. Les cellules de la mœlle osseuse e´changent
des signaux qui re´gulent le comportement cellulaire. Nous e´tudions ensuite une e´quation integro-diﬀe´rentielle
qui de´crit la communication cellulaire et nous prouvons l’existence d’une solution du type onde progressive en
utilisant la the´orie du degre´ topologique et la me´thode de Leray et Schauder. L’approche multi-agent est utilise´e
aﬁn d’e´tudier la distribution des diﬀerents types de cellules dans la mœlle osseuse.
Finalement, nous e´tudions un mode`le de type ”Physiologically Based Pharmacokinetics-Pharmacodynamics”
du traitement de la leuce´mie par l’AraC. L’AraC agit comme chimiothe´rapie et induit l’apoptose de toutes les
cellules prolife´rantes, saines et malignes. La pharmacocine´tique donne acce`s a` la concentration intracellulaire
d’AraC. Cette dernie`re, a` son tour, de´termine la dynamique des populations cellulaires et, par conse´quent,
l’eﬃcacite´ de diﬀe´rents protocoles de traitement.
Mots-cle´s: mode`le multi-e´chelle de l’e´rythropo¨ıe`se, re´seau de re´gulation intracellulaire, ondes progressives,
e´quation integro-diﬀe´rentielle, mode`le multi-agent, me´thode de Leray-Schauder, PK/PD, mode´lisation du traite-
ment de leuce´mie.
Mathematical modelling of haematopoiesis and blood diseases
Abstract
This PhD thesis is devoted to mathematical modelling of haematopoiesis and blood diseases. We investigate
several models, which deal with diﬀerent and complementary aspects of haematopoiesis.
The ﬁrst part of the thesis concerns a multi-scale model of erythropoiesis where intracellular regulatory
networks, which determine cell choice between self-renewal, diﬀerentiation and apoptosis, are coupled with
dynamics of cell populations. Using experimental data on anemia in mice, we evaluate the roles of diﬀerent
feedback mechanisms in response to stress situations.
At the next stage of modelling, spatial cell distribution in the bone marrow is taken into account, the
question which has not been studied before. We describe normal haematopoiesis with a system of reaction-
diﬀusion-convection equations and prove existence of a stationary cell distribution. We then introduce malignant
cells into the model. For some parameter values the disease free solution becomes unstable and another one,
which corresponds to leukaemia, appears. This leads to the formation of tumour which spreads in the bone
marrow as a travelling wave. The speed of its propagation is studied analytically and numerically. Bone marrow
cells exchange diﬀerent signals that regulate cell behaviour. We study, next, an integro-diﬀerential equation
which describes cell communication and prove the existence of travelling wave solutions using topological degree
and the Leray-Schauder method. Individual based approach is used to study distribution of diﬀerent cell types
in the bone marrow.
Finally, we investigate a Physiologically Based Pharmacokinetics-Pharmacodynamics model of leukaemia
treatment with AraC drug. AraC acts as chemotherapy, inducing apoptosis of all proliferating cells, normal
and malignant. Pharmacokinetics provides the evolution of intracellular AraC. This, in turn, determines cell
population dynamics and, consequently, eﬃcacy of treatment with diﬀerent protocols.
Keywords: multi-scale model of erythropoiesis, intracellular regulatory network, travelling wave solutions,
integro-diﬀerential equation, individual based model, Leray-Schauder method, PK/PD, Michaelis-Menten ki-
netics.
